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Summary 
Two distinct biosynthetic pathways to the essential amino acid L ~Iysine 
(A) are found in nature. The a -aminoadipate pathway operates in fungi and 
yeasts. The diaminopimelate (OAP) pathway occurs in bacteria and higher 
plants. Our studies were concerned with the DAP pathway and particularly with 
the first two steps of this pathway. These steps involve condensation of L-
aspartate-p-semialdehyde (ASA) (8) with pyruvate (C) to form L ~2,3-
dihydrodipicolinic acid (DHDPS) (D) and subsequent reduction to L-2,3,4,5-
tetrahydrodipicolinic acid (THDPA) (E). The first step is catalysed by the 
enzyme dihydrodipicolinate synthase (OHDPS). The second step is catalysed 
by the enzyme dihydrodipicolinate reductase (DHDPR) and utilises NADPH as 
a co-factor. 
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Our primary objective was the inhibition of this biosynthetic pathway. 
Inhibitors of this pathway have potential as antibacterial or herbicidal agents. A 
number of substrate analogues of the DHDPS and DHDPR enzymes were 
prepared and tested as inhibitors of these enzymes. In previous studies by our 
group, heterocyclic compound (F) showed promising activity. In our work, a 
number of analogues of compound (F) were prepared. Inhibition studies with 
these compounds constituted a valuable insight into the characteristics of these 
enzymes. The level of inhibition with these compounds and for a range of other 
substrate analogues indicate high substrate selectivity for the enzymes. 
IV 
The condensation catalysed by DHDPS is mechanistically interesting. In 
chemical terms, C-C bond formation is commonly a high energy process 
involving highly reactive compounds such as organometallic agents or strong 
bases. In such cases the strategy must be directed towards protecting other 
functionality or introducing it at a later stage. Clearly, achieving this task under 
mild conditions with the high regio- and stereoselectivity associated with 
enzymic catalysis could be of tremendous advantage. 
Once again, however, we were restricted by the high substrate specificity 
of the DHDPS enzyme. In earlier studies by our group, Dr J.E. McKendrick 
found evidence of substrate activity for 2- and 3-methyl substituted ASA, (G) 
and (H), respectively. In our work, an improved preparation of these compounds 
was developed and the subsequent biotransformations with DHDPS were 
examined both qualitatively and quantitatively. Interestingly, compound (G) was 
shown to display a greater substrate activity than ASA. The preparation of ASA 
methyl ester (I) was achieved. This compound also displayed a moderate level 
of substrate activity and was the only compound found to show substrate 
activity for a DHDPS/DHDPR coupled substrate assay. 
0 0 0 
H -o~t3~ ~H -02C Me02C NH3+ 
(G) (H) (I) 
A significant proportion of our effort was concentrated on the 
investigation of glutamate-y-semialdehyde (GSA) (J), the higher homologue of 
ASA, as a substrate of DHDPS. Problems were encountered with earlier studies 
in this area because of cyclisation of GSA, even in protected forms. To counter 
this problem two novel strategies were considered. The first involved in situ 
enzymic deprotection of the N-acetyl derivative of GSA. Although this was 
successful for N-Acetyl-ASA, problems with cyclisation were once again 
experienced for the GSA equivalent. The second strategy utilises the reversible 
nature of enzymic catalysis. The synthesis of the proposed 7-membered 
heterocyclic product (K) of DHDPS catalysed condensation of GSA and 
pyruvate is not a trivial task. Some progress was made and further direction 
detailed. Further validation for this study was demonstrated on preparation of 5-
hydroxyproline (L). Compound (L) is a cyclic equivalent of GSA and was found 
to display clear evidence of substrate activity. 
v 
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One other application of our 'reverse' strategy for enzymic activity was 
successfully implemented. This involved the development of an inhibition assay 
for detection of DHDPR activity. The natural substrate of DHDPR, (D), has very 
low stability. Consequently, inhibition studies on this enzyme are most 
commonly performed by means of a DHDPS/DHDPR coupled assay. By 
synthesising the enzymic product of DHDPR, (E), we have developed a 
'reverse' assay for inhibition studies on DHDPR alone. The synthesis of 
compound (E) was previously achieved by our group. A selection of our 
synthetic inhibitors was evaluated by this new enzyme assay. 
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Chapter 1 a-Amino Acids, Proteins and 
Enzymes 
1.01 Importance of a-Amino Acids1 
There are a very large number of amino acids known to occur in nature. 
Of these, the most important are the twenty a-amino acids which almost 
exclusively comprise the structure of all known proteins. Proteins are found in 
all living cells. They are the principal material of skin, muscles, tendons and 
nerves as well as enzymes, antibodies and many hormones. The twenty 
amino acids most commonly found in proteins are listed in Figure 1. All of 
these a-amino acids (with the exception of glycine) have the L-
stereochemistry and the highly specific stereoenvironment that results when a 
number of these amino acids are joined through peptide linkages is crucial to 
the high chemical selectivity of these biomolecules. Proteins are the end 
products of the genetic processes of every living organism (Scheme 1) and 
are the workhorses of all biological transformations. 
replication Q transcriPti~n RNA translatio~ Protei n 
Scheme 1 The Genetic Process 
Amino acids are amphoteric in nature; that is, they contain both an acid 
function in the carboxyl group and a basic function in the amine group. In their 
commonly encountered neutral aqueous environment they exist mainly in the 
doubly ionic or zwitterionic form shown in Figure 1. As a result the free amino 
acids display similar chemical behaviour to ionic solids: high melting points; 
solubility in polar solvents; and very low acidity and basicity constants. For 
example, glycine has Ka = 1.6 X 10-10 and Kb = 2.5 X 10-12. At low pH the 
carboxylate group of the amino acid is protonated and it exists as an 
ammonium cation. At high pH the ammonium group of the amino acid is 
deprotonated and it exists as a carboxylate anion. The nature of the ionic 
species determines how the amino acid will migrate in an electric field. The 
hydrogen ion concentration of a solution in which a particular amino acid does 
not migrate towards either electrode in a magnetic field is an important 
physical constant known as the isoelectric point. An amino acid usually shows 
its lowest solubility in a solution at its isoelectric pH. The value of this constant 
1 
is dependent on the ratio of acidic and basic groups, including those in the 
side chain. Glycine, glutamic acid and lysine have isoelectric pH values of 
5.97, 3.22 and 9.74, respectively.2 
C02-
L -Leucine (Leu) L 
HO~'H 
+H3N CO£ 
L -Serine (Ser) S 
Me 
~".H 
+H3N CO
2
-
L-Alanine (Ala) A 
L-Proline (Pro) P 
HO 
+HaN 
L-Threonine (Thr) T 
+H3N~~2 
L-Valine (Val) V L-Isoleucine (lie) I 
L-Arginine (Arg) R L-Lysine (Lys) K 
HS~H 
+H N 
3 CO£ 
'S~H 
+H3N CO
2
-
L-Cysteine (Cys) C L-Methionine (Met) 
L-Aspartic Acid (Asp) D L-Phenylalanine (Phe) F 
H2NOC +H3N~~~2-
L-Asparagine (Asn) N 
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j=N 
HN~.H 
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2
-
L-Histidine (His) H 
C02-
L-Tryptophan (Trp) W 
Figure 1 The 'Natural' a-Amino Acids 
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1.02 Biosynthesis of a-Amino Acids3 
The entire basic set of twenty one genetically encoded a-amino acids, 
including the less commonly occurring selenocysteine, are derived from six 
intermediates produced from only three biosynthetic pathways: glycolysis; the 
pentose phosphate pathway and the citric acid cycle. Bacteria such as 
Escherichia coli and plants can synthesise the entire set required for protein 
synthesis. Humans can only synthesise twelve of the genetically encoded a-
amino acids. These are known as the 'nonessential' amino acids: alanine; 
arginine; asparagine; aspartate; cysteine; glutamate; glutamine; glycine; 
proline; selenocysteine; serine and tyrosine. The remaining nine 'essential' 
amino acids must be supplied in the diet: histidine; isoleucine; leucine; lysine; 
methionine; phenylalanine; threonine; tryptophan and valine. The pathways to 
the amino acids are summarised in Scheme 2. The essential amino acids 
are in bold type and the biochemical pathway from which the precursor is 
derived is bracketed. 
I Oxaloacetate (Citric) I 
~ Aspartate 
~ ~ ~-------Asparagine Lysine Methionine Threonine 
IsoleLcine 
Phosphoenolpyruvate (Glycolysis) 
+ 
Erythrose 4-phosphate (Pent. Phosphate) 
/ \ ~ 
Phenylalanine Tryptophan Tyrosine 
T .. yrosme 
I Ribose 5-phosphate (Pent. Phosphate) I 
Hist'dine 
I pyruvate (Glycolysis) I 
Alan' Leutine ~line 
I a-Ketoglutarate (Citric) I 
j 
Glutamate 
A .. ~GI ~ ,------P I' rglnlne utamlne ro Ine 
13-Phosphoglycerate (Glycolysis) I 
setine 
/ ~ 
Cysteine 
selenoJysteine 
Glycine 
Scheme 2 Biosynthetic Routes to the a-Amino Acids 
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The synthesis of the carbon skeleton of the a-amino acids from the 
biochemical precursors is performed by simple enzyme controlled 
transformations. The transformations in the case of essential amino acids are 
generally more complex. 
Two prosthetic groups, tetrahydrofolate and S-adenosylmethionine, 
play important roles in the synthesis of the carbon skeletons (Figure 2). 
Tetrahydrofolate is a vitamin for mammals and must be supplied in the diet. In 
amino acid synthesis it acts as a supply of an activated methyl group. The key 
parts of the molecule are the N-5 and N-10 positions (Figure 2) which can 
carry methyl, methylene, formyl, formimino (-CHNH-) or methenyl (-CH=) 
groups. Tetrahydrofolate can also act as a one carbon acceptor in 
degradation reactions. S-Adenosylmethionine is a somewhat more reactive 
source of methyl groups and consequently is responsible for the majority of 
biosynthetic methylations. S-Adenosylmethionine is synthesised by transfer of 
an adenosyl group from adenosyltriphosphate (ATP) to the sulfur atom of 
methionine. The methionine can be regenerated from the S-
adenosylhomocysteine byproduct by hydrolysis to homocysteine and 
subsequent methylation with N5-methyltetrahydrofolate. 
Tetrahydrofolate 
HO OH 
S-Adenosylmethionine 
Figure 2 Structure of Tetrahydrofolate and S-
Adenosylmethionine 
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The incorporation of nitrogen into a-amino acids is another important 
biosynthetic feature. Nitrogen is the major constituent of atmospheric gases. 
N2 gas from this source is reduced to water soluble ammonium ions (NH4+) by 
nitrogen-fixing microorganisms. The NH4+ reacts with a-ketoglutarate, 
NADPH and H+ to produce glutamate, under catalysis by the enzyme 
glutamate dehydrogenase. Further biosynthetic reaction with NH4+ and ATP, 
catalysed by gluamine synthetase, produces glutamine. The a-amino group of 
most amino acids comes from a transamination reaction with glutamine. 
1.03 Protein Structure4 ,5 
Proteins are large macromolecules with molecular masses typically in 
the region 10 000 to 1 000 000 Daltons. They consist of a large number of 0.-
amino acid units covalently linked through amide bonds to form long 
unbranched chains. With twenty amino acids arranged in varying number and 
order an almost infinite library of compounds is possible. At physiological pH, 
the amino acids can be classified into three forms by the polarity of their side 
chains: non-polar; neutral polar and charged polar. As a result proteins differ 
enormously in structure for both steric and electronic reasons. The sequence 
of these side chain groups is unique to each protein and gives each its distinct 
biochemical properties. 
The shape of a protein can be described in terms of primary, secondary 
and tertiary structure. Primary structure is the basic covalent structure made up 
of peptide bonds and disulfide linkages between distant neighbouring 
cysteine residues. To determine the composition of a protein the peptide is 
hydrolysed in acid solution, since alkaline solution causes racemization. The 
resulting amino acid mix is then analysed by ion exchange chromatography 
or, after conversion into their methyl esters, by gas chromatography. 
Determination of protein sequence is a somewhat more difficult task and is 
accomplished by a combination of reductive cleavage, partial hydrolysis and 
terminal residue analysis. The first step of sequencing is the reductive 
cleavage of the covalent disulfide linkages and protection of the resulting 
cysteine groups by alkylation (Scheme 3). In practice it is not feasible to 
extend the analysis of stepwise removal of terminal residues beyond about 20 
residues because of the interference from the accumulation of residues. It is 
therefore necessary to subject the chain first to partial hydrolysis. The resulting 
fragments are then identified by terminal residue analysis. This technique 
5 
relies on the fact that there is a free amino group a to a peptide link at one end 
of the peptide chain and a free carboxylate group at the other end. 
HN~~~ 
S 
I 
HN~ 
o 
/"".... /SH 
HO ..... ~ 
• 
o 
+ 
/"".... .... S, /'... /OH 
HO' ~ S." ~ 
Scheme 3 Reductive Cleavage of S-S Crosslinks 
The most commonly used method of terminal residue analysis involves 
selectively hydrolysing the N-terminal residue after treatment with phenyl 
isocyanate. The phenyl isothiocyanate reacts with the free amino group to 
form a thiourea. Mild hydrolysis with aqueous hydrochloric acid selectively 
removes the N-terminal residue, as a phenylthiohydantoin, and leaves the rest 
of the peptide intact (Scheme 4). It is also possible to remove the C-terminal 
residue by selective hydrolysis with the enzyme carboxypeptidase, found in 
the pancreas. Standard notation is to list the protein sequence with the N-
terminal end containing a free amino group on the left and the C-terminal end 
containing a free carboxyl group on the right. 
X-Ray studies of dipeptides indicate that the entire amide group is flat. 
The oxygen, carbonyl carbon, nitrogen and three other atoms attached all lie 
in a plane. The carbon to nitrogen distance of 1.32 A compared to the usual 
1.47 A for a carbon-nitrogen single bond indicates considerable double bond 
6 
character (- 50%). As a result the angles around both the carbonyl carbon 
and the nitrogen are similar to those observed around a trigonal sp2 carbon. 
Ph-N=C=S 
Scheme 4 Terminal Residue Analysis 
Different proteins have different proportions of acidic and basic side 
chains and hence have different isoelectric points. The movement of the 
protein towards a particular electrode is not only dependent on the pH of the 
medium, which controls the magnitude of the net charge, but is also reliant on 
the molecular size and shape. This difference in behaviour in an electric field 
is the basis of electrophoresis. Electrophoresis is one method of separation 
and analysis of protein mixtures. 
Secondary structure describes the way in which the protein chains are 
arranged in space to form coils, sheets or compact spheroids. The 
environment around the protein, aqueous or non-aqueous, plays a key role in 
the arrangement of the chains and side groups. As observed for nucleic acids 
and colloidal aggregates, proteins tend to hold their polar amide linkages and 
side chains to the outside where they are surrounded by a polar aqueous 
environment. The non-polar hydrophobic side chains are commonly held 
within this structure to the exclusion of water. The importance of the 
environment around the protein poses a problem for the protein 
crystallographer. The high vacuum environment required for X-ray analysis 
can cause the protein to distort by unfolding. Crystal structure of a normally 
folded protein is required to predict the sequence of events promoted within 
the active site. With this information and the skills of the molecular modeller, 
compounds can be designed to interact with the protein for chemotherapeutic 
or other useful purposes. Fortunately the skills of the protein crystallographer 
7 
are well advanced in crystallisation techniques and this problem is 
surmountable. The shape of the protein is principally determined by the 
intramolecular hydrogen bonds between distant N-H and C=O groups in 
amide bonds. This interaction has a stabilising effect of the order of 5 to 10 
Kcal per mole per hydrogen bond. And since the attraction is electrostatic, and 
not governed by molecular orbital theory, then the N-H .... O=C bond is close to 
linear. The simplest arrangement that fulfils this criterion is the linear ~-sheet 
interaction (Figure 3). For a linear peptide chain the repeat distance 
between similarly orientated alternate residues is 7.2 A. It is however 
noteworthy from Figure 3 that alternate side chains lie on the same side of 
the sheet. The result of this significant steric interaction is that the ~-sheet 
structure is only observed when the neighbouring side chains concerned are 
small in size. Even when the side chains are small enough to permit this 
structure, the chain undergoes a puckering to accommodate the steric 
requirements. The protein silk fibron closely approaches the fully extended flat 
sheet structure and has a repeat distance of 7.0 A. This protein is composed of 
84% glycine, alanine and serine residues. When the side chains are larger 
the thermodynamically favoured conformation is the familiar a-helical shape 
that is observed with DNA (Figure 4). Again, the predominant factor in 
adopting this structure is the thermodynamic gain of the hydrogen bonding 
interactions that hold it together. The stereochemistry of the individual amino 
acid residues imposes specific steric requirements that direct the formation of 
the highly stereospecific right handed helix. The a-helix has 3.6 amino acid 
residues per turn and has a repeat distance of 1.5 A, measured along the 
helical axis. 
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Figure 3 ~-Sheet Structure 
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Figure 4 a-Helical Protein Structure 
The influence of the amino acids proline and 4-hydroxyproline on 
secondary structure is worth consideration. When incorporated in the peptide 
chain both lack the N-H bond necessary for hydrogen bonding and impose 
significant steric requirements for the pseudo co-planar amide group and 
pyrrolidine ring . As a result , these residues can effect severe distortions or 
termination of both a-helical or p-sheet secondary structure. 
Tertiary structure concerns the spatial arrangement of remote amino 
acid residues. The distinction between secondary and tertiary structure is not 
clear-cut. Both involve hydrogen bond interactions. Perhaps a simple 
interpretation would be to consider secondary structure as uniform or ordered 
and tertiary structure as random interaction between incidental neighbours . 
The disulfide bonds between cysteine residues , which have been discussed 
here as part of the covalent primary structure , are commonly considered as 
tertiary structure . Tertiary structure is clearly thermodynamically dictated and 
in some cases a degree of order is observed. It is suggested that each helix 
can itself be coiled into a superhelix with one turn for every 35 turns of the a-
helix . 
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1.04 Enzymes, Active Sites and Co-enzymes 
Proteins have a number of functions in living systems. The greatest 
diversity of function is observed in the field of protein-based biological 
catalysts, enzymes. Every physical function of a living system is in some way 
controlled or influenced by the action of these enzymes. The highly 
stereospecific structure of proteins ensures a selective function of each and 
every enzyme. Enzymes were originally considered to bind substrates into an 
'active site' by a highly stereospecific 'lock and key' mechanism. Later 
structural evidence showed that most enzymes undergo a conformational 
change to accommodate substrates.6 This 'induced fit' hypothesis accounts for 
the activity of enzymes commonly observed with 'unnatural' substrates of 
varing structural diversity. When in position, the substrate is located next to 
activated groups, protected from the exterior environment, and undergoes a 
chemical transformation. The catalytic mechanism is then completed by the 
release of the transformed substrate and regeneration of the catalyst by 
release of a used cofactor or reverse reaction with a co-substrate. 
The specific function of enzymes is a product of evolution. Each 
enzyme has evolved through genetic processes to promote a specific 
biological function. Evolution is the process of altering the biological function 
of an organism for the purpose of increasing its chances of survival. It is 
estimated that it takes in the region of ten million years for one amino acid 
substitution to occur.4 Such a change is due to a change in base sequence in 
a molecule of nucleic acid. A very small change in amino acid sequence can 
make a significant difference to the function of a protein. Replacement of one 
of the 300 residues, valine for glutamic acid, in haemoglobin is responsible for 
the fatal disease of sickle-cell anaemia. 
Commonly the chemical transformation promoted at the active site of an 
enzyme is performed by a non-peptide portion held within the protein structure 
specifically for this purpose. This non-peptide portion is called a prosthetic 
group or co-enzyme and the protein is known as a conjugated protein.4 An 
example of this is the tetrapyrrole structure of 'haem' (Figure 5) which 
chelates iron and is responsible for oxygen transport in mammals. Haem is 
held within a peptide portion (globin) of the protein haemoglobin. In our work 
we encountered the reducing enzyme dihydrodipicolinate reductase 
(DHDPR), responsible for the reduction of l-2,3-dihydrodipicolinic acid 
(DHDPA) to l-2,3,4,5-tetrahydrodipicolinic acid (THDPA) (Chapter 2, 
Scheme 11). The reduction is performed by hydride transfer from the 
reduced form of the co-enzyme nicotinamide adenine dinucleotide phosphate 
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(NADPH) (Figure 5). Metal ions such as zinc and magnesium are also 
frequently involved as co-factors in enzyme-catalysed reactions. 
Haem 
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Figure 5 Structure of the Co-catalysts Haem and NADPH 
1.05 Enzyme Catalysis7 
Enzymes, like all catalysts, speed up the rate of attainment of 
equilibrium. They do not affect the position of equilibrium and are regenerated 
in their original form after reaction. The rate of any chemical transformation is 
determined by the difference in free energy between the starting materials and 
the high energy transition state. This energy difference is known as the free 
energy of activation, ilG:t. A catalyst is a species that can lower the energy of 
the transition state through a stabilising interaction or by offering an alternative 
lower energy route to the products. Commonly, enzyme catalysis proceeds 
through a number of 'low energy' intermediates and thus offers an 'optimum' 
route from starting materials to products (Figure 6). 
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Figure 6 Energy Profile for an Uncatalysed and an Enzyme 
Catalysed Transformation 
The nature of enzymes as catalysts dictates their effectiveness even at 
concentrations much lower than that of their substrates. However, in living 
systems many intercellular enzymes are present in relatively high localised 
concentrations, which may even exceed the concentration of the substrates. 
The substrates of these enzymes are likely to exist predominantly in their 
enzyme-bound form. Clearly this is a product of the evolutionary process, 
protecting unstable substrates from undesirable reactions. We might predict 
that the DHDPR enzyme is one such case. The substrate DHDPA is readily 
irreversibly oxidised by atmospheric oxygen to the aromatic derivative 
dipicolinic acid (DPA). 
1.06 Enzymes as Chemotherapeutic Targets 
Each biological entity is unique in its existence. Both modern and 
premodern medicine owe their successes to the inhibition of biological 
processes. If we target a biological transformation specific to an organism we 
can potentially selectively destroy the organism. The commonly targeted 
transformations are those of nucleic acids, enzymes and cell signalling 
processes. Many chemotherapeutic agents are derived from the massive 
library of compounds available from natural sources. In early days whole 
plants were used for medicinal purposes. Through time and scientific 
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advancement it has become possible to identify and isolate active constituents 
from the cocktail of chemicals of the natural source. We can draw an 
interesting analogy between early medicine and the current rapidly expanding 
field of combinatorial chemistry. Many modern day medicines are still based 
on the discovery of lead compounds from natural sources. 
In modern drug development an understanding of biological processes 
at a molecular level allows us to design compounds for a specific purpose. 
The synthesis of drug compounds may be performed from scratch using 
readily available chemicals or by chemical derivatisation of a biological 
product which can be produced in sufficient bulk. The latter of the two methods 
is useful when the target compound requires many synthetic steps or involves 
formation of a complex stereochemical structure. An example of this is the 
recent much publicised anticancer drug Taxol™ (Scheme 5). This 
compound occurs naturally at very low levels in the bark of Taxus brevifolia, 
the Pacific Yew Tree. Although the total synthesis of this compound has been 
ach ieved, 8,9,1 0 the method used for commercial purpose 11,12 involves a 
relatively short convergent synthesis utilising the readily available and more 
easily renewable biochemical intermediate 10-deacetylbaccatin III, from the 
leaves of Taxus baccata L (Scheme 5). 
HO 
10-Deacetylbaccatin III 
Scheme 5 The Semisynthesis of Taxol 
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The importance of enzymes as biological catalysts has already been 
mentioned. Most biological transformations are kinetically disfavoured and 
rely on enzymes to promote the reaction. By inhibiting the action of enzymes 
we can effectively stop an undesirable process. The greatest problem in 
inhibiting enzymic activity is the selectivity of action. Many unrelated 
organisms have evolved different enzymes for important common purposes. 
Frequently the active sites of these enzymes have a great deal in common. As 
the acceptance of a substrate into an active site is made possible by an 
induced fit mechanism, then the inhibitor of one enzyme would very likely 
inhibit structurafly related enzymes by a similar degree and would therefore 
display poor selectivity of action. This problem is equafly troublesome in 
targeting cell signalling processes and nucleic acids. A clear illustration of this 
can be seen with the current problems in selective cancer chemotherapy. 
Inhibition of enzymic activity can be either reversible or irreversible. 13 
An irreversible inhibitor binds very strongly, either covalently or non-
covalently, and essentially does not dissociate from the enzyme. Reversible 
inhibition is characterised by rapid dissociation and reassociation of the 
enzyme-inhibitor complex. 
A competitive inhibitor is one which binds reversibly to the enzyme at 
the active site and therefore prevents the substrate from binding. Competitive 
inhibitors slow the rate of enzymic catalysis by reducing the number of 
substrate molecules binding to the active site. This effect can be minimised by 
increasing the ratio of substrate to inhibitor so that binding of the substrate is 
favoured. Molecules which are close analogues of the transition state of 
enzymic processes are commonly good competitive inhibitors. 
A non-competitive inhibitor is one which binds away from the active site 
but disrupts the enzymic structure in such a way that the efficiency of the 
catalysis is diminished. A non-competitive inhibitor works by decreasing the 
turnover number rather than the number of substrate molecules bound to the 
active site. As a result the inhibition effect cannot be overcome by simply 
increasing the ratio of substrate to inhibitor. This subtle difference allows us to 
distinguish between the types of inhibition by studying the kinetics. If the 
extent of inhibition increases with concentration of inhibitor then competition 
for the active site is evident. This is a simplified view of inhibition study. 
Commonly inhibitors can bind both at and away from the active site and 
therefore display mixed inhibition. 
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1.07 Enzymes for Chemical Uses14 
In designing inhibitors we look for analogues of similar shape and 
electronic structure to substrates or transition state intermediates. Usually the 
inhibitor is suitably functionalised so it will bind to the enzyme but not undergo 
enzyme catalysed reaction. Similarly, unnatural enzyme substrates are 
closely modelled on the natural substrates or transition state intermediates of 
the enzyme but differ in that they are suitably functionalised so as to undergo 
an enzyme catalysed chemical transformation. Individual enzymes vary 
enormously in their substrate specificity. Enzymes that display low substrate 
specificity are generally more useful as biotransformation catalysts as they will 
accommodate a variety of unnatural substrates. The fermentation of sugar into 
ethanol by yeast is a biotransfomation process which has been known for a 
very long time. 
Proteins are an obvious source for the isolation of the genetically 
encoded amino acids. The oldest method of production of these important 
primary metabolites involves enzyme catalysed degradation of proteins. 
Indeed, the amino acids L-cysteine, L-glutamate, L-Iysine, L-glutamine and L-
arginine are still produced by microbiologically based processes. 
Enzymes play an equally important commercial role in the production of 
secondary metabolites. Penicillins and cephalosporins are produced in fungi 
by Penicillium spp. and Cephalosporium spp. respectively. The annual world 
production of penicillin-G (1) and penicillin-V (2) (Figure 7) is 
approximately 12 000 tonnes. Many other commercially important penicillins 
are produced by chemical derivatisation of 6-aminopenicillanic acid (3) 
(Figure 7). This important intermediate is produced from (1) or (2) by the 
bacterium E coli or by the appropriate amidase isolated from the micro-
organism. 
Biotransformation catalysts play many other important roles in both 
small, laboratory scale and large, industrial scale chemical transformations. 
Tightly controlled enzyme structure ensures highly regioselective and 
stereoselective recognition processes and therefore highly selective catalytic 
activity. Following the recommendations of the International Union of 
Biochemistry enzymes are categorised into six groups: Oxidoreductases; 
Transferases; Hydro/ases; Lyases; Isomerases; and Ligases. 
Oxidoreductases catalyse oxidation and reduction reactions involving the 
addition or removal of oxygen and hydrogen. An enzyme catalysing the 
reduction of a ketone to a secondary alcohol would fall into this class. 
Transferases catalyse the transfer of groups, such as amino groups, from one 
molecule to another. Hydrolases catalyse hydrolysis of molecules such as 
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esters and amides. Lyases catalyse the addition of HX (X ;j; OH) to alkene, 
imine and carbonyl groups. Isomerases catalyse isomerization process such 
as racemisation and epimerization. Ligases catalyse condensation reactions 
with the formation of C-O, C-N and C-C bonds. 
(1) (2) 
(3) 
Figure 7 Commercially Important Penicillins 
When using enzymes for biotransformations we can use either the 
whole cell or purified enzymes. There are advantages and disadvantages to 
each. When using whole cells we do not need to add any of the expensive co-
factors required. Whole cells are cheap and readily available. However, in 
using whole cells we can encounter problems such as undesirable side 
reactions and difficult work up from large aqueous volumes. Transport of 
substrates into the cells and of products out of the cells, may also be 
troublesome. Using purified enzymes makes biotransformations easier to 
control and monitor. The transformations are highly selective, the work up is 
simplified and the use of organic co-solvents can be better tolerated. Purified 
enzymes can also be crystallised for X-Ray diffraction and modelling studies. 
The major disadvantage of using purified enzymes is the expense. Isolation of 
enzymes in reasonable yield often requires the organism to be genetically 
engineered to overexpress the required protein. Purification is also a difficult 
process, usually requiring several chromatographic steps to separate the 
required enzyme from the mixture of proteins and other biomolecules. Using 
purified enzymes may also require the addition of co-factors. Co-factor 
recycling may also be necessary. 
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1.08 Protein Purification 
Electrophoresis, along with chromatographic techniques are the key 
tools in the purification of proteins. 15 Very high levels of purity can be 
achieved by crystallisation of pre-purified protein. Indeed the uniform structure 
of the ordered crystal lattice is essential for three dimensional structural 
elucidation by X-ray analysis. 
The principle behind electrophoresis was mentioned briefly in section 
1.03. The migration of each individual component in a mixture of 
macromolecules in an electric field depends on the field strength, the net 
charge on the macromolecule and the frictional coefficient. The frictional 
coefficient depends on the mass and shape of the migrating compound and 
the viscosity of the medium. Electrophoretic separations are most commonly 
performed on gels but can also be done on solid materials such as paper 
(cellulose). Polyacrylamide gels are often the ones of choice because they are 
chemically inert and easily manufactured with control over pore size. 
Separations by electrophoresis are roughly in the order of mass, with the 
smallest compounds migrating more quickly. pH gradients can also be used in 
electrophoretic separations because at the isoelectric pH of a protein the net 
charge is zero and the 'electrophoretic mobility' is also zero. 
Electrophoretic techniques are limited in that they do not supply large 
quantities (milligrams) of the proteins in their native form. This is necessary for 
three dimensional structural and mechanistic studies. Other characteristics 
such as size, solubility, charge and specific binding affinity can be utilised to 
purify proteins. Proteins can be separated from small molecules by dialysis 
through a semipermable membrane. Centrifugation can be used in unison 
with dialysis to force the equilibrium towards removal of the small molecules, 
essentially the impurities are 'washed out.' 
Another widely used technique is gel filtration which relies on size 
distribution (Figure 8). The sample passes through a column containing a 
polymeric carbohydrate stationary phase with fixed pore sizes. Smaller 
molecules enter the pores and interact strongly. Larger molecules cannot 
enter the pores and so pass through the column more quickly. Gel filtration 
can be used to separate much larger quantities of protein than electrophoresis 
but the resolution is lower. 
Ion exchange chromatography (Figure 8) separates molecules on the 
basis of their net charge. For example a macromolecule with a net positive 
charge will bind strongly to a stationary phase containing carboxylate groups 
(cation exchanger), whereas a macromolecule with a net negative charge wi" 
pass through this system very quickly. pH gradients are used in ion exchange 
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chromatography to vary net charges when required . Salt solutions can also be 
used to 'displace' the bound macromolecules in a competitive manner. 
Affinity chromatography (Figure 8) is a powerful method of protein 
purification . A substrate of the enzyme is incorporated in the stationary phase, 
say glucose. The enzyme 'recognises ' the glucose and binds strongly. Other 
proteins and impurities are washed through . The desired protein is then 
displaced by washing with a solution of 'free' glucose. All of these purification 
techniques have been used by different groups to purify DHDPS from a 
variety of sources. 
Ion Exchange 
000 
oG) 0 
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Gel Filtration j Proteins of ~ different size 
~Add~n of 
Affinity Chromatography 
Figure 8 Chromatographic Techniques 
Recently the new technique of displacement chromatography has 
proved to be of value. 16 Displacement chromatography involves loading of the 
impure material onto a stationary phase as normal. The column is then eluted 
with a low molecular weight polyelectrolyte displacer (Mw < 2000) which 
totally displaces the other components from the adsorbent material. This 
results in the formation of a highly concentrated zone of components and 
competition for the adsorbent sites. As the displacer travels down the column 
the poorer binding components are eluted in the solvent flow first. This high 
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concentration technique results in excellent resolution with potential for 
separating closely related materials and for large scale industrial purifications 
which suffer from loss of resolution on scale up. Separation of the desired 
product from the displacer can be troublesome but ultrafiltration is a useful 
procedure to achieve this end. 
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Chapter 2 The Biochemistry of L-Lysine 
2.01 Introduction 
In this chapter we will concentrate on the biochemical importance of the 
a-amino acid L-Iysine. The need for lysine in mammalian nutrition and the 
chemical synthesis of this amino acid will be discussed. The biosynthetic 
pathways to this amino acid found in fungi, plants and bacteria and the value 
of targeting these pathways for chemotherapeutic benefit will be considered. 
Our studies are concentrated on the transformations promoted by the first two 
enzymes of the diaminopimelate (DAP) biosynthetic pathway to L-Iysine: 
dihydrodipicolinate synthase (DHDPS) and dihydrodipicolinate reductase 
(DHDPR). These enzymes will be discussed in detail. In the following chapters 
we will look at the synthesis and testing of potential inhibitors and substrates 
of these enzymes. 
2.02 The Importance of L-Lysine 
The requirement for lysine in mammalian diets dictates the commercial 
importance of this amino acid. The estimated daily nutritional requirements of 
the nine 'essential' amino acids are detailed in Table 1. Proteins from meat, 
fruit, vegetables and dairy produce are the main sources of amino acids in the 
human diet. In the body proteins are metabolised by hydrolase enzymes into 
their amino acid units. The free amino acids are then available for the 
genetically controlled synthesis of proteins essential for sustaining life. 
Amino acid Required daily amount (mg/kg) 
Isoleucine 10 
Leucine 14 
L-.Ysine 12 
Methionine 13 
Phenylalanine 14 
Threonine 7 
Tryptophan 4 
Valine 10 
Table 1 Nutritional Requirements of the Essential Amino Acids 
20 
The nutritional value of proteins in the diet is dependent on the quantity 
and balance of their constituent amino acids. The balance of amino acids in 
the diet is very important because protein synthesis is restricted by deficient 
levels of anyone of the amino acids. In plant protein, and especially cereal 
protein, L-Iysine is the limiting amino acid. It is common practice for food 
manufacturers to supplement their produce with synthetic sources of important 
nutrients such as L-Iysine. 
As well as the life sustaining role of L-Iysine in proteins, L-Iysine also 
plays an important role as a metabolite in the biosynthesis of some alkaloids. 
Alkaloids are a very large and diverse family of nitrogen-containing natural 
products with a wide range of biological activities. Typical examples are: 
cocaine; nicotine; mescaline; morphine and strychnine (Figure 9). 
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The early stages of the biosynthetic pathways involving L-Iysine (4) and 
its lower homologue L-ornithine (5) to form monocyclic systems are very 
similar (Scheme 6).17 The amino acids undergo decarboxylation to the 
diamines cadaverine (6) and putrescine (7), respectively. N-Methylation by 
S-adenosylmethionine, transamination (primary amine to aldehyde) and 
subsequent cyclisation produces the iminium salts (8) and (9). By this 
pathway and variations on it L-Iysine and L-ornithine are incorporated into 
pyrrolidine, piperidine, pyrrolizidine and quinolizidine alkaloids such as 
hyoscyamine, pseudopelletierine, retronecine and lupinine (Figure 10).18 
The biosynthesis of the pyrrolidine alkaloid hyoscyamine (10), from the 
iminium salt (9) is illustrated in Scheme 7. 19 
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Scheme 6 Lysine and Ornithine in the Biosynthesis of Alkaloids 
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Figure 10 Alkaloids Derived from Lysine and Ornithine 
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2.03 Commercial Production of L-Lysine 
The important biochemical role of the generic a.-amino acids means 
that there is an industrial demand for all of them for research and commercial 
purposes. All of the amino acids found in proteins are synthesised industrially. 
Monosodium glutamate and L-Iysine are produced in the largest bulk with 
annual production of 370 000 and 40 000 tons, respectively.20 Commercial 
production of amino acids is performed by extraction from proteins, enzymatic 
processes and by chemical synthesis. Extraction from proteins involves their 
formation by fermentation by microorganisms. Modern genetic engineering 
techniques allow the production of most proteinogenic amino acids by 
fermentation methods. Auxotrophic mutants are microorganisms which lack 
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one or more of the enzymes required for the biosynthesis of an amino acid. 
Mutants of Corynebacterium glutamicum and Escherichia coli which lack 
homoserine are found to accumulate L-Iysine. 21 Lysine is a member of the 
aspartate family of amino acids. Blocking the route at the branching point to 
homoserine directs the biosynthesis towards lysine (see Scheme 10). 
Regulatory mutants are genetically modified to prevent the slowing or 
stoppage of the production of the required material. This usually involves the 
mutation of a protein in the biosynthetic pathway so that the organism cannot 
respond to the appropriate signalling mechanisms. L-Lysine can be produced 
in this manner by the mutated bacterium Brevibacterium flavum. 22 
Indus~rial production of L-Iysine from the synthetic unit DL-a-
aminocaprolactam (11) utilises enzymatic processes.23 Biotransformation of 
L-a-aminocaprolactam with L-aminocaprolactam hydrolase produces L-Iysine 
and the resulting D-aminocaprolactam is recycled by the enzyme a-
aminocaprolactam racemase (Scheme 8). 
NOH 
0 NOGI eYel NH3 .. .. 
cyclohexene 
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L-Lysine (1) 
L -Aminocaprolactam Hydrolase 
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D-a- aminocaprolactam -------
a- Aminocaprolactam Racemase (11) 
Scheme 8 Commercial Production of L-Lysine 
Chemical synthesis of the 'natural' amino acids is generally less useful 
because of the requirement for enantiomerically pure material. Although the 
field of asymmetric synthesis is well developed, the cost of chiral auxiliaries 
and catalysts counter the viability of this methodology for commercial purpose. 
Chemical synthesis is however very useful for the synthesis of 'unnatural' and 
novel amino acids. The synthesis of novel amino acids is very important in 
enzyme chemistry. Many enzyme metabolites are amino acids and the 
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synthesis of novel analogues of enzyme substrates is key to the study of the 
behaviour of an enzyme. Indeed, the synthetic work involved in our studies of 
the enzymes DHDPS and DHDPR has been almost exclusively in the field of 
amino acid chemistry. Lysine can be synthesised by a number of classical 
chemical procedures for the synthesis of a-amino acids such as alkylation of 
glycine derivatives; the Strecker synthesis and Curtius, Hofmann and Schmidt 
rearrangements. The synthesis of a-amino acids will be reviewed in the next 
chapter. Resolution of 'natural', 'unnatural' and novel racemic a-amino acids 
can be achieved by enzymic and diastereomeric derivatisation techniques. In 
our work we have utilised the enzymic resolution of N-acetylated amino acids 
by the enzyme porcine kidney acylase (PKA) and we will discuss this in the 
following chapters. 
2.04 Biosynthesis of L-Lysine 
The biosynthesis of L-Iysine in nature is observed via two mutually 
exclusive pathways.24 The a-aminoadipate (AAA) pathway (Scheme 9) is 
adopted in yeasts and fungi and the diaminopimelate (DAP) pathway 
(Scheme 11) is found in bacteria and higher plants. In the next section we 
wi" briefly discuss the AAA pathway. The remainder of this chapter 
concentrates on a detailed review of the DAP pathway.25 
2.05 The AAA Biosynthetic Pathway to L-Lysine 
The starting point for the AAA pathway is 2-oxoglutarate (12), a product 
of the Krebs cycle. Labe"ing studies with 14C-acetate in Saccharomyces 
cerevisiae26 and Torulopis utilis27 have shown that the carbon skeleton of this 
important metabolite is derived from acetate units. The first step of the AAA 
pathway involves carboxylation of 2-oxoglutarate with acetyl-CoA to form 
homocitrate (13). Homocitrate is isomerised to homoisocitrate (15) by 
dehydration to homoaconitate (14) and subsequent rehydration. Oxidation, by 
NAD+, and decarboxylation gives a-ketoadipate (16). The key amino acid 
intermediate a-aminoadipate (17) is produced by aminotransfer to a-
ketoadipate from glutamate and reduction. Regiospecific reduction gives a-
aminoadipate semialdehyde (18), which undergoes condensation with 
glutamate and further reduction to give saccharopine (19). Lysine (4) and 2-
oxoglutarate (12) are then produced from saccharopine by reaction with 
NAD+. 
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Scheme 9 The AAA Biosynthetic Pathway to l-Lysine 
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2.06 The DAP Biosynthetic Pathway to L-Lysine 
In Chapter 1 we mentioned that lysine, asparagine, methionine, 
threonine and isoleucine belong to the aspartate family of amino acids 
(Scheme 10). Aspartate (20) is derived from oxaloacetate via the citric acid 
cycle. In plants and bacteria, lysine is synthesised from aspartate by the 
diaminopimelate pathway. The basic carbon skeleton of lysine is formed by 
the condensation of aspartate and pyruvate (21) units. Biosynthesis of the 
aspartate family of amino acids involves the formation of the common 
intermediate aspartate-~-semialdehyde (23).28 This important metabolite 
results from selective phosphorylation and reduction of aspartate, catalysed by 
aspartate kinase and aspartate semialdehyde dehydrogenase, respectively 
(Scheme 10). At this point the biosynthetic pathway branches. Biosynthesis 
of lysine proceeds through a chain extending condensation with pyruvate. The 
other amino acids are biosynthesised via homoserine. 
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Scheme 10 The Aspartate Family of Amino Acids 
The DAP biosynthetic pathway to L-Iysine is illustrated in Scheme 11. 
L-Dihydrodipicolinate synthase (DHDPS) catalyses the condensation of L-
aspartate-~-semialdehyde (L-ASA) (23) with pyruvate (21) to produce L-2,3-
dihydrodipicolinic acid (L-DHDPA) (24).29 Recent X-Ray and NMR studies by 
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Blickling and co-workers30 have shown that the product of DHDPS at pH 
values above 9 is (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinic acid 
(HDPA) (33) (Scheme 14). Rapid decomposition of HDPA was noted at 
physiological pH. UV studies suggest that the decomposition proceeds by 
dehydration and subsequent oxidation to the stable aromatic derivative 
dipicolinic acid (DPA) (28). 
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Scheme 11 The CAP Biosynthetic Pathway to L-Lysine 
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The second step of the DAP pathway involves reduction by 
nicotinamide adenine dinucleotide phosphate (NADPH) under catalysis by the 
enzyme L-dihydrodipicolinate reductase (DHOPR) to L-2, 3,4,5-
tetrahydrodipicolinic acid (L-THDPA) (25). It is not certain if the substrate of 
the second enzyme is HDPA (33) or L-DHDPA (24), although rapid 
dehydration at physiological pH is likely. 
At this point the pathway splits; there are three known pathways to 
meso-DAP (27) and L-Iysine (4). The succinylase31 ,32 and 
dehydrogenase33.34.35 pathways are illustrated in Scheme 11. The third is 
the acetylase36 pathway which differs from the succinylase pathway only in 
that an acetyl group is transferred on ring opening of THOPA (25). Dual 
pathways are known to occur in some bacteria. The bacteria Corynebacterium 
glutamicum37 and Mycobacterium bovis38 are known to utilise both the 
succinylase and dehydrogenase pathways from THDPA (25) to meso-OAP 
(27) and lysine (4) and Bacillus maceranas39 is known to use both the 
acetylase and dehydrogenase pathways. 
In the dehydrogenase pathway L-THDPA is converted directly into 
meso-DAP (27) by the enzyme meso-diaminopimelate dehydrogenase. 
The first step of the succinylase pathway is the L-tetrahydrodipicolinate 
N-succinyltransferase catalysed succinylation of L-THDPA by succinyl-
coenzymeA. Subsequent amination by L-glutamate is catalysed by the 
enzyme N-succinyl-LL-diaminopimelate aminotransferase. Desuccinylation, 
catalysed by the enzyme N-succinyl-LL-diaminopimelate desuccinylase, 
produces LL-diaminopimelic acid (27), which is selectively epimerised to 
meso-DAP (28) by the enzyme meso-diaminopimelate epimerase. meso-
DAP (28) is common to all three pathways and is selectively decarboxylated 
to L-Iysine (4) by the enzyme meso-diaminopimelate decarboxylase. 
The later branching of pathways makes the search for potent inhibitors 
of the first two enzymes of the DAP biosynthetic pathway to L-Iysine and meso-
DAP particularly attractive. By inhibiting the pathway prior to the branching 
point we have potential for broad spectrum antibacterial activity. 
2.07 Inhibition of Lysine Biosynthesis 
A good understanding of a biological system can be of great advantage 
if we wish to utilise it. By far the most common example of this is the design of 
enzyme inhibitors for the purpose of blocking biological reactions. A very large 
proportion of modern day chemotherapeutic medicines rely on specifically 
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inhibiting undesirable biological transformations in the body. Similarly, 
enzyme inhibitors play an important role in agriculture, for the same reason. 
Understanding of a biological system can also be of great use to the 
biochemist and geneticist in manipulating the overexpression of a desired 
protein for isolation and purification. Indeed, we have relied heavily on our 
biochemical colleagues for the isolation and purification of the DHDPS and 
DHDPR enzymes for our studies. 
The biosynthesis of lysine in plants and bacteria is not fully understood. 
The earlier enzymes of this pathway, namely the condensing enzyme 
dihydrodipicolinate synthase (DHDPS) and the reductive enzyme 
dihydrodipicolinate reductase (DHDPR), have received little attention. Our 
studies have concentrated on the first two steps of this biosynthetic pathway, 
catalysed by DHDPS and DHDPR. Labelling studies have confirmed the 
occurrence of meso-2,6-diaminopimelic acid (meso-DAP) (38) in the pathway 
to lysine in pea chloroplasts.4o meso-DAP is utilised in the cell wall 
biosynthesis of many Gram positive and Gram negative bacteria. meso-DAP is 
attached to a N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) 
polymer via a short peptide unit and is employed in a cross-linking role 
between pentapeptide units (Scheme 12). This key role of meso-DAP lends 
mechanical strength to the bacterial cell wall. 41 
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Clearly in the DAP biosynthetic route to L -lysine we have all the 
attributes for targeting for antibacterial agents. Firstly, the amino acid is 
'essential' for mammals and must therefore be supplied as part of the diet. 
Consequently enzyme inhibitors of the DAP pathway are likely to display low 
levels of mammalian toxicity. Secondly, by inhibiting the production of meso-
DAP, we are denying the bacteria a key metabolite. Analogies can be drawn 
with the mode of action of the penicillin antibiotics where disruption of the 
bacterial cell wall biosynthesis results in osmotic stress and ultimate cell 
rupture. 
2.08 DHDPS as a Biotransformation Catalyst 
Another area of growing interest in enzyme chemistry is study of 
biotransformations with unnatural substrates. The DHDPS enzyme is of 
particular interest here because there are relatively few known enzymes which 
catalyse carbon-carbon bond formation with unnatural substrates.42 It is 
understandable that achieving this goal with the high regioselectivity and 
stereoselectivity and mildness of conditions commonly associated with 
enzymes is of great value in organic chemistry. 
One problem encountered in using isolated enzymes such as purified 
DHDPS is the regeneration of co-factors. In some cases this problem has 
been solved on a scale of several moles of substrate. The condensation 
catalysed by DHDPS involves imine formation between amino and ketone 
groups followed by aldol condensation and dehydration between an activated 
methyl group and an aldehyde. This process involves the loss of two 
molecules of H20 and does not involve any co-factors. Another factor in our 
favour is that the product of the condensation, the thermodynamically 
disfavoured DHDPA, is rapidly oxidised in air to the aromatic derivative 
dipicolinic acid. This forces the conversion of substrates into product to 
completion but unfortunately removes the stereocentre in the process. Recent 
studies30 suggest that keeping the pH above 9 will preserve the S-
stereochemistry at both the 2 and 4 positions. 
Because of the high substrate selectivity displayed by enzymes, 
inhibitors and unnatural substrates are very commonly closely related 
structural analogues of the natural substrates. In the following chapters we will 
discuss the synthesis of the natural substrates of the DHDPS and DHDPR 
enzymes and the synthesis of potential substrates and inhibitors modelled on 
each of the natural substrates. 
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2.09 Dihydrodipicolinate Synthase (EC 4.2.1.52, dapA) 
Characterisation of DHDPS has been achieved from bacteria and a 
range of plants including maize seedlings (Zea mays L.),43 spinach (Spinacia 
o/eracea)44 and wheat germ (Triticium aestivum). The enzyme has been 
purified from wheat cell suspension cultures, tobacco leaves (Nicotiana 
sy/vestris) and bacteria (E. colf29). The protein has been sequenced in E. coli, 
C. glutamicum, wheat and maize45•46 and has been shown to exist as 
homotetramers with four identical sub-units. 
For our studies we have used DHDPS purified from E. coli and are 
grateful to our biochemical colleagues here at Glasgow University for the 
overexpression and purification of both the DHDPS and DHDPR enzymes 
from this source. Purification of DHDPS of over 5000 fold from crude cellular 
extracts of E. coli W was first performed by Shedlarski and Gilvarg.29 They 
were able to study the enzyme and found that it was indeed a homotetramer 
comprising of four identical subunits. The molecular weight of the sub unit was 
determined to be 33 000 by SDS polyacrylamide gel electrophoresis.47 The 
amino acid sequence45 shows an absence of the amino acid methionine from 
the protein. The nucleotide sequence of the dapA gene locus predicts that the 
molecular weight of the protein produced from that gene sequence should be 
in the region of 31 372. The molecular mass of the native protein was 
estimated by the more gentle technique of gel permeation chromatography. 
The molecular weight obtained by this technique was 134 000; in agreement 
with the proposed existence of a tetrameric native form of DHDPS.29,47,48 
Purification of DHDPS from pea (Pisum sativum) was achieved by 
Schar and co-workers. 49 The protein from this source proved to have some 
interesting characteristics. The protein is a homotrimer of molecular weight 
127 000 and sub-unit molecular weight 43 000. It was found that the native 
protein contained 22 units of methionine in its composition, compared to zero 
in the composition of E. coli DHDPS. This suggests that these DHDPS 
enzymes are of a different evolutionary origin. Interestingly, the initial step of 
the enzymic mechanism was found to be common, namely, the formation of a 
Schiff base between pyruvic acid and the enzyme. 
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2.10 Purification of DHDPS 
A typical purification procedure for DHDPS, summarising the relative 
activity after each step, is detailed in Table 2. This method for the purification 
of E. coli DHDPS was elucidated by Borthwick,47,50 a former biochemical co-
worker here at Glasgow University. The cells were grown by incubation of an 
overproducing strain of E. coli (MV1190/pDA2) in MM63 minimal growth 
medium supplemented with ampicillin at 30°C for 48 h. The cells were broken 
in a French press at 95 MPa and centrifuged to remove particulate matter. 
Heating to 70°C and further centrifugation removed further unwanted 
proteinogenic material. The sample was then chromatographed on an DEAE-
Sephacel anion exchange resin, eluting with an increasing gradient of 
potassium chloride (0.1 to 1.0 M). The fractions showing DHDPS activity by 
UV assay were pooled and concentrated by dialysis. Ammonium sulfate was 
added to a final concentration of 0.5 M and the sample was further 
chromatographed on a phenyl-Sepharose column (hydrophobic interaction). 
The column was eluted with a decreasing linear gradient of potassium 
chloride (0.0 to 0.5 M) then fractions were pooled and dialysed as previously. 
Final chromatographic purification on a Mono-Q FPLC column (HR 10/10) was 
carried out by eluting with a two phase gradient of 0.1 to 0.5 M potaSSium 
chloride over 20 minutes and then a gradient of 0.1 to 0.5 M for a further 40 
minutes. The active fractions were pooled and dialysed once more and then 
stored as a 50% buffered aqueous 1 glycerol solution at -20 ce. the overall 
purification using this method was 49 fold. The enzyme can be obtained free 
from glycerol by centrifugation in a Centricon, a membrane filtration device, 
washing with approximately 4 ml of water. 
Volume Conc. Total Activity Specific Yield Purification 
(ml) (mglml) (mg) (ioU.) Activity (%) (fold) 
Step (units/mg) 
Crude 38 31 1180 1240 1.1 100 1.0 
extract 
Heat step 30 10 300 940 3.1 75 3.0 
DEAE- 170 0.43 72 2710 38 218 35 
Sephacel 
Phenyl- 192 0.25 48 2110 44 170 42 
Sepharose 
Mono-Q 35 1.0 35 1820 52 146 49 
Table 2 Purification of OHOPS from E. coli (MV1190/pOA2) 
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2. 11 Characterisation of DHDPS Activity 
Three assay systems have been developed to monitor DHDPS activity. 
The first involves monitoring the interaction between the enzymic product, 
DHDPA, and o~aminobenzaldehyde at 540 nm (OAB assay).51 The self 
condensing nature of o~aminobenzaldehyde, the chemical instability of 
DHDPA and the unidentified nature of the adduct make this a rather 
ambiguous assay. For this reason we have not used it in our studies. 
The second and most commonly used assay involves monitoring the 
production of the aromatic compound dipicolinic acid (DPA) (28) at 270 nm 
(synthase assay). DPA is produced by spontaneous air oxidation of 
DHDPA (24) (Scheme 13). In Chapter 6 we will detail the limitations of this 
assay for inhibition studies. We will also briefly mention our development of a 
related new assay system for the qualitative detection of substrate activity with 
DHDPS. This assay involves in situ deprotection of N-acetylated amino acids 
with the enzyme porcine kidney acylase (PKA) and is useful for unstable 
substrates. 
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The third assay is a coupled assay system involving both the DHDPS 
and DHDPR enzymes (coupled assay). In this assay the consumption of the 
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co-factor, NADPH, is monitored at 340 nm (Scheme 13). This assay is not 
subject to the same limitations as the previously mentioned synthase assay 
and has proved to be of great value in our studies. limitations arise in 
inhibition studies when we wish to determine the competitive nature with 
respect to the second enzyme, DHDPR. In Chapter 6 we will detail our work on 
a new assay system for the DHDPR enzyme alone. 
Using these assay systems with DHDPS derived from a number of 
sources the Km value for ASA (23) has been found to vary between 0.4 mM 
and 3.1 mM. The Km value for pyruvate (21) varies between 0.5 mM and 11.8 
mM. Kinetic studies in E. coli,52 wheat53 and maize54 (z. mays L.) suggest that 
the enzymic reaction involves binding of pyruvate (21), with loss of a 
molecule of water, followed by the binding and condensation with ASA (23). 
In E. coli DHDPS displays Ping Pong BiBi kinetics.29,48,53 
2.12 Mechanistic Studies on DHDPS 
Electrospray Mass Spectrometry (ESMS) is a mild method of studying 
compounds with large molecular masses. The technique involves formation of 
polycations by the polyprotonation of the compound in a 0.2% formic acid 
solution in water/acetonitrile (1: 1). A fine spray of this solution is then 
introduced into the mass spectrometer under high vacuum. Under these 
conditions the solvents are rapidly evaporated, leaving the 'dry' polycationic 
species. The polycations are then deflected by an electrostatic/magnetic field 
for detection. This technique is also of use for large molecules other than 
peptides, such as nucleic acids and man-made polymers and macrocycles. An 
illustration of an ESM spectrometer is shown in Figure 11. 
electrostatic 
lenses 
I 
CyUndricaJ 
electrode -~JIIII£ 
~====!' 
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Drying i First pumping 
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Figure 11 An Electrospray Mass Spectrometer 
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Using ESMS it has been established that the first step in the biological 
reaction catalysed by DHDPS is the binding of pyruvate to a lysine residue on 
the enzyme50 (Scheme 14). It is known that pyruvate (21) binds via the c-
amino group of lysine residue-161 in E. coli DHDPS.29,48,53 
One problem associated with the detection of any reaction intermediate 
is the short lifetime and low concentration of these states. Although 
observation of the first formed DHDPS/pyruvate imine intermediate (29) can 
be observed by ESMS as a very weak signal, the imine (29) can be 
selectively reduced by NaBH4, irreversibly binding the pyruvate to the enzyme 
(Scheme 14). As a result, the chemically reduced enzyme intermediate (30) 
can be easily observed by ESMS (Figure 12). The parent enzyme has a 
molecular weight of 31 272. The reduced intermediate (30) has a molecular 
weight of 31 344. The peak at 31 404 Daltons in the electrospray mass 
spectrum is presently unidentified. 
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36 
10 
31,344 
~-< 
eOOH 
% 
31272.0 
31044.0 
" ' ' / "\ .' ' 
31344.0 
1\ 
1 
31404.0 
/ 
\ (\ 
\ / \ \ ' 
-' \ 
\ 
\ 
\ 
~ ~'\ 
l~ '" f'...-...-~~--., 0+, -4-r,....,.....;..,.-,...,...,...,.-'o-r-.--rr-r..,...,...,...,....,....,..,...,.......,....,....,-,--,...,....,..,...-r-r:~...,...,-r-r-I-r.,-" """"""71"-" --r-r- mass 
31000 31100 31200 31300 31400 31500 
Figure 12 NaBH4 Reduced Pyruvate/DHDPS Intermediate (30) 
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The observation of the binding of ASA (23) to DHDPS by ESMS has 
been rather inconclusive, either with ASA on its own, with pyruvate, or with the 
reduced intermediate (30). As a result little is known about the binding of ASA 
to form the condensed intermediate (32). Chemically reducing the 
intermediate (29), or the enamine (31), blocks condensation with the ASA. 
Early evidence suggests that the ASA may bind with this deactivated complex 
(30). Further investigation of this is required. The cavity that accommodates 
ASA could interact through a covalent or an electrostatic binding mechanism. 
The early evidence indicates a covalent binding. However, if the aldehyde 
group is held as an imine, then trapping it with NaBH4 should be possible. 
Clearly there are too many possibilities to draw any firm conclusions. It is likely 
that the ASA-bound intermediate is too short lived for detection or trapping 
and it is notable that the imine intermediate (32) has also not been observed. 
X-Ray studies of Blickling and co-workers30 have however given some clues 
to this binding (see Scheme 15). 
Blickling and co-workers30 further identified the product of the 
condensing enzyme at pH 9 as (2S,4S)-4-hydroxy-2,3,4,5-
tetrahydrodipicolinic acid (HDPA) (33). This was achieved using 1 D and 20 
1 Hand 13C NMR spectroscopy. Labelling studies with pyruvate, [3-13C]-
pyruvate and [2,3-13C]-pyruvate allowed them to assign the signals. The 
assignment of 1 H NMR signals for unlabelled HDPA is illustrated in Figure 
13. 
Ha' 2.8 ppm (dd, J 18,6 Hz) 
He' 2.0 ppm 
!!is' 4.0 ppm 
Figure 13 Assignment of 1 H NMR Signals for HDPA (33) 
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2.13 The Crystal Structure of DHDPS 
The crystallisation and elucidation of the three dimensional structure of 
E. coli DHDPS has been achieved at 2.5 A resolution by Huber and co-
workers55 (Figure 14). The active site is a cavity formed by two monomers. 
Pyruvate binding residue Lys 161 lies at the bottom of a cavity 10 A wide by 30 
A long. The entrance to this cavity is formed by two aspartate residues (Asp 
187 and Asp 188). Interestingly, this adjacent aspartate relationship is 
common in all known DHDPS sequences. This implicates an important 
mechanistic role for this grouping. 
Figure 14 The Crystal Structure of E. coli DHDPS 
X-Ray studies by Blickling and co-workers3o involving DHDPS with 
pyruvate and pyruvate/succinate-~-semialdehyde identified the key 
interactions of the amino acid residues: Thr 44; Thr 45; Try 107; Try 133; Lys 
161; G Iy 186 and lie 203. The binding role of these residues for the proposed 
biosynthetic mechanism are summarised in Scheme 15. Isoleucine residue 
203 is considered to playa catalytic role in enamine formation from B prior to 
aldol condensation with ASA. The binding of the OH group of the condensed 
intermediate C was determined by experiments using pyruvate and succinate-
~-semialdehyde. 
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2.14 Activity of OHOPS with Unnatural Substrates 
A number of substrate analogues of DHDPS have been investigated as 
inhibitors. The enzyme has proved to be highly substrate specific. Pyruvate 
analogues such as phosphoenolpyruvate, phenylpyruvate, a-ketobutyrate, a-
ketoglutarate, oxaloacetate and fluoropyruvate are not recognised by the 
enzyme. Analogues of L-ASA such as N-acetyl-ASA,51 succinate 
semialdehyde,51 and D-ASA56 also show no activity. 
The best inhibitor of DHDPS reported to date is acetopyruvic acid (34), 
Kj 5 ~M.57 This compound has structural similarities with both ASA and 
pyruvate. Acetopyruvate exists in a number of tautomeric forms (Scheme 16) 
and is a less effective inhibitor at pH values above 8. This suggests that the 
most effective tautomer is in greater concentration at lower pH values. 
0 0 0 HO 
~o- AAyo-
(34) 0 0 
II II 
OH 0 OH 0 AJyo- AJyo-
0 0 
Scheme 16 Tautomerisation of Acetopyruvate 
Bromopyruvic acid was found to inhibit DHDPS (Kj 1.6 mM for E. coli 
and 1.8 mM for wheat).58 Coggins and co-workers showed by ESMS that it 
was possible to mono-alkylate DHDPS with four equivalents of this acid and 
that the enzyme retained 72 % activity under these conditions.5o This suggests 
that alkylation occurs close to but not at the active site. Treatment with an 
excess of bromopyruvic acid resulted in further alkylation (ESMS) and 
significant inhibition of activity. 
Dipicolinic acid inhibits the E. coli DHDPS with an IC50 of 1.2 mM.48 
This prompted a systematic investigation of numerous heterocyclic analogues 
of both dipicolinic acid (28) and DHDPA (24) by our group in Glasgow.59 
Substituted pyridine and piperidine derivatives were found to show moderate 
inhibition of E. coli DHDPS with 1Cso values of less than 1 mM (Figure 15). 
The best of the inhibitors were the dinitrile (36), the N-oxide (37) of pyridine-
2,6-dicarboxylic acid, the diimidate (38), the ditetrazole (39) and chelidonic 
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acid (41). Detailed kinetic studies60 showed that compounds (36) and (37) 
were non-competitive inhibitors with respect to either substrate. The X-Ray 
studies of Blickling and co-workers3o showed that DPA (28) does not bind 
directly into the active site but does however coordinate with mechanistically 
important residues Thr 44 and Tyr 133. The studies also showed that esters 
were poorer inhibitors than their acid congeners; a planar distribution of the 
substituents was preferred around the nitrogen atom; and that mono-
substituted ring systems also displayed poorer inhibition. In vivo studies of 
both DPA (28) and chelidonic acid (41) have shown inhibitory activity against 
the fungus Phytophthora infestas.61 
(28) R = H, IC 50 0.46 mM 
(35) R = Me, IC 60 4.6 mM 
(38) IC 50 0.20 mM 
(40) IC60 3.2 mM 
n NC ~N CN 
(36) IC 60 0.30 mM (37) IC 60 0.25 mM 
(39) IC60 0.25 mM 
(41) IC 60 0.30 mM 
Figure 15 Heterocyclic Inhibitors of DHDPS 
Lysine plays a regulatory role in plants and some bacteria. In wheat 
DHDPS L-Iysine is a weak competitive inhibitor with respect to ASA. In the 
bacteria E. coli and B. sphaericus, ICso values of 1 mM and 0.6 mM were 
observed, respectively.62 L-Iysine binds at the interface of two monomers of E. 
coli. DHDPS.30 Two lysine molecules are involved, in contact with both 
monomers and with each other. This interaction causes an appreciable 
conformational strain on the protein structure. Inhibition by L-Iysine has not 
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been observed in other bacterial stains.63 L-Lysine is a potent allosteric 
inhibitor of a range of plant DHDPS enzymes (Table 3). 
Plant IGso (IlM) 
wheat germ64 11 
tobacc065 15 
spinach66 20 
maize54 23 
wheat53 51 
Table 3 Allosteric Inhibition of DHDPS by L-Lysine 
L-Lysine analogues such as threo-~-hydroxy-L-Iysine (42) and (2-
aminoethyl)-L-cysteine (AEG) (43) show similar patterns of activity, but to a 
lesser extent. For wheat, compound (42) is inhibitory with an IGso of 141 IlM, 
as is AEG (43) with an IGso of 288 JlM.53 Other plant DHDPS enzymes show 
similar patterns of inhibition: AEG (43) inhibits DHDPS from tobaccos7 with an 
ICso of 120 IlM, and the enzyme from spinach with an IGso of 400 IlM.64 
OH 
H2N~C02H 
NH2 
(42) (43) 
2.15 Dihydrodipicolinate Reductase (EC 1.3.1.26, dapB) 
Dihydrodipicolinate reductase (DHDPR) catalyses the reduction of 2,3-
dihydrodipicolinic acid (DHDPA) (24) to 2,3,4,5-tetrahydrodipicolinic acid 
(THOPA) (25) (Scheme 11) by hydride transfer from NADPH. This enzyme 
has been purified from E. coli,68,69 maize,7o and Bacillus spp,71 DHDPR 
activity has also been detected in Chlamydomonas, corn, soybean and 
tobacco.72 The E. coli dap B gene has been sequenced by two groups. The 
resulting peptide is predicted to have 273 amino acid units73 and a molecular 
weight of 28 798. Overexpression, in E. coli, and subsequent ESMS studies 
on the protein have shown the molecular weight to be 28 758 ± 8,74 The native 
protein is a homotetramer. The maize enzyme shows similar behaviour 
towards substrates and inhibitors but has a molecular weight of approximately 
80000 for the native protein.70 
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2. 1 6 Characterisation of DHDPR Activity 
DHDPA is stable only if stored in basic solution at pH values greater 
than 10. The instability of the substrate DHDPA (24) makes the task of 
monitoring DHDPR activity rather difficult. DHDPA rapidly undergoes air 
oxidation to DPA (28). Indeed, it is this oxidative process that is utilised in the 
synthase assay for DHDPS activity. 
Two assay systems have been developed for DHDPR involving the 
synthesis of DHDPA. L-DHDPA (24) has been synthesised chemically70 by 
the condensation of L-ASA (23) with oxaloacetic acid (44) in alkaline solution 
(Scheme 17). L-DHDPA was precipitated as its barium salt. The compound 
was unstable and was stored at -80 DC. Only freshly prepared samples could 
be used in assays. Kimura75 synthesised DPA (28) by the direct condensation 
of ASA and pyruvate in alkaline solution. DPA was only produced when an 
aliquot of the reaction mix was incubated at 37 DC and pH 6.1 for 60 min. It 
was proposed that the formation of DPA under these conditions was by a 
disproportionation reaction of DHDPA. The final yield of DPA was enhanced 
by the presence of HgCI2 in the reaction mixture. It was considered that the 
mercuric ions were acting as electron acceptors in the oxidation of DHDPA to 
DPA. 
a 
H02C:L 
+H3N{: 
NaOH 
HocMco. + .. H02C 0 2 H+ 2 
(44) L-ASA (23) L-DHDPA (24) 
Scheme 17 Chemical Synthesis of L-DHDPA 
Shedlarski and Gilvarg29 synthesised L-DHDPA enzymically by the 
DHDPS-catalysed condensation of L-ASA (23) and pyruvate (21). We have 
already mentioned this method for monitoring DHDPS activity in section 2.11 
(coupled assay) and acknowledged limitations in quantifying results from 
combined enzyme systems. Shedlarski and Gilvarg suggested that the 
product of condensation of L -ASA (23) and pyruvate (21) is the heterocyclic 
compound 2,5-dihydrodipicolinic acid (45) in equilibrium with 2,3-
dihydrodipicolinic acid (24) and 4-hydroxy-2,3,4,5-tetrahydrodipicolinic acid 
(33) (Scheme 18). The recent mechanistic studies30 suggest that the latter, 
(33), is the immediate enzymic product. Dehydration of compound (33) at 
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physiological pH is a rapid process and would likely lead to the 
thermodynamically favoured compound (24). Furthermore we would 
acknowledge a likelihood of the presence of the conjugated enamine, 1,2-
dihydrodipicolinic acid (46) . 
. ~~ 
"-C' lN~CO H '-'~ H+ 2 U -.\\', ~-n-c .. , N CO H ....,.~ H+ 2 
(33) (24) 
1l 
ell \\\\ 
-0 C"" N CO H 2 H
2
+ 2 
Cl ,\\\\ ~ 
-n-c'" N CO H 
'-'".! H+ 2 
(46) (45) 
Scheme 18 Products of the Condensation Catalysed by 
DHDPS 
In the two assay systems using DHDPR, activity is assessed 
spectroscopically by the consumption of the co-factor NADPH at 340 nm. The 
instability of DHDPA makes both of these assays of rather limited value. In our 
studies we noted that at the preferred substrate solution pH (> 10) the activity 
of DHDPR is significantly lowered. For these reasons we have developed a 
new assay system involving the reverse reaction of DHDPR with its natural 
product L-THDPA (25) and co-factor NADP+ (reverse reductase assay). 
The L-OHOPA (24) produced by this process is irreversibly oxidised to DPA 
(28), thus driving the process to completion. The assay can be monitored 
spectroscopically by the production of NADPH at 340 nm or by the production 
of DPA (28) at 270 nm (Scheme 19). The synthesis of THDPA is important 
for the study of the OHDPR enzyme and as a substrate of the 
tetrahydrodipicolinate-N-succinyl transferase and meso-DAP dehydrogenase 
enzymes. Shapshak76 claimed to have made D-THDPA by the treatment of DL-
D A P (27) with the L-amino acid oxidase from Neurospora crassa. 
Unfortunately no chemical or spectroscopic evidence of the formation of D-
THDPA was provided. Kimura and Sasakawa77 reported the formation of DL-
THDPA (49) and OPA (28) by the disproportionation of 1,4-dihydrodipicolinic 
acid (48), formed by treatment of aa'-dioxopimeJic acid (47) with ammonia, 
either in the presence or absence of oxygen (Scheme 20). NMR spectra of 
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the products of this reaction produced in the absence of oxygen showed a 
mixture.78 Isolation of the required product proved impossible. 
Cl DHDP~ Cl ox~~tio~ n~ .,\\\, Q NADP+ .,\\\, Q Q 
-0 C·· N CO H -0 C·· N CO H HO C N CO· 2 H+ 2 2 H+ 2 2 H+ 2 
L.THDPA (25) 
Scheme 19 
Scheme 20 
(47) 
L·DHDPA (24) 
Production of NADPH can 
be monitored at 340 nM 
DPA (28) 
Production of (28) can 
be monitored at 270 nM 
Development of a New Assay for DHDPR Activity 
HOC£,lCO-2 H
2
+ 2 
.. 
(48) 
~ I 
HocMco-2 H+ 2 HocMco-2 H+ 2 
(28) (49) 
Kimura and Sasakawa Synthesis of DL-THDPA 
These problems were some of the first encountered in the project by our 
previous group members. After extensive research, a new chemical synthesis 
of racemic THDPA as its stable dipotassium salt (52), involving the 
elimination of p-toluenesulfinic acid from dimethyl cis-N-tosyl-piperidine-2,6-
dicarboxylate (51) by tert-BuOK was established78 ,79 (Scheme 21). 
Detailed study of the product by NMR spectroscopy showed it to exist in 
equilibrium with the enamine (53) and the open chain form (54) in the ratio 
2.8:3.7: 1, respectively. We have used this synthetic method for producing 
THOPA for the development of our reverse reductase assay. 
46 
HocMco-2 H+ 2 
(28) 
Ratio (52): (53) : (54) 
2.5: 3.7 : 1.0 (NMR) 
Scheme 21 
MeOH, c.H2S04 n 
.. Me02C NQ C02Me 
.. 
TsCI, py . 
(34) i H2, Pt02 
~04. 
Me02C'" N "'C02Me 
H 
(50) 
(54) 
Synthesis of THDPA 
2. 17 Mechanistic Studies on DHDPR 
Production of significant quantities of DHDPR from an overexpressing 
strain of E. coli allowed Reddy and co-workers to investigate the enzymic 
mechanism. 6o It was found that the enzyme could utilise both NADH and 
NADPH as a co-factor. NADH was the better cofactor with a Km (1.6 J.1M) 
approximately four times lower than that obtained for NADPH (5.6 11M). This is 
unusual because the rate of reaction with NADPH was approximately twice 
that observed when NADH was used (Vrel 100 for NADPH and 62 for NADH). 
Previously, tritium labelling studies had proved that NADPH donates its pro-R 
hydrogen to DHDPA (24). Reddy and co-workers investigated the position of 
hydride addition to DHDPA by deuterium labelling. DHDPA was reduced by 
NADPD under DHDPR catalysis and the product was then carried through to 
produce doubly deuterated meso-DAP (55), using meso- 0 A P 
dehydrogenase (Scheme 22). It is known that meso-DAP dehydrogenase 
transfers its pro-S hydrogen to the substrate to form the D-stereocentre.60 
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DHDPR 
.. 
NADPD Q \\\\\ b 
-f"\....C··· N CO H ,,~ H+ 2 
(24) 
.. 
(55) 
meso-DAP 
Dehydrogenase 
NADPD 
11- H20 
Scheme 22 Investigation of the Mechanism of DHDPR 
Comparison of the 500 MHz 1 H NMR spectra of unlabelled (A) (27) 
and labelled (8) (55) confirmed the donation of the pro-R hydrogen of 
NADPD to the 4-position of L-DHDPA (24) (Figure 16). In the doubly 
labelled sample (55) the signal at 0 1.83 ppm was not observed. The signal at 
() 4.35 ppm has a very similar coupling pattern in each case but is only half the 
intensity in the labelled sample. No attempt was made to distinguish the two 
C-4 proton signals to determine the face of the deuterium delivery onto L-
DHDPA (24). Thus the proposed mechanism (Scheme 23) involves transfer 
of the 4-pro-R hydride from the cofactor to the ~-position of the a~-unsaturated 
immonium ion, generating the enamine (56). Enzyme assisted protonation 
and subsequent release completes the reduction of L-DHDPA 24) to L-
THOPA (25). 
r.S- Enz 
GR -~ Q~l A' 1.~ ,,,, ~ 
-0:2C'''' t'J CO H -0:2C'" N CO H W 2 H 2 
L-DHDPA (24) (56) "-
rLc<,··QOH '-'"~ H+ 2 
L-THDPA (25) 
Scheme 23 Proposed Mechanism for DHDPR 
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Figure 16 500 MHz 1H NMR Spectra of Labelled (55) and 
Unlabelled (27) meso-DAp74 
2.18 Crystal structure of DHDPR 
The crystal structure of E. coli DHDPR and the bound NADPH co-factor 
at 2.2 A resolution was reported by Scapin and co-workers.80 The 
crystallisation was achieved for both the apoprotein and for the 
protein/NADPH complex. It is thought that a group of positively charged 
residues (His 159, His 160, Arg 161, His 162 and Lys 163) form the substrate 
binding site. Theoretical studies with DHDPA showed that these residues 
accommodate the substrate efficiently. A 30° rotation of the protein is required 
to bring the substrate and co-factor together for reaction. Further 
crystallographic investigations involving DHDPR with bound NADP+ and DPA 
(28) are currently ongoing. 
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2. 19 Inhibition of DHDPR 
Dipicolinic acid (28) is a linear competitive inhibitor of E. coli DHDPR 
with respect to DHDPA (24), with a Ki of 26 11M, and inhibits non-competitively 
with respect to NADPH, with a Ki of 330 11M. Inhibition by dipicolinic acid (28) 
is taken as evidence that it is the cyclic form, and not any ring opened form, of 
DHDPA (24) that is the substrate of the enzyme. Dipicolinic acid (28) was 
also found to be an inhibitor of DHDPR isolated from maize with a Ki value of 
0.9 mM.70 As with the E. coli enzyme the maize DHDPR binds the product in its 
cyclic form. A number of analogues of DHDPA (24) were also found to inhibit 
maize DHDPR (Table 4),70 iso-Phthalic acid (57) showed moderate 
inhibition with an IC50 value of 2 mM. Compounds with only one carboxylate 
group such as pipecolinic acid (58) and picolinic acid (59) were much less 
effective with ICso values of greater than 20 mM. Pyridinedicarboxylic acids 
such as 2,5-pyridinedicarboxylic acid (60) were found not to be inhibitory. 
(57) 
~Ci) 
H+ 
(59) 
Inhibitor % inhibition 
20mM 10 mM SmM 1 mM 
Picolinic acid (59) 24 4 8 0 
Pipecolinic acid (58) 23 30 0 0 
Iso-phthalic acid (57) 44 20 0 0 
Isocinchomeronic acid (60) - - 50 0 
Dipicolinic acid (28) - - - 100 
Table 4 Inhibition of Maize DHDPR 
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2.20 Alternative Targets for Inhibition of DHDPS/DHDPR 
THOPA (24) is a substrate for the enzymes L-tetrahydrodipicolinate N-
succinyltransferase, meso-diaminopimelate dehydrogenase and L-
tetrahydrodipicolinate N-acetyltransferase. Competitive inhibitors and 
substrates of these enzymes, particularly cyclic ones, are likely to show similar 
binding characteristics with both the DHOPR and DHDPS enzymes. Efficient 
binding into the active site of the enzyme is key to our search for potential 
inhibitors and substrates. 
2.21 L-Tetrahydrodipicolinate N-succinyltransferase 
(dapO) 
L-THOP N-succinyltransferase catalyses the ring opening succinylation 
of L-THDPA (25) to the stable aliphatic derivative N-succinyl-a-amino-E-
ketopimelic acid (61) (see Scheme 11). The co-factor succinyl CoA 
supplies the succinyl group which serves to protect against recyclisation. 
o C02H 0 
H02C~N~C02H 
H 
(61) 
Berges et al.32 investigated a number of cyclic and acyclic substrate 
analogues as inhibitors of L-THDP N-succinyltransferase. In general, the cyclic 
substrate analogues were shown to be poorer inhibitors (Figure 17). 
The trends noted here are very similar to those noted previously for 
heterocyclic inhibitors of DHDPS (see Figure 14). DPA (28), chelidamic 
acid (40) and chelidonic acid (41) show lower levels of inhibition in this case. 
It was noted that the trans-isomers were better inhibitors than the 
corresponding cis-compounds. 2-Hydroxytetrahydropyran-2,6-dicarboxyJate 
(62) was found to be a very potent inhibitor (Kj 58 ~M). It was proposed that 
compound (62) may be a transition state analogue of the hydrated 
intermediate (63). Related synthetic work in this area has been conducted by 
Roberts et al.81 
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C02H 
H02CYJ0 
H OH 
X=NH, Kj 2.0 mM 
X=O, Kj 0.68 mM 
X=CH2, Kj 144 mM 
X=S, Kj 1.1 mM 
Kj 1.8 mM 
(63) 
X=NH, Kj 63 mM 
X=O, Kj 3.9 mM 
X=CH 2, Kj 265 mM 
X=S, Kj 4.4 mM 
X= N (28), Kj 12.8 mM 
X=CH, Kj 8.5 mM 
X=NH (40), Kj 2.6 mM 
X=O (41), Kj 3.1 mM 
Ho,cMco"H HO,C4CO'H 
OH Y OH 
Y=H (62), Kj 58 11M 
Y=OH, Kj 200 11M 
cis, Kj 12 mM 
trans, Kj 5.6 mM 
Figure 17 Cyclic inhibitors of L-THDP Succinyltransferase 
3,4-Dihydro-2H-1,4-thiazine-3,5-dicarboxylic acid (DHT) (64) and L-2-
aminopimeJate (66) were found to be substrates of L- T H D P 
succinyltransferase (Table 5). The 1 H NMR spectrum of compound (64) 
shows it to exist mainly as an enamine. Compound (64) has a Km value of 2 
mM because only a very small proportion is present as the imine form (65) 
(Scheme 24). The activity of compound (64) with the DHDPS and DHDPR 
enzymes will be discussed in chapter 7. LL-a-Amino-£-hydroxypimelafe (67) 
and L-a-amino-D-£-hydroxypimeJate were also shown to display good 
substrate activity. Compound (67) was succinylated at 43% of the rate of (66) 
and a stereoisomeric mixture was succinylated at 121 % of the rate of (66). 
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(65) 
NH3+ OH 
-o.,C~C02H 
(67) 
Scheme 24 Substrates of L-THDP Succinyltransferase 
Substrate Km {8DD} V m{8DD} 
THDPA (25) 20 flM 21 flmol/min 
(64) 2mM 9.8 ~mol/min 
(66) 1 mM 14 ~mol/min 
Table 5 Substrates of L-THDP Succinyltransferase 
Berges et al.32 found that acyclic compounds were generally better 
inhibitors of L-THDP N-succinyltransferase (Figure 18). D-2-Aminopimelate 
(68) was a reasonable inhibitor with a Kj value of 0.76 mM compared to 4.5 
mM for pimelic acid (69). 0- and L-Aminoadipic acid (70), DL-aminosuberic 
acid (71) and 0- and L-norleucine (72) were very poor inhibitors of the 
enzyme. This indicates that both carboxylate groups are required for efficient 
binding to the enzyme and the chain length is equally important. LL-DAP (26) 
was found to be a poor inhibitor (Kj 19 mM) and meso-OAP (27) showed no 
inhibition. Replacement of a methylene group with a sulfur atom had little 
effect as DL -2-amino-5-thiapimelic acid (73) was found to have a Kj value of 
1.1 mM. 0- and L-2-hydroxypimelic acid (74) and the conformationally 
restricted compound, (2E,5E)-y-ketoheptadienedioic acid (75). were shown to 
be good inhibitors with Kj values of 0.19, 0.33 and 0.53 mM, respectively. 
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NH + ~ 3 
-~C~C02H 
(68) 
NH3+ 
-~C~ 
(72) 
OH 
H02C~Co..H 
(74) 
NH3+ 
-o..C~S~Co..H 
(73) 
o 
Ho..c~C02H 
(75) 
Figure 18 Acyclic Inhibitors of L-THDP N-succinyltransferase 
2.22 L-Tetrahydrodipicolinate Dehydrogenase 
(EC 1.4.1.16, ddh) 
L-THDP dehydrogenase catalyses the direct conversion of L-THDPA 
(25) into meso-DAP (27), utilising NADPH and ammonia (see Scheme 11). 
Lam et al.82 investigated the activity of several DAP analogues against 
L-THDP dehydrogenase from Bacillus sphaericus and LL-DAP epimerase from 
E. coli. They found that the enzymes were both specific for the meso-geometry 
of their natural substrates. The dehydrogenase enzyme was not appreciably 
inhibited by a range of DAP analogues. LL-Lanthionine (76) was a weak 
noncompetitive inhibitor with respect to meso-DAP with a Kj value of 38 mM. 
N-Hydroxy-DAP (77), N-amino-DAP (78) and 4-methylene DAP (79) 
showed 22%, 4% and 4% substrate activity, respectively, compared to meso-
DAP. 
meso-Lanthionine was a weak competitive inhibitor of the epimerase 
enzyme with a Kj of 0.18 mM, compared to 0.42 mM and 9.1 mM for the LL-
(76) and DD-stereoisomers respectively. N-Hydroxy-DAP (77) was found to 
be a very potent inhibitor with a Kj of 5.6 J,lM. N-Amino-DAP (78) also inhibited 
with a Kj value of 2.9 mM. 
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-~CfSIC02-
NH3 + NH3 + 
(76) 
(79) 
Abbott et al.83 conducted a similar study involving heterocyclic 
analogues of THDPA (25) (Figure 19). Isoxazole (80) was found to be a 
very potent competitive inhibitor of the dehydrogenase enzyme with respect to 
THDPA (25) with a Ki of 4.2 J.LM. The diastereoisomer (81) and imidazole 
(82) were much poorer inhibitors showing only 13% and 7% inhibition at 1 
mM. Interestingly compounds (83) and (84), lacking the side chains which 
make them close analogues of DAP are very poor inhibitors (7.5% and 2% at 
7.75 mM respectively). Heterocycles (80 to 84) were very much poorer 
inhibitors of LL-DAP epimerase from E. coli. 
-~C Ho,c'i~~'\fNH3 · 
N~ 
(82) 
(81) 
(84) 
Figure 19 Heterocyclic Inhibitors of L-THDP Succinyltransferase 
The inhibition of DHDPS by simple isoxazoles (85 to 88) and their 
open chain derivatives (89 to 91) was investigated by Dr J.E. McKendrick,84 a 
former member of our group (Figure 20). The ring opening was achieved by 
Pd catalysed hydrogenolysis of the N-O bond. These compounds also showed 
low levels of inhibition (Table 6). 
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Table 6 
R = CN (85) 
R = CO 2Me (86) 
R = COMe (87) 
R = CHO (88) 
Et02~R 
o OH 
R = CO 2Me (89) 
R = COMe (90) 
R = CH20H (91) 
Figure 20 Inhibitors of DHDPS 
Compound Inhibition of DHDPS at 1 
(85) 8% 
(86) 12% 
(87) 11% 
(88) 5% 
(89) 5% 
(90) 7% 
(91) 9% 
mM 
Inhibition of DHDPS by Isoxazoles and Open-chain 
Derivatives 
2.23 Conclusion 
In this chapter we have discussed the biochemical role played by of L-
lysine. The value of investigating the first two steps of the DAP biosynthetic 
pathway to L-Iysine has been in detailed. In the following chapters we will 
consider the synthesis and biological evaluation of metabolites and 
analogues of the DHDPS and DHDPR enzymes. 
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Chapter 3 Synthesis of Aspartate-~­
semialdehyde and Analogues 
3.01 Introduction 
In this chapter we will briefly review the basic principles behind the 
chemical synthesis of a-amino acids. The role of proctecting groups in amino 
acid synthesis will be considered. The synthesis of aspartate-~-semialdehyde 
(ASA) and analogues from allylglycine precursors will be discussed in detail. 
L-Aspartate-~-semialdehyde L-(ASA) (23) plays a key role in the DAP 
biosynthetic pathway to L-Iysine (Scheme 11, Chapter 2). In Chapter 2 we 
discussed the importance of ASA, derived from oxaloacetate via the citric acid 
cycle. The amino acids lysine, methionine, threonine and isoleucine are 
biosynthesised from L-ASA (23). Our studies in Glasgow have concentrated 
primarily on the DHDPS catalysed condensation of ASA and pyruvate (21) to 
produce the heterocyclic intermediate L-DHDPA (24). Purification of the 
second enzyme of the DAP pathway, DHDPR, by our biochemical colleagues 
here at Glasgow has allowed us to extend our studies over the last two years. 
It is of fundamental importance to the detailed study of any enzyme that 
a ready supply of the enzyme's natural substrates is available. These 
substrates are required for biological testing and mechanistic studies. The 
synthetic route may also allow us to make a number of analogues for testing 
as potential enzyme inhibitors or substrates. We are fortunate in that one 
substrate of the DHDPS enzyme, pyruvate, is a common metabolite and 
readily available as its pure, water soluble, sodium salt. 
The first synthesis of DL-ASA was reported in 1954 by Black and 
Wright. 85 Ozonolysis of DL -allylglycine (92) in 1 M HCI at 0 °C produced the 
required aldehyde. Black and Wright did not present any characterisation data 
for the ASA they produced but showed it to be reduced by homoserine 
dehydrogenase. In order to produce ASA in a form that could be isolated, 
characterised and stored, a former member of our group, Dr D.W. Tudor 
modified the Black and Wright synthesis. It was established that the purity and 
stability of ASA is greatly enhanced if the starting material (92) was first 
protected at both the acid and amine groups. After ozonolysis, the doubly 
protected aspartate semialdehyde was deprotected using trifluoroacetic acid, 
to yield the product as the stable trifluoroacetate salt of DL-aspartate-~-
semialdehyde hydrate (93), which was suitable for work with the DHDPS 
enzyme56 (Scheme 25). The overall yield for the four step process from (92) 
was 14%. Both stereoisomers of ASA have been prepared by this route from 
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enantiomerically pure starting material. D-ASA was shown not to be a 
substrate of E. coli DHDPS.56 
In our work, further modifications of protecting groups and reaction 
conditions have been implemented to optimise the purity of product and 
reproducibility of the synthesis. This will be discussed in section 3.06. 
(92) 
KHC03 
Me0'n 
~o 
Me0'n 
~o 
~B-CI/DMF 
o 
j 1.03/ CH2CI2 2. Et3N 
o 
I 
~~o\: 
o 
j CF,C02H I CH2CI2 
H02cJ.:~H CF,Co,-
(93) 
Scheme 25 Synthesis of ASA 
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3.02 Synthesis of Amino Acids 
The number of naturally occurring non-proteinogenic amino acids is of 
the order of 1000. Rapid expansion within the fields of chemical synthesis and 
semisynthesis of natural products and automated synthesis of polypeptides on 
solid supports ensure a constant demand for many amino acids. To satisfy this 
requirement there is a need for reliable synthetic methods for their 
preparation. Understandably, the research devoted to this task and detailed in 
the literature is truly immense. There is of course no definitive right or wrong 
way to set about the synthesis of a particular target and factors such as 
stereochemical requirements, economics, scale and environmental 
considerations must be taken into account. With so many options a good 
starting point is the many literature reviews in this area.86 Notable in this 
regard are the extensive studies of O'Donnell87 and Duthaler88 and the 
textbooks of Williams89 and Jones.90 
The stereospecific nature of most enzymes dictates the demand for 
stereochemicaJly pure material. As a consequence, for most applications in 
this field, there is a requirement for enantiomerically pure building blocks. To 
this end, the synthesis of amino acids is weighted towards asymmetric 
techniques, although enantiomeric resolution by chemical or enzymic 
methodology has appreciable value. 
As the literature concerning the synthesis of amino acids is so 
extensive, we will concentrate exclusively on a-amino acids, outlining the 
principles of their synthesis. In section 3.04 we will briefly discuss some of the 
asymmetric routes to allylglycines. 
Principally, there are five ways to synthesise a-amino acids: 
introduction of the acid group; introduction of the amino group; alkylation at the 
a-position; derivatisation of suitably functionalised amino acids and 
rearrangement of appropriate precursors. 
Introduction of an Acid Group 
The methods by which an acid group can be introduced during a 
synthesis are limited. The Kolbe-Schmitt reaction utilises carbon dioxide as a 
carboxylate synthon in the reaction with a phenoxide anion (Scheme 26). In 
theory, this could be applied to the synthesis of amino acids, using a 1,3-
dithiane as the nucleophile and generating an a-keto acid after hydrolysis. 
However, the role of the counter ion is very important in the Kolbe-Schmitt 
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reaction. Chelation to the carbon dioxide serves to activate the electrophile 
and generates a favourable six-membered transition state (94). 
+ 
Na·_ 
6
-0' .~ 
I : --J Na+ 
(94) 
Scheme 26 The Kolbe-Schmitt Reaction 
An alternative method, introducing the carboxylate group as the 
nucleophile, utilises the cyanide anion. This is the basis of the Strecker 
synthesis for amino acids, first reported in 1850.91 Condensation of ammonia 
or a primary amine with an aldehyde yields an imine. Treatment with cyanide 
and hydrolysis of the resulting a-aminonitrile yields the a-amino acid 
(Scheme 27). This method is highly versatile provided the alkyl side chain 
can withstand the reaction conditions, particularly the harsh conditions 
required for hydrolysis. Acid hydrolysis is commonly preferred since basic 
conditions would promote racemisation in asymmetric cases. 
Carboxylate groups can also be intoduced by oxidation of primary 
alcohols. Oxidation of 2-amino-2-alkylethanolic compounds could produce a-
amino acids. 2-Amino-2-alkylethanolic compounds could be produced by 
basic hydrolysis of terminal aziridines . 
• • • 
Scheme 27 The Strecker Synthesis of a-Amino Acids 
Introduction of the Amino Group 
Amino groups can be introduced in the final step of a-amino acid 
synthesis by addition of ammonia equivalents to a-keto or a-halo acids. 
Halogenation a to an acid group can be easily achieved by a variety of 
methods.92 Overalkylation is potentially a problem when using ammonia and a 
number of alternative strategies may be considered to introduce primary 
amino groups, such as: the Gabriel synthesis93 (Scheme 28); addition of the 
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azide anion followed by reduction; treatment with hexamethylenetetraamine94 
(95) and subsequent cleavage in ethanolic HCI; reaction with bis-
(trimethylsilyl)amide95 (96) and hydrolysis. 
Amino groups can be introduced as electrophilic species using 1-
chloro-1-nitrosocyclohexane (97). Standard enolate chemistry can thus be 
employed to incorporate the amino group. Classical methodology by Oppolzer 
et al.96 has been used to achieve this in an asymmetric manner. 
o 
DMF 
o 
R ~2NH2 A ~COH 
H2N C02P 
o 
Scheme 28 Amination of a-Halo Acids 
/ - Na+ 
rD. ~I -Si /\ N:: L-N::J ........ S/ N~ -I 0 
(95) \ (97) 
(96) 
Reaction between ammonia and highly reactive a-keto acids to yield an 
a-imino acid is relatively straightforward. Mild reduction conditions. such as 
NaBH4. must then be chosen to reduce the imine selectively in the presence 
of the carboxylic acid or equivalent group. A speculative method of achieving 
this in an asymmetric manner, linked to the asymmetric Strecker synthesis of 
Patel and Worsley,97 is illustrated in Scheme 29. In this case it is also 
possible to introduce stereoselectivity at the final reduction step by catalytic 
asymmetric hydrogenation.98 
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Scheme 29 Amination of a-Keto Acids 
Alkylation of Glycine Equivalents 
Modification of the carbon skeleton of glycine by alkylation can be 
achieved by nucleophilic or electrophilic reactions of appropriate glycine 
equivalents. N-Acylaminomalonates and N-benzylimino acid equivalents are 
important nucleophilic glycine equivalents in this regard (Scheme 30). 
P.h P~N/"'-...CN 
(98) 
R 
+HaN~co, .. 
NHAc 
Na/ EtOH R I .. 
--_ .. ~C02Et 
Decarboxylation 
AX 
.. 
50% NaOH / Et20 
BTEAC 
5% NaOH, /). 
C02Et I Hydrolysis 
NH3+ R0co2-
C02H 
Ph R Ph~~CN 
12M HCI 
R 
cr +H3N~CN 
Scheme 30 Alkylation of Nucleophilic Glycine Equivalents 
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Both are readily deprotonated at the a-position by virtue of their acidic 
hydrogens. Condensation with appropriate alkyl halides and hydrolysis yields 
the desired amino acids. N-Benzylimino acid equivalents such as N-
(diphenylmethylene)aminoacetonitrile (98) are normally alkylated under 
phase transfer conditions to avoid over-alkylation. 99 O'Donnell and co-
workers100 have performed asymmetric alkylations by this method using chiral 
Cinchona-derived phase transfer catalysts (99) and (100). Catalyst (99) 
favours formation of the (R)-enantiomer and catalyst (100) gives mainly the 
(S)-enantiomer. Reaction with allyl bromide under these conditions in the 
presence of catalyst (99) produced the protected allylglycine in 78% yield and 
62% ee. 
(99) (100) 
Electrophilic glycine equivalents are also of great value in amino acid 
synthesis. a-Bromo-N-BOC-glycine tert-butyl ester (101) can be prepared in 
high yield by irradiating the protected amino acid in the presence of N-
bromosuccinimide in CCI4. 101 , 102 Alkylation of the a-bromo species by 
Grignard reagents and deprotection yields the required amino acid. 103 
Protected a-hetero a-amino acids are known to exist in equlibrium with their 
imine forms (102) (Scheme 31). Loss of chirality at the a-position suggests 
that this would not be a useful procedure for asymmetric synthesis. However, 
as for many asymmetric syntheses, induction from further chiral tunctionallity 
can be a very useful technique. An example of this from Schollkopt and co-
workers 104 is illustrated in Scheme 32. 
Another important electrophilic glycine equivalent is the commercially 
available 2-acetoxy-N-(diphenylmethylene)glycine ethyl ester (103) which 
has been shown to be a very useful reagent in condensation with a wide 
range of carbon nucleophiles.105 
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(101) (102) 
(103) 
Scheme 31 Electrophilic Glycine Equivalents 
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Scheme 32 Asymmetric Alkylation of Electrophilic Glycine 
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Derivatisation of Commercially Available a-Amino Acids 
Partial synthesis of amino acids from suitably functionalised and readily 
available amino acid precursors can be a very useful procedure. This 
technique has been used for the synthesis of ASA from allylglycine (92) 
(Scheme 25). An advantage of this method is the opportunity to utilise the 
chiral pool for stereochemical purity. An elegant use of this methodology by 
Vederas and co-workers106 involves the displacement of the hydroxyl group of 
0- or L-serine by a wide range of nucleophiles. Intramolecular Mitsunobu 
esterification generates a reactive ~-Iactam (104) from N-protected serine 
(Scheme 33). There are restrictions to this process in the case of C-C bond 
formations. Deprotonation of the acidic NH proton by reactive organometallic 
reagents can lead to oxazoline or oxazolinone formation by nucleophilic 
attack at the ~-positon and the carbonyl of the ~-Iactone, respectively. 
Problems associated with regioselectivity of these hard nucleophiles could 
also be envisaged. Vederas and co-workersl07 performed selective 
alkylations in high yield using doubly protected amino-~-Iactams and relatively 
soft dialkylcuprate nucleophiles. 
N-Protected L -Serine 
R = tSu or Bn 
Scheme 33 
(104) 
Derivatisation of L-Serine 
Rearrangements Leading to a-Amino Acids 
A number of rearrangement reactions have also been employed in the 
synthesis of amino acids. The Hofmann, Curtius and Schmidt rearrangements 
all involve the replacement of a carboxyl function of a malonic equivalent by 
an amino group and proceed through a common isocyanate intermediate after 
migration of the alkyl group. Hydrolysis of an isocyanate yields a carbamic 
acid which rapidly decarboxylates under these conditions to yield the amino 
group (Scheme 34). 
In section 3.05 we will discuss the synthesis of allylglycine and 
analogues by a Claisen rearrangement of allylic esters. 
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Scheme 34 Hofmann, Curtius and Schmidt Rearrangements 
3.03 Protecting Groups in a-Amino Acid Chemistry 
Protecting groups play a very important role in synthetic chemistry_ 
Functional groups which are liable to take part in undesirable side-reactions 
for a particular process are first protected by transformation to a suitably 
unreactive derivative. Good synthetic strategy involves introducing the most 
reactive mOiety at the latest possible stage, by further chemical transformation 
or simply by deprotection. In Sheehan's10B total synthesis of penicillin V the 
highly reactive ~-Iactam ring was introduced at the final step by DCC coupling 
of the ~-amino acid precursor. 
To be useful for a particular task suitable protecting groups must fulfil 
certain criteria: the functional group to be protected must be selectively 
derivatised in good yield; the derivatised compound should ideally be easily 
crystallisable; the protected group must be inert to the conditions of any further 
reactions; after reaction the original functional group should be regenerated in 
high yield by deprotection under suitably mild conditions. 
Clearly, as for synthesis of amino acids, protecting groups play an 
immensly important role in synthetic chemistry. Unsurprisingly, the field of 
protecting group chemistry is well developed. The many literature reviews109 
and texbooks, such as those by Greene and Wuts110 and by Kocienski,111 are 
useful starting pOints when deciding on synthetic strategies. 
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Amino acids are an interesting class of compound with regard to 
protecting groups in that the amino and carboxylic acid groups can readily 
react with each other. Fortunately the process involves a simple and reversible 
proton exchange to form the familiar zwitterion. At high temperatures a-amino 
acids are known to self-condense, forming 6-membered bis-Iactam dimers. 
The simple proton exchange between acid and amino group has a 
fundamental effect on the properties of amino acids. The biological 
implications were discussed in chapter 1. Chemically, the uncharacteristically 
high polarity of amino acids means they are only soluble in highly polar protic 
solvents. Many synthetic applications require a less polar aprotic medium. For 
this reason the protection of amino acids for synthetic manipulation is almost 
routine. Carboxylic acids are most commonly protected as esters but can also 
be protected as amides and hydrazides. The latter two are somewhat less 
useful because harsh conditions are generally required for their cleavage. 
Amino groups are most commonly protected as carbamates but can also be 
protected as amides and as a range of other derivatives. In the synthesis of 
THDPA (Scheme 21) the amino group of the piperidine was effectively 
protected by tosylation, although in this case for the purpose of activation 
towards elimination. 
In our studies we have extensively used the protection of the amino and 
acid groups as tert-butoxycarbonyl (carbamate) and tert-butyl ester, 
respectively. These protecting groups have all the required attributes and can 
both be removed in the final step by treatment with anhydrous acid (see 
Scheme 35). Protecting both the acid and amino groups also allows us to 
use standard organic purification and analytical techniques such as 
chromatography in organic media. Chromatography in aqueous media is 
generally of lower resolution. On a preparative scale, removal of large 
quantities of water is considerably more difficult. 
o=c=o 
Scheme 35 Deprotection of tert-Butylcarbamates 
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3.04 Synthetic Objectives 
Previous studies within our group have shown that analogues of L -ASA 
(23), including D-ASA, are generally very poor inhibitors of the DHDPS 
enzyme. Importantly, D-ASA was also shown not to be a substrate of the 
enzyme.56 These results indicate a high substrate specificity for the synthase 
enzyme. Dr Tudor reported poor inhibition characteristics for a number of ASA 
analogues functionalised at the aldehyde, amino and carboxylate groups.112 
Dr S.J. ConnelP 13 prepared oxime, methoxime, semicarbazone and 
thiosemicarbazone derivatives of ASA. These compounds showed low to 
moderate levels of inhibition with DHDPS. Dr J.E. McKendrick prepared a 
number of alkyl substituted ASA analogues 114 (Figure 21). Once again 
these compounds were found to be very poor inhibitors. A key result however 
was that 2-methyl-ASA hydrate trifluoroacetate (105) and 3-methyl-ASA 
hydrate trifluoroacetate (107) were reported to show substrate activity with 
DHDPS. Compound (107) was reported to show 14% substrate activity. 
Interestingly the 2-ethyl (106), 3,3-dimethyl (108) and 2,3-dimethyl (109) 
analogues did not show substrate activity. In Chapter 2 we briefly mentioned 
the potential value of enzyme mediated C-C bond formation with unnatural 
substrates. DHOPS catalysed biotransformations with 2-methyl-ASA and 3-
methyl-ASA will be discussed in chapter 6. 
(107) 
OH 
(108) (109) 
Figure 21 Alkylated ASA Analogues 
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Our key objectives were therefore directed towards further 
understanding the nature of the interaction between DHDPS and compounds 
(105) and (107). Study of these compounds allows us a greater 
understanding of the mechanistic features of the enzyme and indicate any 
commercial potential. An important element of this study was the revision of 
the synthetic route to these compounds and further optimisation of existing 
methods. The syntheses were chosen with potential asymmetric application in 
mind, but, at this preliminary stage the stereoselection was left to the DHDPS 
enzyme. Although it is extremely likely that the enzyme will select only the L-
stereoisomer in each case, this would have to be proved on further 
development. 
2-Me-ASA is a very interesting case because it was shown that the 
product of DHDPS-catalysed condensation with pyruvate (21) had an 
absorbance maximum at 271 nm, similar to DPA (28). This evidence strongly 
suggests that the product is an aromatic compound. Complete substitution at 
the 2-position in 2-Me-ASA should prevent aromatisation. The expected diene 
product (110) would be expected to have a UV absorbance maximum at 
approximately 240 nm. Although there is clearly a thermodynamic drive for 
aromatisation there appears no obvious mechanism for the event. Prior to 
further investigation it was considered that there were three possible routes to 
aromatisation: decarboxylation; demethylation; through a 1,2-methyl shift 
(Scheme 36). This will be discussed further in chapter 6. 
OH 
2-Me-ASA 
Scheme 36 
(21) 
----'?~~~~--- ~ 
.", b HO c" N co -2 H+ 2 
" 
(110) 
, 
I 
, 
"" : 1 ,2-Methyl shift 
"", - C02 • 
~/ n ~NAC02- Ho"C N
H
+ C02-
H+ 
(111) (112) 
2-Me-ASA as a Substrate of DHDPS 
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3.05 Literature Syntheses of Allylglycines 
Allylglycine (92) is a key intermediate in Black and Wright S85 synthesis 
of ASA. For our studies a readily available supply of allylglycine and 
analogues was required. Analogues of allylglycine are not commercially 
available and must therefore be synthesised. To achieve this objective we are 
interested in adaptable synthetic routes. In an ideal case the synthesis could 
be directed asymmetrically towards either enantiomer and would involve a 
minimum number of protection and deprotection steps. In this section we will 
briefly discuss the synthesis of allylglycine by classical asymmetric 
methodology. The methods used previously within our group will be 
considered. In section 3.08 we will detail two other synthetic routes used in our 
current work. 
Allylglycine is commercially available as its D- and L-stereoisomers, as 
well as racemic material (92). DL-Allylglycine can be resolved by acetylation 
and subsequent enantioselective cleavage catalysed by the enzyme porcine 
kidney acylase (PKA) (Scheme 37).115 
PKA 
• 
(92) (113) 
Scheme 37 Enzymic Resolution of Allylglycine 
McKintosh et al. 116 produced D-allylglycine (115) by alkylation of 
camphor imine (114) (Scheme 38). The desired product was isolated in 
85% yield and 76% ee after hydrolysis. It is possible that the tert-butyl ester 
could be retained under milder deprotection conditions. This synthesis could 
however not be adapted to produce the opposite stereoisomer. 
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1. LOA 
2. allyl bromide 
.. 
3. 6M Hel 
Scheme 38 Asymmetric Synthesis of O-Allylglycine 
Evans and co-workersl17 have synthesised optically active allylglycines 
by the asymmetric introduction of the amino group (Scheme 39). Williams 
and co-workers118 have also achieved this by asymmetric alkylation of chiral 
glycine equivalents. In these cases the enantioselectivity is induced from 
chiral esters and oxazinones (2,3,5,6-tetrahydro-4H-oxazin-2-ones), 
respectively. Similar work by Oppolzer and co-workers,119 involving 
introduction of the amino group to chiral esters, could also be adapted for this 
purpose. 
0 
HO~R 
HolyR .. 
N3 
Scheme 39 
Bu Bu 
\ I 
O~N--CR ,/B, BU2BOTf {(~R ... 
oh;"" au.II.~ LCPh R3N 
recycled jNBS 
LiOH O~N~R . N3- O~N--LR LC ~ LCPh'*' Ph~r 
Asymmetric Amino Acid Synthesis by Evans 
Methodology 
Previous studies within our group by Dr McKendrick evaluated a 
number of synthetic routes to allylglycines: alkylation of nucleophilic glycine 
equivalent (98) under phase transfer conditions; direct alkylation of N-80C-
allylglycine tert-butyl ester (116); and Claisen rearrangement of N-protected 
glycine and alanine allylic esters. In the remainder of this section we will 
consider each of these in detail. 
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80CHN~02t8U 
(116) 
Alkylations of Amino Acids 
Synthesis of 3-substituted allylglycines by alkylation of glycine 
equivalents can be troublesome. Skinner et al. 120 synthesised 3-
methylallylglycine in approximately 5% yield by alkylation of ethyl 
acetamidocyanoacetate. Electrophilic allylic equivalents (117) can undergo 
competing SN2 conjugate additions and nucleophilic a"ylic equivalents 
(118) react more commonly through the less substituted position (Scheme 
40). These effects can be controlled in some cases by chelation (see later). Dr 
McKendrick used the two alkylation methods for the synthesis of 2-substituted 
allylglycines only. Both routes presented some difficulty. The phase transfer 
route to unsubstituted glutamate analogues is discussed in the next chapter. 
)R'2 x, SN2' ~ ~ x-:~ ~ ~ 
(117) 
X (Rn) 
",v M orMRn 
M Rny # • 
... 
--V ~ ~R" '".' 
(118) 
Scheme 40 Side Reactions with Allylic Equivalents 
Clasien Rearrangement Route to Allylglycines 
The Claisen rearrangement route to allylglycines from N-protected 
glycine and alanine allylic esters, originally reported by Bartlett and 
Barstow,121 is illustrated in Scheme 41. A combination of chelation control in 
formation of the enol ether and steric factors favouring the positioning of the 
bulky group in a pseudo-equatorial position for the rearrangement, favour anti-
diastereoselection in this case (Scheme 42). Addition of chelating agents 
such as ZnCI2 can improve diastereoselectivity.122 
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DCC/DMAP 
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1. LOA (2 equiv) 
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TMSO ~ 'B..o~N~O 
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(121) 
Scheme 41 Claisen Rearrangement Route to Allylglycines 
Scheme 42 
TMSCI ~ Th4S0y~ 
otsu H 
(121) 
Stereochemical Control in the Claisen 
Rearrangement 
3.06 Synthesis of Aspartate-~-semialdehyde 
Other than the original synthesis of ASA by Black and Wright and that of 
Robins and co-workers there has been one other synthesis reported by 
Gerrard and co-workers.123 l-ASA was isolated by a multi-step process 
involving enzymic resolution and protection of the aldehyde function as an 
enol ether. A number of syntheses of protected ASA have been reported. The 
aldehyde functionality of ASA is useful for further structural manipulation. A 
modification of the method of Cooper et al.124 by Baldwin and Flinn125 yielded 
protected L-ASA by PCC oxidation of L-homoserine derived from L-
methionine. Protected L-ASA was isolated in 40% yield for the one-pot 
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process. Similar studies by Rapoport and co-workers 126 resulted in the 
preparation of L-N-80C-ASA tert-butyl ester L-(122) from L-aspartic acid. The 
7 step process involved Et3SiH/Pd/C reduction of a thioester to generate the 
aldehyde function. 
For our studies the ozonolysis of protected allylglycine was the 
preferred method (Scheme 25). Previous work within our group had 
determined that the purity of the ASA synthesised was enhanced when the 
acid function was protected as a tert-butyl ester rather than the para-
methoxybenzyl ester. It is also noteworthy that the para-methoxytoluene 
byproduct must also be removed after deprotection. One disadvantage of 
protecting the acid as a tert-butyl ester was the poor recovery of material 
(43%). Formation of tert-butyl esters is most commonly achieved by treating a 
solution of the acid with isobutylene in the presence of a catalytic quantity of 
c. H 2 SO 4. Reversible protonation of isobutylene generates the 
thermodynamically stable tert-butyl cation which condenses with the 
carboxylate nucleophile. A high concentration of isobutylene in the reaction 
mix results in significant self-addition (Scheme 43). It is very important to 
realise that for this reaction with an amino acid a catalytic quantity of C.H2S04 
is actually greater than one equivalent. The first equivalent of C.H2S04 
protonates the amino acid, generating the acid salt. 
Scheme 43 Cationic Polymerisation of Isobutylene 
In our work it was found that side reactions were minimised and the 
yield of ester was improved to 83% if the reaction mixture was cooled to -78 
DC, prior to addition of isobutylene. After addition of C.H2S04 the suspension 
was stirred for 6 h at -78 DC and then at room temperature for a further 12 h. 
After BOC protection of the amino function with di-tert-butyldicarbonate 
(BOC20), ozonolysis generated the desired protected aldehyde (122). Ozone 
added to the olefin by a [3 + 2] dipolar cycloaddition (Scheme 44). 
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Scheme 44 
BOCHN 
) Et3N-O-
~_ CH20 
BOCHN C02tBu 
(122) 
Mechanism for the Ozonolysis of Alkenes 
Deprotection of N-BOC-ASA tert-butyl ester (122) proved to be a key 
process. Assay of ASA hydrate trifluoroacetate (93) with DHDPS indicated a 
poor yield (-40%). In order to develop a reliable biotransformation system for 
further development it was considered very important to optimise the purity of 
our ASA. It appears likely that the conditions of deprotection (50% TFA in 
CH2CI2, room temperature) promote decomposition. To address this problem 
a number of alternatives were considered, including in situ generation of ASA 
by enzymic cleavage of its N-acetyl analogue. This process is discussed in 
detail in the next chapter. 
Rapoport and co-workers127 reported selective cleavage of N-BOC 
protecting groups in the presence of tert-butyl esters by treatment with 500 
mol% of 1 M HCI in anhydrous EtOAc at room temperature. Consequently, it 
was considered that alternative protecting groups to the tert-butyl ester could 
be more appropriate for our studies. One protecting group which can be 
removed under milder conditions is the cumyl ester. Brunwin and Lowe 128 
showed that cumyl esters could be selectively removed in the presence of a ~­
lactam and a tert-butyl ester by anhydrous HCI in CH2CI2 at 0 °C for 3 min. 
N-BOC-allylglycine cumyl ester (123) was prepared in 72% yield by 
DCC coupling of the acid with cumyl alcohol. However, no further 
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investigations of compound (123) proved necessary because consecutive 
investigation of the deprotection of N-80C-ASA tert-butyl ester (122) with 
anhydrous HCI in EtOAc proved to be very successful. Treating the protected 
amino acid (122) with 1000 mol% of >2M Hel in anhydrous EtOAc at 0 C for 
4 h resulted in quantitative recovery of ASA as a white hydrochloride salt. As 
for the previous deprotection with TFA, NMR spectroscopy in 020 showed the 
compound to exist in its hydrated form (124) in solution. The advantage of this 
method over TFA deproteclion is the ease of handling of the Hel solution and 
the simple removal of the volatile byproducts under reduced pressure. TFA is 
a difficult material to handle and colour changes in stock solutions suggest a 
tendency for decomposition. In reaction with protected amino acid (122) the 
trifluoroacetate salt (93) produced Is a yellow coloured salt. One minor 
disadvantage of the deprotection. common to both TFA and HCI, is the 
tendency of the product to retain solvent. The 1 H NMR spectrum of compound 
(124) is illustrated in Figure 22. Signals are observed for both EtOAc and 
Et20 (used for trituration). Extensive drying under high vacuum, with genlle 
heating, did not remove this solvent. 
5.5 5.8 4.5 
PI''! 
cr NH3-f. OH 
HO,C¥OH 
, 
(124) 
II II 
4.8 3.5 3.8 2.5 2.11 1.5 
Figure 22 The 1 H NMR Spectrum of Compound (124) 
76 
BOCHN 
(124) 
ASA hydrate hydrochloride (124), produced by this method, was 
shown to display 218% relative activity when compared to its trifluoroacetate 
analogue (93) in a standard DHDPS assay. UV studies suggest a >80% 
conversion of L-ASA hydrate hydrochloride into DPA on DHDPS catalysed 
condensation with pyruvate (21). The modified synthesis of ASA is detailed in 
Scheme 45. The overall yield of compound (124) from allylglycine was 
66%. 
1. Isobutylono I C.H"so4 ) 
2. HCI.Et20 ... ~_ 
83% (92) 
o 
) 1.03 ~_ ----2-. E-t-3N--
BOCHN Co2tSu 82% 
(122) 
100% ' 5 
cr +H3N~C02:H 
(124) 
cr +H3N C02tBu 
(125) 
96%j BOC20 I KHCO, 
BOCHNJC021BU 
(116) 
Scheme 45 Modified synthesis of ASA 
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3.07 Synthesis of ASA Methyl Ester 
This modified synthesis of ASA was further utilised for the synthesis of 
aspartate-~-semialdehyde methyl ester hydrochloride (129) (Scheme 46). 
Previous attempts to make the trifluoroacetate salt of this compound had 
resulted in decomposition on deprotection with TFA. The milder HCI.EtOAc 
deprotection allowed us to negotiate this problem. Allylglycine methyl ester 
(126) was prepared in 33% yield from allylglycine (92) by stirring in 
methanolic HCI and basic work up. Protection with BOC20 gave N-80C-
allylglycine methyl ester (127) in 90% yield. Subsequent ozonolysis gave N-
BOC-aspartate-~-5emialdehyde methyl ester (128) in 53% yield. 
Deprotection, as described, yielded the desired amino ester (129) 
quantitatively. 
(92) 
1. dry HCII MeOH 
o C - room temp. 
.. 
2. basic work up 
CI"+H~~: 
(129) 
Scheme 46 
.. 
dry HCII EtOAc 
o 
BOCHNico,.Me 
(128) 
Synthesis of ASA Methyl Ester 
3.08 Synthesis of Methyl Substituted ASA Analogues 
In our work we examined a number of strategies to substituted 
allylglycines for the synthesis of ASA analogues: alkylations of amino acids; 
the Claisen rearrangement route used by Dr McKendrick and zinc coupling of 
a-imino esters and allylic bromides. The merits of each are discussed in the 
remainder of this section. 
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Alkylations of Amino Acids 
In this work the direct alkylation of amino acids by the =::self-reproduction 
of chirality method of Seebach and Fade/1 29 was investigated (Scheme 47). 
In the cyclisation step the bulky acid chloride, commonly pivaloyl chloride, 
approaches away from the neighbouring methyl group of the trans-imine 
(130). Resulting attack of the carboxylate group on the opposite face 
generates the (2S,4S)-cis-oxazolidinone (131) in high diastereoselective 
yield. After treatment with base the resulting enolate undergoes alkylation 
away from the bulky A-group in the 2-position. The overall result is retention of 
stereochemistry at the 2-position of the final substituted amino acid. Berner 
and co-workers 130 used this methodology for the asymmetric synthesis of 2-
methylallylglycine. Further development by Alonso and Davis,131 using 
ferrocene carboxaldehyde to form the imine (130), resulted in recovery of 2-
benzyl-L-alanine in 63% overall yield and >98% ee. 
.. 
Na+ ·0 0 ~X R/ ~N -" ACHO 
(130) 
R' 
-oyO .hydrolysis R .... '''<oyO _ .. _R_"X_ 
+H3N--'t·· .. · N~"-" 
R" O~ R" 
R' 
Scheme 47 Self-Reproduction of Chirality 
In our work the usefulness of this alkylation process was investigated by 
attempts to alkylate DL-alanine. The oxazolidinone produced will favour the 
racemic cis-diastereoisomers and the amino acid isolated after hydrolysis will 
be racemic. Essentially we are using the oxazolidinone as a doubly N-
protected amino acid equivalent. Treating sodium DL-alanate and 4A 
molecular sieves in anhydrous ethanol with benzaldehyde gave sodium trans-
N-benzylimino-DL-alanate (132) in 86% yield. NMR spectra of compound 
(132) were recorded in CD30D as it was found to be readily hydrolysed in 
020. In the 1 H NMR spectrum there are signals at 8 1.37 and 3.90, 3J 6.9 Hz, 
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for the protons in the 3- and 2-positions, respectively. The imine proton is 
found at B 8.22. There is no evidence in either the 1 H or 13C NMR spectra for a 
cis/trans isomeric mixture. Attempts to produce the corresponding 
oxazolidinone by cyclisation with pivaloyl chloride were unsuccessful. On 
treating imine (132) in anhydrous dichloromethane with pivaloyl chloride at 
-20°C a colour change was observed. However, after leaving the reaction at 
room temperature overnight, aqueous work up yielded mainly pivaloyl 
byproducts. Further attempts at cyclisation by the varied conditions described 
by Seebach and Fadel129 were also unsuccessful. 
P~N~COi 
(132) 
Claisen Rearrangement of Allylic Esters 
To investigate the usefulness of the Claisen rearrangement for 
preparation of allylglycines, N-BOC-glycine (119) and N-80C alanine (133) 
were prepared in quantitative yields by standard protection with BOC20. DCC 
coupling of compound (119) with (E)-crotyl alcohol produced ester (120) in 
85% yield. Attempts to promote rearrangement of compound (120) by the 
method of McKendrick were successful but the yield (37%) was disappointing 
(see Scheme 41). The highly reactive dianion produced prior to quenching 
with TMSCI may be unstable, with side reactions such as isocyanate formation 
possible. It is likely that these problems could be avoided by doubly protecting 
the amino group. One method of achieving this is detailed in the next chapter. 
Another minor disadvantage of this route is that alternative protecting and 
deprotecting conditions, avoiding C.H2S04, must be used for acid (134). DCC 
coupling of the acid with tert-BuOH gave the desired ester (135) in 43% yield. 
Further investigations with N-acetylglycine allyl ester (136) produced a 
rearranged product that was not easily purified. 
ACHN~O~ 
o 
(136) 
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Zinc Coupling of a-Imino Acids and Allylic Bromides 
The metal mediated coupling of allylic halides with aldehydes and 
ketones in aqueous media has been well documented. The reaction is similar 
to the Reformatski reaction of a-haloesters with aldehydes and ketones. 132 
Luche et al. 133 reported highly selective reaction of aldehydes over ketones 
with allylic halides. More importantly, the tin or zinc induced reactions are 
completely regiospecific. After insertion the metal chelates to the oxygen of the 
carbonyl. Alkylation then occurs via a six-membered transition state away from 
the end that originally bore the halogen (see Scheme 48). Recent studies by 
Hanessian and Yang134 have extended this methodology to the synthesis of 
allylic a-amino acids (Scheme 48). Coupling the allylic halide to a-
benzyloxoimino derivatives of glyoxalates and pyruvates produced the N-
benzyloxoamino acids. Cleavage of the N-O bond by Mo(CO)6 yielded the 
desired allylglycines. 
BnO, 
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A1" Y 
o 
A1 == H, R2 ::::: ipr 
R1 == R2 == H 
A1 == Me, R2 = Et 
+~~Br 
As 
R3 == H, Me 
~ == H, Me, Ph 
Rs == H, Me, C02Me 
~ )(371_ Mo(CO)6 
Zn powder, r.t. 
.. 
THF I NH4 CI(aq) 
(92-98%) 
T TNH2 
Rs C02R2 
MeCN/H~ 
(15:1), reflux 
/ 
Scheme 48 Zinc Coupling Route to Allylglycines 
Hanessian and Yang134 further reported that the process could be 
performed with high stereoselective control using the amide of a-
benzyloxoiminoglyoxylic acid and Oppolzer s (1 S)-( -)-2,1 O-camphorsultam 
(138). Treating compound (138) with allyl bromide yielded (S)-allylglycine in 
high yield and 93% ee after deprotection. When trans-cinnamyl bromide was 
used (2S,3S)-3-phenylallylglycine (139) was isolated in 88% yield and 99% 
ee, The stereochemistry was determined by X-ray analysis of the N-
benzyloxoamino camphorsultam derivative. 
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o 0 (138) 
NH2 
(139) 
To achieve this stereochemistry the phenyl group and amide group 
must be anti in the pseudo-chair transition state (140). It is possible to 
achieve a syn arrangement by rotating 180 about interaction 1-2 (N- -Zn) or 
bond 5-6 (C-C) but the resulting pseudo-boat form is sterically more hindered 
(Scheme 49). The homochiral camphorsultam directs attack to the Si-face 
(bottom as drawn) of the imine. It is worthwhile noting that to achieve this anti-
arrangement of phenyl group and amide group the imine must have the Z-
stereochemistry, contrary to that drawn for the transition state by Hanessian 
and Yang134 (137) (Scheme 48). 
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• 
COR* 
(137) 
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H 
top face 
j 180 rotation about N-Zn 
J;f Ph~l~ *ROC~N"-Zn 
I 
OBn 
pseudo-boat form 
NHOBn 
--. ~h·""COR" 
Ph 
.. 
anti 
(139) 
Ph""I'I'~ ~.,,= 'ROC 8 B NH08n 
anti 
Ph"'r~ "'11: B 
2 
,\,'\ 
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Stereochemistry of Zinc Coupling 
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This route to 2- and 3-methyl substituted allylglycines proved to be very 
useful in our work. The synthesis of these compounds and subsequent 
conversion into the corresponding ASA analogues is detailed in the rest of this 
section. 
Following the method of Ottenheijm and co-workers 135 a-
benzyloxoiminoglyoxylic acid (141) and a-benzyloxoiminopyruvic acid (142) 
were both prepared in 99% yield by coupling the corresponding acids with 0-
benzylhydroxylamine hydrochloride in water. Attempts to couple compound 
(141) directly with allyl bromide by the method of Hanessian and Yang134 
produced a product that was difficult to purify. As a result it was decided to 
protect the acid function as the tert-butyl ester. Treating compounds (141) and 
(142) with isobutylene and C.H2S04 gave a-benzyloxoiminoglyoxylate fert-
butyl ester (143) and a-benzyloxoiminopyruvate tert-butyl ester (144) in 91 % 
and 89% yield, respectively. Both compounds were isolated as colourless oils 
after chromatography. The imine proton of compound (143) is found at B 7.47 
in the 1 H NMR spectrum. The corresponding methyl signal of compound 
(144) is found at B 1.96 in the 1 H NMR spectrum and B 11.6 in the 13C NMR 
spectrum. The NMR spectra show no evidence of a mixture of cis- and frans-
isomers. It is proposed by the argument outlined earlier that the compounds 
have exclusively cis-geometry. 
N/O~ 
H)lC02A 
(141) R=H 
(143) R=tsu 
N/O~ 
Me)lCo,R 
(142) R = H 
(144) R=tsu 
Zinc-induced coupling of compounds (143) and (144) with allyl 
bromide according to the method of Hanessian and Yang134 produced 
protected allylglycine (145) and protected 2-methylallylglycine (146) in 
quantitative yield. In the 1 H NMR spectrum of compound (146) the signal for 
the 3-Me is found as a singlet at 0 1.28. Synthesis of the protected 2-
methylallylglycine (147) required more planning. 
BnOHN~o,tBU 
(145) 
BnOHN C02tsu 
(146) 
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The necessary bromide, crotyl bromide, was purchased as a mixture of 85% 
crotyl bromide and 15% 3-bromo-1-butene. To counter this, the quantity was 
adjusted and the activated zinc powder was added in two portions. As 
expected, the primary crotyl bromide reacted faster than the secondary isomer 
and the desired compound (147) was isolated in 99% yield without 
contamination. Inspection of the 1H NMR (Figure 23) and 13C NMR (Figure 
24) spectra confirm the presence of diastereoisomers. The 3-Me is found as a 
doublet at 8 0.95, 3J 6.9 Hz, in the 1 H NMR spectrum. GC analysis of the 
product showed the diastereomeric ratio to be 100:41. We would predict by 
our earlier argument that the anti-arrangement of ester and methyl group in a 
pseudo-chair transition state would be favoured. This would give a racemic 
mixture of the (28,38)- and (2R,3R)-stereoisomers as the major component. 
Assuming that our (E)-crotyl bromide and (Z)-(143) are stereochemically pure 
then the minor component of the mixture, racemic (28,3R)- and (2R,38)-
(147), must have arisen through a syn-arrangement of ester and methyl 
group in a pseudo-boat transition state. 
The next step of the syntheses involves the cleavage of the N-O bond to 
generate the free amino function and benzyl alcohol as a byproduct. Literature 
procedures for this process involve catalytic hydrogenolysiS or cleavage by 
MO(CO)6. 136 ,137 Since catalytic hydrogenation also reduces the olefinic 
function 134 then only the latter process was considered. Molybdenum 
promoted cleavage of N-O bonds proceeds through ligand exchange, 
reductive cleavage and release. The reaction is performed by heating a 
solution of the compound and 0.7 equivalents MO(CO)6 in 6% aqueous 
MeCN. The small volume of water assists in the release of the product by 
ligand exchange. In our work, early attempts to utilise this process were rather 
low yielding. After further investigations it was found that adding 1 % c.NH3 
(aq) to organic solvents for chromatographic purification improved the yield. It 
was considered that the ammonia further assisted in the release of the product 
from the molybdenum. Treatment of compounds (145) and (146) by this 
method gave allylglycine tert-butyl ester (148) and 2-methylallylglycine tert-
butyl ester (149) in 43% and 48% yield, respectively. Further developments 
revealed that extracting the product into 1 M Hel (aq), basifying (NaOH) and 
reextracting into EtOAc gave the pure product in high yield without 
chromatography. 3-Methylallylglycine tert-butyl ester (150) was prepared by 
this method from compound (147) in 77% yield. The work up involving acidic 
extraction is a very messy process, involving large solvent volumes, but 
produces a lighter coloured purer product in high yield. 
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Figure 24 The 13C NMR Spectrum of Compound (147) 
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After successfully preparing the substituted allylglycines the remaining 
steps to the aspartate-~-semialdehydes were performed as described 
previously for allylglycine tert-butyl ester hydrochloride (125) in section 3.06. 
Reaction of compounds (149) and (150) with BOC20 produced N-BOC-2-
methylallylglycinetert-butyl ester (151) and N-BOC-3-methylallylglycine-tert-
butyl ester (135) in 48% and 85% yield, respectively. Subsequent ozonolysis 
produced aldehydes (152) and (153) in 72% and 59% yield, respectively. 
The aldehyde signal of protected 2-Me-ASA (152) in the 1 H NMR spectrum 
was coupled to the diastereomeric protons at the 3-position: D 9.38; 3J 1.9 and 
1.2 Hz. Corresponding aldehyde signals for protected 3-Me-ASA (153) were 
found as singlets in the1H NMR spectrum at D 9.63 and 9.68 for the major and 
minor diastereoisomers, respectively. Deprotection by HCI in anhydrous 
EtOAc gave quantitative yields of 2-methylaspartate-~-semialdehyde hydrate 
hydrochloride (154) and 3-methylaspartate-~-semialdehyde hydrate 
hydrochloride (155). In the 1 H NMR spectrum of compound (154) the proton 
at the 4-position was coupled to the diastereomeric protons at the 3-position: D 
5.04; 3J 6.7 and 5.1 Hz. In the 13C NMR spectrum C-4 was found at () 88.2. 
The corresponding 13C NMR signals for compound (155) were found at () 
91.8 and D 92.0 for the major and minor diastereomers, respectively. 
The enzyme studies with 2-methyl-ASA, 3-methyl-ASA and ASA methyl 
ester will be discussed in chapter 6. 
(148) R = H 
(116) R = BOC 
RHN C02tBu 
(149) R = H 
(151) R = BOC 
o 
BOCHN~O"BU 
(152) 
(150) R = H 
(135) R = BOC 
cr %NX::H 
(155) 
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Chapter 4 Investigation Towards Glutamate-y-
semialdehyde as a Substrate of DHDPS 
4.01 Introduction 
L-Glutamate-y-semialdehyde L-(GSA) L-(156) is the higher homologue 
of the natural substrate of the DHDPS enzyme, L-aspartate-~-semialdehyde L-
(ASA) (23). L-GSA (156) is known to exist in equilibrium with the aminol 
(157) and the cyclic imine, 3,4-dihydro-2H-pyrrole-2-carboxylic acid (158) 
(Scheme 50). It is involved in the biosynthesis of L-proline from L-glutamic 
acid. 138 
L-(156) 
Scheme 50 Cyclisation of GSA 
-o.c-"""O N H+ 
(158) 
It was considered that this close analogue of ASA could exhibit 
substrate activity with DHDPS. The likely product of successful DHDPS 
catalysed condensation of pyruvate and GSA would be the seven-membered 
heterocycle L-3,4-dihydro-2H-azepine-2,6-dicarboxylic acid L-{1S9) 
(Scheme 51). This heterocycle has an interesting ring oxidation state and 
biotransformation of GSA could open a number of new areas of study. 
Investigation of the inhibitory characteristics of analogues of heterocycle 
(159) with DHDPS and DHDPR as well as the latter succinylase, acylase and 
dehydrogenase enzymes would be of interest. 
~o+ 
-~c NH3+ 
(GSA) 
Scheme 51 
O~C02H 
pyruvate (21) 
DHDPS 
._------------
3~6 
~l~l~ -~C ... ,\ 2 ~+ 7 C02H 
9 8 
L-(159) 
GSA as a Substrate of DHDPS 
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4.02 Literature Preparations of GSA 
3,4-Dihydro-2H-pyrrole-2-carboxylic acid (158) was prepared in 
racemic form by Strecker139 on deprotection of alkylated glycine equivalent, 
y,'y-dicarboethoxy-y-acetamidobutyraldehyde phenylhydrazone (160). Eto 
and co-workers14o achieved the in situ preparation of DL-GSA by acidic 
hydrolysis of GSA dimethyl acetal (161). No characterisation was presented 
for GSA but they successfully synthesised tryptophan by condensing the 
product with phenylhydrazine and subsequent Fischer indole formation. It is 
worthwhile noting that the condensation of phenylhydrazine with the cyclic 
imine (158) would be an equally viable route. GSA dimethyl acetal (161) 
was prepared by the method of Okuda 141 (Scheme 52). Michael addition of 
diethyl nitromalonate (162) to acrolein and in situ acetal formation generated 
alkylated glycine equivalent (163). Deprotection, reduction of the nitro group 
and purification yielded the desired acetal (161). 
NHAc 
Et02C~N"""N/Ph 
Et02C H 
(160) 
CHO N02 
Et02 c--1. ~ ./"'.... ... OMe 
Et02C/ '-" '( 
+) 
2. dry HCI 
.. 
Et02C~0Me _ .. ----H-2 ---
OMe 
(163) OMe 
j 1. NaOEt 2. AcOH 
r2 ~ .... OMe 
Et02C" "'-./ "I 
OMe 
12+ /""'-..... ..... OMe 
-0:2C" "'-./ I' 
(161) OMe 
Scheme 52 Synthesis of GSA Dimethyl Acetal (161) 
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The stability of GSA in aqueous solution is concentration dependent. 
Williams and Frank142 reported that GSA underwent 30% decomposition in 1 
h at 1 M but decomposed at a lesser rate in less concentrated solutions. Eto 
and co-workers14o noted that GSA could be preserved in aqueous solution by 
adding either phenylhydrazine, sodium hydrogensulfate, hydroxylamine or 
semicarbazide. 
In recent work by Bearne and Wolfenden143 compound (158) was 
prepared by periodic acid oxidation of allo-o-hydroxylysine. Proton NMR 
studies showed that compound (158) was in equilibrium with GSA (0.05% at 
physiological pH). At low pO values the spectrum was complex in the region of 
B 2 to 5, but signals were observed for the free aldehyde (GSA) (156) at <5 9.B. 
At pO 6.2 two well separated signals at 0 8.7 and 5.8 were observed for the 
imine (158) and hydrated aldehyde, respectively. The chemical shift of the 
imine proton varied with pD. Importantly, Bearne and Wolfenden made no 
mention of the intermediate 5-hydroxyproline (157) (see Scheme 50). The 
chemical shift of the proton in the 5-position of compound (157) would be 
very similar to the corresponding signal of hydrated GSA. 
Our group previously investigated a number of synthetic routes to GSA. 
Dr S.J. Connell extensively studied the alkylation of a number of glycine 
eqUivalents with 4-bromo-1-butene. 144 Phase transfer alkylation with N-
(diphenylmethylene)aminoacetonitrile (98) was found to be the most effective 
route to the higher homologue of allylglycine, 2-amino-5-hexenoic acid (164). 
Ozonolysis of compound (164), after protection, resulted in spontaneous 
cyclisation (Scheme 53). This cyclisation was noted in a similar process by 
Olsen et a/. 145 Doubly protecting the amino function, according to the method 
of Grehn and Aagnarsson,146 prevented cyclisation on ozonolysis (Scheme 
53). Deprotection with TFA produced impure material. 
NHBOC ~ / MeCN 
cat.D~ 
pMB = para-methoxybenzyl 
---~ 
2. Et3N 
N(BOC)2 rMB02C 
Scheme 53 Synthesis of Protected GSA 
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Derivatisation of glutamic acid is a useful method of synthesising GSA 
analogues. The synthesis requires non-symmetrical substitution of the two 
acid groups of glutamic acid. In earlier studies by our group Dr J.M. 
McKendrick attempted the synthesis of GSA by the derivatisation of glutamic 
acid (Scheme 54).147 The key step involves selective protection of the 
glutamic acid as the o-methyl ester hydrochloride (165). After further 
protection the methyl ester was selectively reduced with LiBH4. Attempts to 
oxidise the resulting alcohol (166) to the aldehyde once again resulted in 
cyclisation. The oxidation was performed by a modified Swern type oxidation, 
according to the method of Moffat148 (Scheme 55). The advantage of 
derivatisation routes is that a number of glutamic acid derivatives are readily 
available in enantiomerically pure form. 
Ho.C~co.­
NH3+ 
L -Glutamic acid 
SOCI2, MeOH, 0 °C 
.. 
~C02Bn 
HO I ~4~---------------------
NHCBZ 
(166) 
MeO.c~Co.H 
NH3+ cr 
(165) 
~ 
! 
Scheme 54 Non-Symmetrical Derivatisation of Glutamic Acid 
There are a number of alternative methods for the non-symmetrical 
derivatisation of glutamic and aspartic acid reported in the literature. Rapoport 
and co-workers126 detailed one such way, generating the free ~-acid function 
with aspartic acid in 5 steps. DCC coupling with EtSH and subsequent 
reduction with Et3SiH and Pd/C yielded the protected ASA (117). Bold et 
al. 149 incorporated the y-aldehyde function into doubly amino protected 
glutamate derivative (167) by a Rosenmund reduction reaction. Lee and 
Miller150 achieved the same transformation on acid chloride (167) by 
reduction with the sterically hindered hydride donors tributyltin hydride or 
lithium tri-tert-butoxyaluminium hydride. 
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HN.D 
TFA (0.5 equiv) / py (1 equiv) +! ~ 
NHCBZ O~ 'J'o 6NH BnO,c~ •• ~ 
+ OMS 
Bn02C~OH 
I 
CBZ 
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Scheme 55 
o 
BOCHN~o.,tBU 
(117) 
(166) 
~ 
Modified Swern Oxidation 
caz, 
~\ 
CI~O 
o 0 
(167) 
J 
+OCU 
a-Benzyl L-N-BOC-glutamate tert-butyl ester (169) can be prepared 
from the commercially available L -glutamate o-benzyl ester (168) by standard 
methodology (Scheme 56).145 Hydrogenolysis then generates the free 0-
acid (170) for further manipulation. Bold et al. 149 prepared bis-N-BOC-L-
glutamate-y-semialdehyde tert-butyl ester L-(174) from compound (169). The 
key step involves generating the aldehyde from the acid chloride (173) by 
Rosenmund reduction (Scheme 57). The acid chloride (173) is prepared 
from the corresponding acid by treatment with enamine (172).151 In the 
presence of acid labile protecting groups this reagent avoids potential 
problems associated with conventional acidic chlorinating agents. Compound 
(174) is of particular interest to us because, as discussed in Chapter 3, it can 
be deprotected in one step under anhydrous conditions and easily purified. 
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(168) 
1. isobutylene. C.H2S04. 
dioxane 
• 
82% 
HO"c~CO:!tBU 
NHBOC 
(170) 
Bn02C~co2tBU 
NHBOC 
(169) 
Scheme 56 Synthesis of Acid (170) 
7 (BOC) 2 
Bn02C~C02t8U 
r-;,J(80C) 2 
H ~ ~C02tBu 
o L-(174) 
.. 
H2.5% Pd/C. EtOH 
.. 
2,6-lutidinerrHF 
1(80C) 2 
H02C~C02IBU 
(171) 
~~~ 
CI (172) 
l(BOC) 2 
CIOC~C02tBU 
(173) 
Scheme 57 Rosenmund Reduction to Generate Aldehyde 
4.03 Objectives 
With little mention of GSA in the literature and lack of any 
characterisation data the low stability of this compound is clearly indicated. It 
was notable that the cyclic analogues prepared previously by our group 
showed no evidence of the open chain aldehyde in the NMR spectra. If the 
equilibrium concentration of GSA is very low then it may be very difficult to 
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realise the substrate potential with DHDPS. For these reasons it was 
considered in our current work that alternative strategies were required. 
It was considered that in situ deprotection of an appropriate aliphatic 
precursor would be worthwhile. Ideally, to achieve this task the aldehyde 
would be protected to avoid cyclisation. Aldehydes can be protected as 
imines, aceta Is and other similar derivatives. It is likely that imine protected 
GSA would also cyclise. Although acetal-protected GSA would not cye/ise the 
acidic conditions required for deprotection are not suitable for enzyme work. 
One other possibility is protection of the aldehyde as a sHyl enol ether. This 
protecting group however would not be stable in an aqueous environment. 
An alternative method of avoiding cyclisation of GSA, prior to in situ 
deprotection, is the protection of the amino function. In section 3.05 we 
mentioned the enzymic resolution of racemic N-acetylallylglycine (113) by the 
enzyme porCine kidney acylase (PKA) (Scheme 37). It was considered that 
this process could also be applied to N-acetylated ASA and GSA. Enzymic 
cleavage of these compounds by PKA under physiological conditions would 
generate the required L-amino acids in situ. To validate this theory our first 
task was the synthesis of N-acetyl-ASA. The preparation and evaluation of N-
acetyl~ASA as an inhibitor of DHDPS has been performed previously by our 
group.152 N-Acetyl-ASA was found to exist in its hydrated form (175) in 
solution. In our work compound (175) was prepared by the same method. In 
situ deprotection by PKA and DHDPS catalysed condensation with pyruvate 
proved successful. The assay system used for this purpose (Scheme 58) will 
be discussed further in Chapter 6. Having successfully developed this new 
assay system for testing protected amino acids the next objective was the 
synthesis of N-acetyl-GSA. This will be discussed in section 4.05. 
(175) 
Scheme 58 
ASA-hydrate (28) 
Monitor production 
of (28) at 270 nm 
Development of a New Assay for Detecting 
Substrate Activity 
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In our studies one other entirely different strategy for investigating the 
biological activity of GSA with DHDPS was considered. One advantage of 
working with enzymes is the reversible nature of catalysis. If the synthesis of a 
potential substrate is troublesome then investigation of the reverse biological 
process is a possible alternative. In this case the cyclisation of GSA would be 
a favourable event, displacing the equilibrium in our favour. The study of 
heterocycle (159) as a substrate of DHDPS is summarised in Scheme 59. 
The chemical synthesis of heterocycle (159) is however not a trivial matter. In 
section 4.06 the synthetic strategy towards this heterocycle will be discussed. 
TW"""O ~ 
(158) 
Scheme 59 Alternative Strategy for Investigating GSA as a 
Substrate of DHDPS 
4.04 Synthesis of N-Acetylaspartate-~-semialdehyde 
DL-N-Acetyl-ASA was required for developing the new assay system for 
in situ generation of amino acids. DL-N-Acetylallylglycine (113) was 
synthesised in 74% yield from DL-allylglycine (92) by treatment with acetic 
anhydride in NaOH (aq) according to the method of Black and Wright. 115 The 
methyl signal is found at 8 1.97 in the 1 H NMR spectrum and at B 22.3 in the 
13C NMR spectrum. DL-N-Acetyl-ASA hydrate (175) was then synthesised 
from compound (113) by the method of Tudor152 (Scheme 60). 
Esterification of compound (113) with isobutylene produced N-
acetylallylglycine tert-butyl ester (176) in 95% yield. Ozonolysis generated 
the desired aldehyde (177) in 82% yield. The aldehyde Signal is found at B 
9.73 in the 1H NMR spectrum and at 8 = 199.4 in the 13C NMR spectrum. 
Deprotecting the acid function of compound (177) with 50% TFA in 
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anhydrous CH2CI2 gave the desired DL-N-acetyl-ASA hydrate (175) in 59% 
yield. In the 1 H NMR spectrum the proton in the 4-position was observed to 
couple to the diastereomeric methylene protons in the 3-position; 0 4.94, 3J 
6.6 and 4.9 Hz. 
Development of the assay involving in situ deprotection of compound 
(175) allowed the original detection of substrate activity in ASA-methyl ester 
(129). Prior to the revision of the TFA deprotection of ASA and analogues, 
compound (129) was found to decompose at this stage in the synthesis. N-
Acetyl-ASA methyl ester (179) was synthesised by a modification of the 
method detailed above (Scheme 61). Testing of compound (179) in the 
assay involving the PKA and DHDPS enzymes showed moderate levels of 
substrate activity. 
(92) 
fl£-;,O 0 
NaoH(aq)" AN 
H 
(113) 
o ~OH 50% TFA in CH,CI, ~N~COH ------------
H 2 
(175) (177) 
Scheme 60 Synthesis of N-Acetyl-ASA 
ACHN~~~ 0 dry HCI / MeOH 1.03 i (113) .. .. o °C to room temp. 2. Et3N AcHN C02Me 
(178) (179) 
Scheme 61 Synthesis of N-Acetyl-ASA Methyl Ester 
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4.05 Attempted Synthesis of N-Acetylglutamate-y-
semialdehyde 
Having successfully synthesised N-acetyl-ASA by the method of 
Tudor152 it was decided to use the same methodology toward the higher 
homologue N-acetyl-GSA (181). It was considered possible that the amide 
(181) would undergo a similar cyclisation to that observed for the carbamate 
analogues prepared previously by our group. The greater electron 
withdrawing effect on the nitrogen lone pair in the amide compared to the 
carbamate was however in our favour. The synthesis of N-acetyl-L-GSA has 
been reported previously by Konodo. 153 N-Acetyl-L-GSA (181) was prepared 
by the persulfate oxidation of N-a-acetyl-L-ornithine (180) (Scheme 62). 
The only characterisation presented was the microanalysis of the 2,4-DNP 
derivative. It is feasible that 2,4-DNP could condense with the cyclic form 
(182). 
(180) (181) (182) 
Scheme 62 literature Preparation of N-Acetyl-GSA (181) 
In order to use the methodology detailed in the previous section it was 
necessary to synthesise first the higher homologue of allylglycine, 2-amino-5-
hexenoic acid (164). Compound (164) has been synthesised previously by 
our group and isolated as its hydrochloride salt (185)154 (Scheme 63). This 
was achieved from glycine equivalent N-(diphenylmethylene)-
aminoacetonitrile (98) by the phase transfer alkylation method of O'Donnell et 
al.99 
In our work, DL-2-(diphenylmethyleneamino)-5-hexenonitrile (183) was 
synthesised in 92% yield from N-(diphenylmethylene)aminoacetonitrile (98) 
and 4-bromo-1-butene in a two phase system (50% aqueous 
NaOH/dichloromethane). Deprotonation of (98) was performed in the 
aqueous medium. The resulting stabilised anion reacts with the alkyl halide in 
the organic medium. Benzyltriethylammonium chloride (BTEAC) ensures a 
significant equilibrium concentration of the anion of (98) in this medium. Mild 
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acidic hydrolysis of compound (183) gave the corresponding aminonitrile 
(184) in 61 % yield after basic work up. The nitrile function is significantly 
more robust to the conditions of hydrolysis required for the imine group and 
more forcing conditions are necessary for this purpose. The hydrolysis was 
performed by heating at reflux in both NaOH and Ba(OH)2 solution. Removal 
of excess barium ions in the Ba(OH)2 (aq) hydrolysis by precipitation as 
BaC03 is an advantage but was lower yielding. Compound (185) was 
isolated in approximately 70% yield by hydrolysis in 5% NaOH and 
subsequent acidification. Removal of the NaCI byproduct was considered 
unnecessary although this could have been achieved by ion exchange 
chromatography. The olefinic signals are found at 0 5.25 and 5.98 in the 1 H 
NMR spectrum and 0117.9 and 137.8 in the 13C NMR spectrum. 
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H02C (185) 
Scheme 63 
(184) 
Synthesis of 2-Amino-5-hexenoic Acid 
Hydrochloride (185) 
Compound (185) was protected as previously for allylglycine 
(Scheme 64). Treatment with acetic anhydride in NaOH solution gave N-
acetyl-2-amino-5-hexenoic acid (186) in approximately 84% yield. The 1 H 
NMR spectrum of compound (186) is illustrated in Figure 25. N-Acetyl-2-
amino-5-hexenoate tert-butyl ester (187) was prepared in 86% yield from 
compound (186) by treatment with isobutyJene and C.H2S04. The tert-butyl 
group is found at 0 1.47 and 0 26.3 in the 1 Hand 13C NMR spectra. 
respectively. 
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Scheme 64 Attempted Preparation of N-Acetyl-GSA (181) 
Unfortunately, ozonolysis of compound (187) resulted in a 77% 
recovery of the cyclic compound N-acetyl-5-hydroxyproline tert-butyl ester 
(189). The NMR spectra are fairly complex showing the presence of both 
diastereoisomers and rotamers. Signals are found at 0 5.49 and 5.75 for the 
proton in the 4-position. A very small signal is observed at 0 9.7 indicating a 
very small equilibrium concentration of the aliphatic aldehyde (188). The 13C 
NMR spectrum shows that the product is also a mixture of rotamers. Signals 
for C-5 are found between 0 80.2 and 81.4. There are eight signals observed 
for the two carbonyl carbons between 0 168.9 and 169.9. There is no evidence 
of any aldehyde carbonyl Signal. Deprotection of compound (189) with TFA 
yielded N-acetyl-5-hydroxyproline (190) in 53% yield. The NMR spectra of 
compound (190) were less complex. In the 1 H NMR spectrum a signal was 
found at 0 5.49 for the 5-position. The corresponding signals for C-5 were 
found at 0 83.2 and 83.6 in the 13C NMR spectrum (Figure 26) and the 
diastereomeric ratio was determined as close to 1: 1. There was no evidence 
in either of the spectra for any of the acyclic aldehyde or iminium ion (191). 
The biological analysis of compound (190) with the DHDPS enzyme will be 
discussed in chapter 6. 
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4.06 Strategy Towards the Enzymic Product of GSA with 
OHOPS 
The evidence suggests that GSA will exist almost exclusively in a cyclic 
form in aqueous solution. This makes it very difficult to gauge its potential as a 
substrate. Clearly the most feasible method for investigating the biological 
activity of GSA with DHDPS is the study of the reverse process (see Scheme 
57). The proposed product of the DHDPS catalysed condensation of GSA 
with pyruvate is the seven membered heterocycle L-(159). However, the 
recent studies by Blickling and co-workers3o indicate a likelihood that the 
hydrated precursor, (2S, 5S)-5-hyd roxy-3,4, 5, 6-tetrahyd ro-4H-azepine-2, 6-
dicarboxylic acid (28,55)-(192), may be the product. Consequently, the 
synthetic strategy should be applicable to both heterocycles (159) and (192). 
OH 
... 
4 j 
,0 
-0:2C ...•• 2 ~+ 7 C02H 
9 8 
(192) 
A number of synthetic strategies to heterocycle (159) have to be 
discounted. Where conjugate addition is possible on cyclisation five 
membered ring formation is both the thermodynamically and kinetically 
favoured outcome. An example of this is illustrated in Scheme 65. To 
overcome this problem it was considered that the unsaturation should be 
introduced after cyclisation. This strategy also assures the required cis-
geometry. 
o 
- -
Scheme 65 Five Membered Ring Formation 
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After consideration of a number of synthetic strategies towards 
heterocycles (159) and (192) it was decided that the direct condensation of 
protected GSA and pyruvate was the most viable route (Scheme 66). 
Enders and co-workers 155 have reported the use of pyruvate derivative (193) 
in the LDA promoted condensation with aldehyde electrophiles. It was 
therefore proposed that condensation of pyruvate derivative (144) with bis-N-
BOC-glutamate-y-semialdehyde tert-butyl ester (174) followed by ozonolysis 
and deprotection of the amino function would yield the required heterocycle 
(194). In section 4.02 (Scheme 57) the synthesis of bis-N-80C-L-
glutamate-r-semialdehyde tert-butyl ester L-(174) by Bold and co-workers149 
was discussed. 
~O 
N(BOC)2 
(174) 
OMe 
/OBn 
N LOA 
Aco,'BU ----------- IBt.O,C 
(144) o 
: 1.03 
: 2. 1 M dry HCI/EtOAc 
t OH 
(194) (195) 
Scheme 66 Proposed Synthesis of the Azepine Ring System 
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On preparation of heterocycle (194) the reaction conditions could then 
be tailored for or against elimination. Elimination to form the dihydroazepine 
(195) could be driven by tosylation of the alcohol function. It is likely however 
that the thermodynamically favoured extension of conjugation would occur 
spontaneously on deprotection of the tert-butyl ester groups in anhydrous 
acid. Indeed, it might be necessary to protect the alcohol to avoid this 
elimination until required. 
4.07 Non-Symmetrical Derivatisation of Glutamic Acid 
In our work, a variation on the derivatisation of glutamic acid used by Dr 
McKendrick (Schemes 54 and 55) was investigated for the synthesis of bis-
N-BOC-GSA tert-butyl ester (174). o-Methyl L-glutamate hydrochloride (165) 
was prepared in quantitative yield by the method of McKendrick (Scheme 
67).147 The methyl signal is found at 03.48 in the 1 H NMR spectrum. The ex-
acid function was protected as the tert-butyl ester (196) in 88% yield by 
treatment with isobutylene and C.H2S04. N-BOC protection was achieved in 
71 % yield by treating compound (196) with BOC20 and KHC03. In order to 
prevent cyclisation on generation of the y-aldehyde a second N-BOC group 
was then introduced by the method of Ragnarsson and co-workers. 146 
Ho,c~co,,­
NH3+ 
L-Glutamic acid 
SOCI2, MeOH, a oc.. Me02C~C02H 
NH3 + cr 
(165) 
j isobutylene, C.H2S04 
MeO,c~co,tBU. BOC.,o, KHCO, 
NHBOC 
Me02C~CO"BU 
NH2 
(197) 
~ ~.,?920, cat. DMAP, 
~N 
t MeO,c~C02BU 
N(BOC)2 
(198) 
(196) 
Scheme 67 Protection of Glutamic Acid 
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Treating a-methyl L-N-BOC-glutamate tert-butyl ester (197) with BOC20 and 
catalytic DMAP in MeCN produced the desired a-methyl L-NN-bis-BOC-
glutamate tert-butyl ester (198) in 67% yield. The signals for the tert-butyl 
ester and bis-N-BOC groups are found at 8 1.33 and 1.39, respectively, in the 
1H NMR spectrum. The corresponding signals are found at a 27.7 and 27.8, 
respectively, in the 13C NMR spectrum. 
4.08 Synthesis of bis-N-BOC-GSA tert-Butyl Ester (174) 
Having successfully protected L-glutamic acid our next objective was 
the selective transformation of the y-methyl ester into an aldehyde. To achieve 
this, selective reduction of the methyl ester to the corresponding alcohol and 
controlled oxidation to the aldehyde was proposed. There are a number of 
classical techniques for this oxidation, such as the Moffat oxidation, detailed in 
Scheme 55, PCC oxidation156 and oxidation catalysed by Dess-Martin 
periodinane (199).157 
(199) 
Brown and Narasimhan158 have reported the trimethylborate-catalysed 
selective reduction of esters over other reducible groups by lithium 
borohydride under a variety of conditions. In our studies it was found that the 
selectivity could be extended to the reduction of methyl esters over tert-butyl 
esters using trimethylborate in a catalytic role. Unfortunately, reduction of 
compound (198) with lithium borohydride in the presence of trimethylborate 
also resulted in cleavage of one of the BOC groups (Scheme 68). The 
resulting product, tert-butyl L-2-(tert-butoxycarbonylamino)-5-
hydroxypentanoate (201), was isolated in high yield (- 90%). It was therefore 
decided that the selective reduction was best performed on the mono-BOC 
precursor (197). After optimisation of the conditions it was found that the 
reaction proceeded efficiently in anhydrous ether at -10 oC, yielding 
compound (201) in 78% yield from compound (197). In the 1 H NMR 
spectrum (Figure 29) the protons in the 5-position are found as a triplet at 8 
3.59, 3J 6.1 Hz and the broad OH signal was found at a 2.42. Problems were 
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however encountered in attempting to introduce a second BOC group with 
compound (201). This problem arises from the nucleophilic nature of the 
alcohol function. Unfortunately, time restraints did not allow us to develop an 
alcohol protection/deprotection strategy to overcome this problem. On 
reflection, this is a highly efficient and economical route to non-symmetrically 
substituted glutamates which can easily be performed on a large scale and 
should be equally applicable to aspartates. 
(197) 
LiBH4, B(OMeb, 
Et20, O°C 
(201) 
O~C02IBU 
N(BOC)2 
(174) 
Scheme 68 
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.. 
MeCN 
x 
.. ' 
.. ' 
.. ' 
.. ' 
.-•••••• •· ••• ·.swern type 
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.' . 
Me02C~Co,.IBu 
N(BOC)2 
(198) 
~C02tBU 
HO I 
.. ' 
.. ' 
N(BOC)2 
(200) 
1 hydroboration 
~C02IBU 
N(BOC)2 
(202) 
Towards Aldehvde (174) 
In order to further the strategy toward heterocycle (159), in a tightly 
restricted time-frame, a two step preparation of the important intermediate 
(174) was performed (Scheme 69). Starting from the previously prepared 
N-BOC-allylglycine tert-butyl ester (116) a further butoxycarbonyl protecting 
group was introduced to the amino function. This was performed as described 
previously, with BOC20 and catalytic DMAP in MeCN, yielding the desired 
doubly protected amine (202) in 76% yield. The bis-N-BOC groups are 
observed at 0 1.43 in the 1H NMR spectrum and at 0 27.9,82.5 and 152.2 in 
the 13C NMR spectrum for the primary, quaternary and carbonyl carbons, 
respectively. The second step towards compound (174) involved a 'one-pot' 
hydroboration/oxidation. This process for conversion of terminal olefins into 
aldehydes was recently described by Yates. 159 After treatment of compound 
(202) with borane.DMS in situ oxidation was achieved by treating with 4-
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methylmorpholine~N~oxide (NMO) and catalytic tetra-n-propylammonium 
perruthenate (TPAP). The desired aldehyde (174) was isolated in 36% yield 
after work up and purification. It is likely that the low yield is due to the ligating 
affinity of nitrogen and oxygen lone pairs for ruthenium. Aldehyde (174) has a 
mp of 42-44 °C and carbonyl stretches at 1786,1732 and 1696 cm-1 in the IR 
spectrum. The distinctive aldehyde signal is found at 89.70 and 0201 in the 
1 Hand 13C NMR spectra, respectively. 
Although without the stereocontrol of the pre'vious derivatisation route 
and not as economical, this simple route allowed the preparation of a small 
quantity of the racemic material for further development of the strategy towards 
heterocycle (159). 
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Scheme 69 Alternative Synthesis of Compound (174) 
4.09 Condensation of Pyruvate with Aldehyde (174) 
Following preparation of aldehyde (174) the next step towards 
heterocycle (192) was the condensation with a pyruvate equivalent (see 
Scheme 66). It was decided to attempt the condensation of the previously 
prepared pyruvate analogue (144) (see section 3.08) with benzaldehyde, 
thus developing the methodology without using our limited supply of aldehyde 
(174). Unfortunately, when this condensation was attempted, following the 
method of Enders and co-workers,155 a 66% recovery of (203) which is the 
self-condensed pyruvate derivative (144) was obtained (Scheme 70). This 
indicates that the tert-butyl ester has insufficient steric bulk to prevent self 
condensation. To counter this problem we need to move more closely towards 
the bulkier 2,6-di-tert-butyl-4-methoxyphenyl ester (193) used by Enders and 
co-workers.155 One disadvantage of using a phenyl ester such as (193) is that 
we would reqUire the introduction of a further deprotection step for removal. 
Phenyl esters are readily cleaved under basic conditions (H202, H20, DMF, 
pH 10.5, 20 ec, 15 min).160 Alternate bulky protecting groups such as cumyl 
esters (-C02CPh(Me)2) and trityl esters (-C02(Ph)s) would also be worthy of 
consideration. Clearly, further development of this method is required, which 
we did not have time to complete. 
Ph, ..... 0 ~ 'N 
tBu02C~ 
(144) 
Scheme 70 
1. LDNLiBr, THF, -78°C 
.. 
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3. sat NH 4C1 (aq) 
o 
I 
N Ph~O/ 
(203) 
Self-Condensation of Pyruvate Derivative (144) 
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4.10 Synthesis of 5-Hydroxyproline (157) 
5-Hydroxyproline (157) is the immediate product of cyclisation of GSA. 
Consequently, the study of the interaction of this compound with the DHDPS 
enzyme is of interest to us. The only record of compound (157) which could 
be found in the literature concerned its synthesis and dated back to 1926. In 
this article Abderhalden and Schwab detailed the synthesis of compound 
(157) by the hydrogenation of pyroglutamic acid in acetic acid. 161 
Unsurprisingly, the characterisation presented for this compound was 
somewhat limited. Abderhalden and Schwab further noted the instability of 
this compound, characterised by a colour change on exposure to light. 
In our work, it was considered that the preparation of N-80C-5-
hydroxyproline tert-butyl ester (204) would allow us to generate the desired 
amino acid under milder conditions. The 'one-pot' hydroboration/oxidation 
method of Yates,159 discussed previously, was used for the synthesis of 
compound (204) directly from compound (116) (Scheme 71). The yield for 
the transformation was only 16% after purification. The 1 H NMR spectrum 
shows evidence of a diastereoisomeric product mix, in a close to 1: 1 ratio. The 
signal for the proton in the 5-position is found as a multiplet at 0 5.49. 
Preparation of 5-hydroxyproline could be achieved by the deprotection 
of either compound (204) or aldehyde (174) (Scheme 71). On 
examination of the characterisation data of these two compounds it was 
decided that aldehyde (174) was the purer of the two and thus presented 
greater chance of success. Consequently, the desired amino acid was 
prepared by treating aldehyde (174) with anhydrous HCI in EtOAc. The NMR 
spectra showed evidence for the preparation of 5-hydroxyproline 
hydrochloride (205), such as disappearance of carbamate carbonyls in the 
13C NMR spectrum and the presence of the expected signals. However, not 
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unexpectedly, the low stability of this compound meant its purity was not 
completely satisfactory. It must therefore be stressed that this method can only 
be described as a crude preparation and the biological results detailed in 
Chapter 6 should be considered similarly. 
tBu02Ct 
one-pot ~OH BH:yDMS, Et20 ... 
then 
NMO, TPAP tBu02C BOC 
(116) (2,04) 
: dry HCI.EtOAc 
t 
L O dry HCI.EtOAc .. ~OH tBU02C N(BOC)2 H02C H2+ cr 
(174) (205) 
Scheme 71 Synthesis of 5-Hydroxyproline Hydrochloride 
(205) 
4. 11 Conclusions 
In this chapter we have detailed two novel indirect strategies towards 
the investigation of GSA as a substrate of the DHDPS enzyme. The argument 
presented supports the view that our target compound, glutamate-y-
semialdehyde (GSA), is of low stability and is only ever present in very small 
equilibrium concentrations. The lack of any conclusive evidence in the 
literature supports this argument. Consequently, it is considered that it would 
be very difficult to derive meaningful conclusion from attempts to study direct 
interaction between GSA and the DHDPS enzyme. Our alternative strategy, 
however, has scope for success. One could query the value of achieving our 
objective, proving that GSA is a substrate of DHDPS, when clearly the 
instability of GSA dictates that little could be gained. We would argue that 
there are potentially two significant gains from our 'reverse' strategy. Firstly we 
would gain knowledge that analogues of both GSA and the seven-membered 
heterocycle have potential as inhibitors or substrates of DHDPS and related 
enzymes. And secondly we would have discovered a mild stereospecific 
method for producing GSA and possibly other analogues. 
The first strategy involved in situ generation of GSA from its N-
acetylated precursor by enzymic cleavage. This theory was validated by the 
synthesis and successful performance of a two enzyme assay system of the N-
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acetylated natural substrate. N-Acetyl-GSA was however observed to cyclise 
immediately upon preparation. This result discounts this strategy for this 
particular target but might be applied to other potential metabolites of DHDPS 
and to other biotransformations. Furthermore, the basic idea of in situ 
generation of GSA could be possible by alternate biotransformations. 
Our second strategy involved the investigation of the reverse process 
between the DHDPS enzyme and its likely product with GSA. Clearly the 
synthesis of the proposed seven membered heterocycle (159) is not a trivial 
task. However, we have established some sound methodology towards this 
end. In particular, the non-symmetrical derivatisation route of glutamiC acid, 
detailed in Section 4.08, is recommended for future adaptation of this strategy 
and for other relevant studies. 
4.12 Future Work 
There is scope for further developing the 'reverse' strategy for the 
investigation of GSA as a substrate of DHDPS. To that end, the proposed 
synthesis of heterocycle (159) by condensation of pyruvate and GSA units, 
will require amendment. The problem arises from generation of an enolate 
from the a-keto moiety (144). Intramolecular interaction can readily occur 
between the enolate and the ester unless there is significant steric restriction. 
In Section 4.09 we discussed the possibility of using bulkier pyruvate units. 
Alternatively, a pyruvate analogue with a non-electrophilic acid equivalent, 
such as one derived from pyruvonitrile, could be considered. Similarly, a 
derivatised free acid of pyruvate could be considered for generating the 
double anion for condensation with the GSA equivalent. 
One alternative strategy for the synthesis of the dihydro-(2H)-azepine 
ring system is detailed in Scheme 72. Key to this process is the construction 
of the carbon skeleton prior to cyclisation. We have proposed an 
'intermolecular ene' reaction between methyl glyoxylate (206) and protected 
amino acid (207) for this purpose. The synthesis of the parent amino acid of 
compound (207) was detailed in Section 4.05 (Scheme 62). Use of a Lewis 
acid catalysed 'ene reaction' for similar purpose has previously been reported 
by Vederas and co-workers. 162 Earlier investigations of this process by 
Agouridas et al. 163 indicated that when the steric bulk of the olefin was remote 
from the reaction site the cis-geometry was favoured (2:1). The next step of the 
synthesis involves oxidation of the secondary alcohol (208) to the a-keto 
moiety (209). Vederas and co-workers162 reported that this transformation 
was achieved efficiently by Dess-Martin oxidation. One difference in our 
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proposed method from that of Vederas and co-workers162 is the use of the 9-
fluorenylmethyl carbamate (FMOC) group for protecting the amino function. 
This protecting group is stable to both Lewis acids and oxidation. After 
oxidation, the FMOC group can be selectively removed from a-keto ester 
(209) by treatment with piperidine. This should lead to spontaneous 
cyclisation and dehydration to yield the dihydro-(2H)-azepine ring system 
(210). Hydrolysis of dimethyl ester (210) by the method of Vederas and co-
workers 162 would give the desired heterocycle (211). 
D Me02C ~ C02Me piperidine ~------------------
(210) 
"" LiOH 
" 
---- L': -~cJ~}C02- u' 
(211) 
OH 
NHFMOC 
(208) 
, 
: Dess-Martin i [0] 
, 
, 
t 
(209) 
NHFMOC 
Scheme 72 Alternative Synthesis of the Dihydro-(2H)-
Azepine Ring 
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Chapter 5 Synthesis of Inhibitors of DHDPS 
and DHDPR 
5.01 Introduction 
Previously, in section 2.06 and 2.07 the potential of blocking the DAP 
biosynthetic route to lysine with compounds which may have antibacterial or 
herbicidal activity has been discussed. In particular, it was noted that blocking 
the pathway at one of the first two steps, prior to branching into succinylase, 
acylase or dehydrogenase pathways to meso-DAP (27), had potential for a 
broader spectrum of activity. In section 2.14 and section 2.19 we reviewed 
work previously done on inhibition of DHDPS and DHDPR, respectively. The 
necessary binding nature of competitive inhibitors dictates, almost without 
exception, that each is a close substrate, transition state or product analogue 
of the enzyme or receptor in question. In sections 2.20 to 2.22 we mentioned 
an application of this property to further our objective of inhibiting the DHDPS 
and DHDPR enzymes. In this chapter we will consider two such cases: 
analogues of pyruvic acid (21) and sulfur-containing heterocyclic analogues 
of DHDPA (24) and THDPA (25). Our interest in these areas is justified by 
examination of previous findings. The synthesis of appropriate analogues to 
further the investigation is discussed. The biological activity of these 
compounds and conclusions therefrom are detailed in the next chapter. 
5.02 Pyruvic Acid Analogues as Substrates of DHDPS 
Since substrates and competitive inhibitors can be considered to 
interact with the active site of an enzyme then one should consider previous 
work in both areas for further development of inhibitors. Earlier studies within 
our group by A.A. Campbell, J.E. McKendrick and principally by Dr P. Mallon 
indicated a positive UV substrate assay for the simple pyruvate analogues 
methyl pyruvate (212), ethyl pyruvate (213) and pyruvamide (214) (Figure 
30). Further investigation showed that all of these compounds have almost 
identical electrospray mass spectra with DHDPS, after reduction with NaBH4, 
to that of pyruvate and DHDPS (Figure 12). From this we can conclude that 
it is likely that the esters (212) and (213) are hydrolysed to pyruvate before 
combining with the enzyme. The amide (214) is not so clear a case. It is very 
much less likely that this compound could be hydrolysed to pyruvate under the 
mild conditions of the assay. We also have the further problem that the 
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reduced DHDPS-pyruvamide adduct would have the same molecular weight 
as that for the reduced DHDPS-pyruvate adduct (30). We could possibly 
navigate around this problem by investigating an analogue with a higher 
molecular weight such as NN-dimethylpyruvamide (215). Ideally we would 
like to isolate, purify and identify products of our biotransformations. Some of 
the problems associated with this are discussed in the next chapter. 
O~C02M. O~C02Et O~CONH2 
(212) (213) (214) 
O~CONM.2 0 ~C02Et o~C02Et 
(215) (216) (217) 
Figure 30 Pyruvate Analogues with Potential Substrate Activity. 
Further studies by Dr. Mallon have shown substrate activity for ethyl 
acetoacetate (216) with DHDPS. On scaling up the process in the presence 
of ASA a small quantity of an amorphous solid was isolated. Treatment of this 
solid with ethereal diazomethane and subsequent GeMS analysis showed 
two peaks. The m/z value of the major product coincided with that of the 
expected biotransformation product. Problems were encountered however, 
with the interpretation of the NMR and IR spectra. It was considered that the 
problem could be in some part be due to the likely tautomerisation of the 
product (Scheme 73). This could possibly be avoided by the study of the 
derivative, ethyl aa-dimethylacetoacetate (217). The synthesis of compound 
(217) should be straightforward and the removal of the two reactive a-
hydrogens could be of further benefit. Dr Mallon also noted problems with 
attempted repetition of the biotransformation of (216). 
In our work, we found that the free acid analogue of compound (216), 
rather unexpectedly showed no substrate activity by UV. This may be related 
to its high reactivity. It is supplied as its lithium salt and it is quite likely that at 
the assay pH of 7.4 it readily enolises and undergoes self condensation and 
possibly decarboxylation. Furthermore it was found by UV assay that the 
'biotransformation' with ethyl acetoacetate (216) in place of pyruvate 
proceeded with equal efficiency without DHDPS enzyme. For these reasons 
we were led to conclude that the interaction of (216) with ASA was a non-
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enzymic aldol interaction producing the pyridine analogue (218) (Scheme 
74). 
EtO 
Scheme 73 Ethyl acetoacetate (216) as a Possible Substrate 
of DHDPS 
O~co,EI 
(216) 
im~ole _O~COzEI 
J ASA (23) 
Scheme 74 Non-Enzymic Reaction of Ethyl acetoacetate 
(216) 
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5.03 Pyruvic Acid Analogues as Inhibitors of DHDPS 
On the basis of the promising results for unnatural substrate activity of 
pyruvate analogues, demonstrating a non-specificity in substrate selectivity, it 
was recognised that there is scope for inhibition of the DAP pathway to L-
lysine at this point. Interest in this area was first explored by our former group 
members L. Couper and D. Tudor, and some promising results were achieved. 
The most effective pyruvate-based inhibitors164 of DHDPS were found to be: 
methyl pyruvate semicarbazone (219); methyl pyruvate thiosemicarbazone 
(220); the ethyl hydrazinoacetate derivative (221) of methyl pyruvate; the 
methyl hydrazinocarboxylate derivative (222) of methyl pyruvate; ethyl 
bromopyruvate semicarbazone (223); ethyl bromopyruvate methyloxime 
(224) and aa-dioxopimelic acid (225) (Figure 31). The results from 
inhibition studies with these compound are summarised in Table 7. 
Compound Inhibition of DHDPS 
(219) 10% at 0.1 mM 
(220) 10% at 0.1 mM 
(221 ) 62% at 0.1 mM 
(222) 100% at 0.5 mM 
(223J 50% at 0.1 mM 
j224) 14% at 0.1 mM 
(225)165 75% at 0.1 mM 
Table 7 Pyruvate Inhibitors of DHDPS 
A H2NCOHN-N C02Me 
(219) 
~Br 
MeO-N C02Et 
(224) 
A ~NCSHN-N C02Me 
(220) 
~Br 
H2 NCOHN-N C02Et 
(223) 
o 0 
H02C~Co"H 
(225) 
Figure 31 Pyruvate Inhibitors of DHDPS 
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5.04 Synthesis of Pyruvic Acid Analogues 
As pyruvic acid is a fairly simple molecule, there are relatively few 
variations on its structure that we can explore. Experience has shown that 
despite their simple appearance, small compounds of this type are often 
highly reactive and therefore difficult to work with and purify. Pyruvic acid itself 
is a rather unstable compound exhibiting a tendency to decarboxylate and 
polymerise. Indeed, pyruvic acid has been noted to polymerise even in frozen 
aqueous solution. 166 There are a number of synthetic transformations leading 
to a-keto acids and these have been well documented in a review by Cooper 
and co-workers.167 Our studies have followed on from the recent work of our 
group and concentrated on the derivatisation of pyruvate esters. Pyruvate 
esters are generally easier to handle than their free acid counterparts and in 
most cases can be purified by crystallisation or chromatography. 
In our recent work to further this investigation derivatisation of methyl 
pyruvate with the amino acids homoserine, homocysteine and homocystenic 
acid was attempted. These compounds, (226), (227) and (228), respectively 
(Figure 31), are structurally related to the more effective pyruvate derivatives 
found at that stage. They are similarly functionalised to the proposed enzyme 
intermediate and importantly, are very unlikely to participate in cyclisation. 
S03H 
.~ci~c~~ 
(228) 
Figure 31 Original Targets for the Extension of the Study into 
Inhibition of DHDPS. 
However, although the formation of Schiff bases between amino acids 
and ketones has been reported,168 we found that the extensive functionality 
present here posed us a number of problems. Also, the zwitterion nature of the 
products made separation from any unreacted starting amino acids rather 
difficult. We found great difficulty in forming the required product with methyl 
pyruvate and cysteine under a range of conditions - acidic or basic catalysis. 
We also attempted removing the water produced with activated molecular 
sieves (4A) under a N2 atmosphere. To simplify the synthesis we also 
attempted to form a Schiff base using the less functionalised amino acid 
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alanine. With this amino acid an exothermic process accompanied by a colour 
change (clear to yellow) was observed almost immediately. The 1 H NMR 
spectrum however was not easily identifiable and the material proved to be 
difficult to purify. 
The ethyl ester analogues of some of the more effective pyruvate 
inhibitors of the DHDPS enzyme, compounds (229) to (232), along with 
known compound (220) for comparison, were synthesised by the method of 
VogeP69 (Figure 32). The derivatives were isolated in yields of 67 to 98% 
after crystallisation from ethanol/water. 
~ H2NCOHN-N C02Et 
(229) 
Br 
01co,Et 
(233) 
Me02C/~"-.. ~ 
N C02Et 
(232) 
faY 
H2NCOHN-N C02Et 
(234) 
Figure 32 Other Pyruvate Analogues Synthesised. 
The synthesis of derivatives of ethyl bromopyruvate (233) was much 
more troublesome. The extra electrophilic site not surprisingly reduces the 
yield of our desired product, in some cases introducing further possibilities 
such as cyclisation, and in all cases there is a requirement for extensive and 
often difficult purification steps. Known compound (224) was synthesised in 
low yield (50%) by direct condensation of ethyl bromopyruvate (233) and 
methoxylamine hydrochloride in ethanol. The synthesis of the semicarbazone 
derivative of ethyl bromopyruvate (233), however, caused us a great deal of 
problems. The method used by D. Tudor164 did not detail any purification steps 
and was therefore of little use to us. The polar nature of the compound limited 
us to using alcohol for chromatographic separation. The only workable 
purification system we found involved using an iPrOH/CHCI3 solvent mix on a 
silica column. Unfortunately it appears that the alcohol displaces the bromine 
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under these conditions to yield the corresponding isopropyl ether (234), in 
excellent purity but poor yield (5%). 
The activity of these compounds with the DHDPS and DHDPR enzymes 
and the associated problems are discussed in detail in the next chapter. The 
results did not warrant any further investigation in this area. 
5.05 Analogues of DHDPA and THDPA as Inhibitors of 
DHDPS and DHDPR 
We will consider DHDPA (24) and THDPA (25) together because of 
their structural similarity. Due to their low stability, as experienced with the 
synthesis of these metabolites, we find that our search for analogues most 
commonly involves changing certain structural features markedly in order to 
introduce stabilisation. As a consequence our investigation has focused 
almost exclusively on the search for inhibitors. An exception could be made for 
those compounds that show substrate activity with DHDPS. By means of a 
DHDPS/DHDPR coupled assay, discussed in more detail in the next chapter, 
we can test for dual enzymic activity. DHDPR is of less interest as a 
biotransformation catalyst, since the reduction reaction is chemically less 
interesting, and secondly, because of the restriction on potential substrates 
imposed by the stability problems. 
Prior to the recent purification of DHDPR by our biochemical 
colleagues, a number of analogues of DHDPA and THDPA were tested as 
inhibitors of DHDPS. In section 2.14 we detailed earlier studies by our group 
concerning the inhibition of DHDPS by pyridine and piperidine analogues 
(Figure 15). Notable from this study59 was that esters were poorer inhibitors 
than their carboxylic acid analogues. Likewise, monoacid systems were 
poorer inhibitors than their diacid counterparts. Most interestingly, the 
saturated piperidine analogues were very much poorer inhibitors. As these 
piperidines have similar polarity to their pyridine equivalents, this suggests a 
high substrate 'shape' selectivity tending towards the planar ring system. 
5.06 Thiazines and Thiazoles as Inhibitors of DHDPS 
Our interest in thiazines and thiazoles as inhibitors of the DHDPS 
enzyme was originally aroused by our former group members D. Tudor17o and 
S.J. Connell. 171 Compound L-(64) and compounds (235) to (239) showed 
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some interesting activity (Figure 33). The results from inhibition studies with 
these compounds with DHDPS are detailed in Table 8. 
(
81 \\\\ HO c···· N co-2 H
2
+ 2 
(
81 \\\\ EtO c···· N co Et 2 H 2 
L-(64) (235) 
(238) (239) 
Figure 33 Thiazines and Thiazoles with Interesting Inhibitory 
Properties of DHDPS 
Compound Inhibition of DHDPS 
L-(64) 88% at 0.5 mM, 0% at 0.1 mM 
(235) 10% at 0.1 mM 
1236) 20% at 0.1 mM 
(237) 30% at 0.5 mM 
(238) 15% at 0.1 mM 
(239) 18% at 0.1 mM 
Table 8 Inhibition of DHDPS by Thiazines and Thiazoles 
It is difficult to draw firm conclusion from some of these early results. In 
our recent work it was found that employing the DHDPS/DHDPR coupled 
assay for inhibition studies helped in obtaining reliably reproducible results. 
Extension of this library of compounds has allowed us to build up a valuable 
inhibition profile of the DHDPS/DHDPR enzymes incorporating steric, 
electrostatic and stereochemical factors. 
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5.07 Synthesis of Thiazines 
As with previous studies59,172 compound L-(64) was synthesised by the 
direct condensation of L-cysteine and bromopyruvic acid in water. Similarly, 
the enantiomer D-(64) was synthesised from D-cysteine. The separate 
enantiomers were isolated in 88% and 83 % yield, respectively. They were 
shown to have optical rotations of -70.7° and +70.6°, respectively, in 
methanolic solution and the NMR spectra show no evidence of the imine or 
open chain forms. Diethyl (R)-3,4-dihYdro-2H-1,4-thiazine-3,5-dicarboxylate 
(235) was synthesised, in 87% yield, by the direct condensation of L-cysteine 
ethyl ester and ethyl bromopyruvate, according to the method of Berges and 
Taggart.173 The dimethyl ester (240) and di-tert-butyl (241) esters were also 
synthesised by direct esterification of compound L-(64) by classical 
methodology. The respective ester signals were found as singlets in the 1 H 
NMR spectra at 0 3.71 and 3.72 for compound (240) and 0 1.44 and 1.46 for 
compound (241). 
2,2-Dimethyl substituted thiazine analogues (243) and (244) were 
synthesised from DL-penicillamine (242). Compound (244) was prepared in 
low yield (7%) by direct condensation with bromopyruvic acid in glacial acetic 
acid and subsequent esterification. The molecular ion for the parent 
compound was found at m/z 273 in the mass spectrum. The free acid 
analogue (243) was an interesting case. It was first isolated as a solid in an 
NMR tube while investigating the failure of the desired compound to 
precipitate from an aqueous solution. The subtle differences in solvation 
between 020 and H20 were enough to promote precipitation. It is likely that 
other small changes in the physical conditions, such as polarity of the medium 
and temperature, would have similar effect. The exchange of a proton for a 
deuterium in the 3-position of bromopyruvic acid suggests a rapid 
eqUilibration between imine and enamine forms (Scheme 75). In the 1 H 
NMR spectrum a small signal at 0 6.09 is observed for unexchanged protons 
in the 6-position. Once again there is no evidence in either the 1H or 13C NMR 
spectra for the imine form. 
Imidate and tetrazole groups are known to be good carboxylic acid 
mimics in biological systems. In earlier studies by J.E. McKendrick59 pyridine-
2,6-dimethylimidate (38) and pyridine-2,6-ditetrazole (39) (Scheme 15) 
were found to show interesting activity with the DHDPS enzyme. It was 
considered that the thiazine equivalents (247) and (248) may also be of 
interest. Diimidates and ditetrazoles can be synthesised via the corresponding 
dinitrile (246) (Scheme 76). 
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~CX:3' + • 
(242) 
HOCX:X: 2 H
2
+ 2 
(243) 
Et~):::lC02Et 
H 
(244) 
Scheme 75 Synthesis of 2,2-Disubstituted Thiazines 
iSH 
Et02C NH2 
cysteine 
NCi::lCN 
H 
(246) 
· 
· 
· 
· /MeOH/HCI 
. 
f 
Mea (8,) OMs 
y~~ 2CI-
NH2+ NH2+ 
(247) 
.. 
dehydration 
~-----------------. 
S Et02cfN~C~Et 
H 
(235) I NH,lMeOH 
S 
H:!NociN :lCONH2 
H 
(245) 
(248) 
Scheme 76 Synthesis of Imidates and Tetrazoles 
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Treating compound (235) with anhydrous methanolic ammonia gave 
the corresponding dicarboxamide (245) in 59% yield. Unfortunately, the 
forcing conditions required for the dehydration of 3,4-dihydro-2H-1 ,4-thiazine-
3,5-diamide (245) to the dinitrile (246) proved too severe. Even mild 
dehydrating agents such as chlorosulfonyl isocyanate174 (249) (Scheme 
77) effected decomposition. This transformation has previously been 
achieved for the corresponding thiazole (238) and pyridine (35). We 
therefore conclude, that without aromatic stabilisation, decomposition is 
observed under the forcing conditions required. 
~NH + Et3NH+ 
I O=C=N-SO 2C1 ~ (249) 
R-G:=N 
+ C02 + Et3N ....... f-----
+ H2 NS02 CI 
Scheme 77 Dehydration by Chlorosulfonyl Isocyanate (250) 
Another variation on the thiazine ring system that we are interested in 
are different ring oxidation states. Varying the extent of unsaturation of the ring 
results in a change of shape of the ring and orientation of the acid groups. 
Treating the thiazine dimethyl ester (240) with 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) resulted in oxidation to dimethyl 1,4-
thiazine-2,5-dicarboxylate (250) in 72% yield (Scheme 78). Interestingly, in 
the 1 H NMR spectrum a coupling is observed (1.2 Hz) between the methylene 
protons in the 2-position (~ 3.39) and the olefinic proton in the 6-position (~ 
7.66). Hydrolysis of compound (250) was attempted by a variety of methods: 
including acidic and basic hydrolysis; treatment with NaBH4/12;175 treatment 
with AICI3/DMS;176 and treatment with KOtBu/H20 (4:1) (a source of 
anhydrous hydroxide).l77 Although there were signs of success for most of 
these methods, a combination of low stability and difficulty in purification 
meant that it was impossible to isolate the desired product (251). 
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j8l Me02C N C02Me 
H 
(240) 
Scheme 78 
, 
, 
, 
, 
/mild 
jI,-' hydrolysis 
S ~cJ:Nlco-2 H+ 2 
(251) 
Preparation of the Fully Oxidised Thiazine 
Fortunately, the preparation of the saturated ring system was a 
somewhat easier task. Thiomorpholine-3,5-dicarboxylic acid (253) has been 
prepared, as early as 1937, by Coghill.178 Compound (253) was formed by 
treating thiodiacetaldehyde (252) with ammonium cyanide and subsequent 
hydrolysis (Scheme 79). 
(8, 
CHO CHO 
(252) 
Scheme 79 
8 N~CN (l 
.. H NOC.AN CN 2 H 
c.HCI (8l 
"HO C.ANA co -2 H2+ 2 
(253) 
Synthesis of Thiomorpholine-3,5-dicarboxylic 
Acid (253) 
In our work, we chose to follow the more recent method of Lucente and co-
workers 179 for the preparation of dimethyl thiomorpholine-3,5-dicarboxylate 
(256). Direct condensation of L-cysteine methyl ester hydrochloride (254) 
and racemic methyl 2,3-dibromopropionate (255) yielded the desired diester 
(256) as a mixture of cis- and trans-isomers in 75% overall yield (Scheme 
80). The two diastereoisomers were separated by chromatography on silica 
gel. The compounds were identified by GCMS analysis (M+ 219) and the 
diastereomeric ratio was found to be 60:40 in favour of the cis-isomer. The 
pseudo-axial/axial arrangement of ester groups in the cis-isomer was 
thermodynamically favoured. Interestingly, in accord with the findings of 
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Lucente and co-workers, 179 the trans-isomer was found to be the more polar of 
the two. The relative polarities were indicated by their respective At values on 
silica gel. Furthermore, in the 13C NMR spectrum of the chiral trans-isomer we 
do not see separate signals for C-2 and C-6 or for C-3 and C-5. Conclusive 
distinction between the meso- and threo- diastereoisomers is therefore found 
in their optical rotations, which compare with the literature.179 cis- and trans-
Isomers of thiomorpholine-3,5-dicarboxylic acid (253) were prepared by 
basic hydrolysis of the individual diesters (256) to yield the desired 
compounds in high yield (Scheme 80). This method of hydrolysis was 
suggested by Portalone and co-workers18o and was shown not to result in 
racemisation. 
SH 
MeO,c""'(NHs+ Ct' + 
(254) (255) 
S 
3 (~~\( )/',; (S) 
MeO 2C···· N ""C02Me 
H 
s 
+ 3 (';1.( 15 (A) 
Me02C"" N~C02Me 
H 
cis-(meso)-(256) trans-(threo )-(256) 
JKOH JKOH 
K+ '~C'~C:)"CO' ~ H 2 K+ '~C.~C:~CO' ~ H 2 
cis-(meso)-(253) trans-(threo)-(253) 
Scheme 80 Alternative Synthesis of Compound (253) 
5.08 Synthesis of Thiazoles and Thiazolidines 
Our interest in five membered heterocycles followed from the earlier 
results within our group for the thiazoles (238) and (239) (Table 8). As for 
the six-membered heterocycles, it was considered necessary to have 
carboxylic acid groups, or equivalents, adjacent to the nitrogen atom. A 
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number of possible targets were identified from an extensive literature search 
(Figure 34). 
(238) 
IjS H2NOC~NAcONH2 
(258) 
IjS Et02C~NANH2 
(259) 
(261) (262) 
Figure 34 Target Thiazoles and Thiazolidines 
It was originally intended to synthesise thiazole-2,4-dimethylimidate 
and thiazole-2,4-ditetrazole from dinitrile (239), as detailed for the 6-
membered equivalent in Scheme 76. The preparation of dinitrile (239) is 
detailed in Scheme 81. The aliphatic precursor (265) to heterocycle (238) 
was prepared, in 94% yield, on treating cysteine ethyl ester hydrochloride 
(263) with ethyl oxalyl chloride (264). In the 1H NMR spectrum of compound 
(265) the thiol proton is observed as a triplet (8 1.55, 3J 9.0 Hz), by virtue of a 
coupling through sulfur with the adjacent methylene protons. When two 
equivalents of ethyl oxalyl chloride were used double substitution on cysteine, 
at both nitrogen and sulfur, was observed in 84% yield. The 
cyclisation/oxidation of precursor (265) (step 2, Scheme 81) proved 
troublesome. The transformation was achieved in 14% yield with P4S1Q, 
according to the method of Tudor,181 but problems with disposal of the 
byproducts made this route impractical on a large scale. Attempted cyclisation 
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with PCI3, POCI3 (Bischler-Napieralski182 type cyclisation) or with catalytic 
quantities of acid (PTSA) or base (DMAP) under dehydrating conditions, were 
all shown to favour elimination of H2S. Any product that was formed in each of 
these cases was found to present further purification problems (TLC). A 
related cyclisaton was found in the Iiterature183 using anhydrous HCI in Et20. 
However, when this transformation was attempted, dimeric derivative (267) 
was recovered as the product after approximately ten weeks reaction time 
(see Scheme 82). 
(263) 
(258) 
Scheme 81 
1 ~OEt 
CI/ Y 
o (264) 
dry NH3! MeOH 
• 
~3 J:S 
NC N~CN 
(239) 
Synthesis of the 
(238) 
Dinitrile (239) 
Because of the problems associated with the cyclisation of compound 
(265) an alternative synthesis of thiazole diester (238) was also used. Direct 
condensation of ethyl bromopyruvate and ethyl thiooxamate (268), according 
to the method of Erlenmeyer et al., 184 yielded a 60% recovery of the desired 
heterocycle. The single aromatic proton is found at 0 = 8.42 in the 1 H NMR 
spectrum. Hydrolysis of compound (238) in EtOH/KOH(aq), adapted from the 
method of Erlenmeyer et al.,184 gave the thiazole diacid (257) in 23% yield. 
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Scheme 82 
o EI02C~~)lC02Et 
(266) 
Attempted Cyclisation ot Compound (265) 
Treating compound (238) with anhydrous methanolic ammonia 
resulted in precipitation of the dicarboxamide derivative (258). Subsequent 
dehydration of the dicarboxamide by phosphorus oxychloride resulted in a 
44% recovery of the target thiazine dinitrile (239). Signals for the nitrile 
carbons are found in the 13C NMR spectrum at 8 111 and 112. Inhibition 
results, detailed in the next chapter, dictated that no attempt was made to 
transform the dinitrile (239) into the dimethylimidate or ditetrazole. 
Ethyl 2-amino-1,3-thiazole-4-carboxylate (259) was prepared by a 
similar process to that of compound (238). Direct condensation of ethyl 
bromopyruvate with thiourea yielded a 61 % recovery of the desired 
heterocycle. In the 1 H NMR spectrum, a signal is observed for the aromatic 
proton at 8 7.60. Diethyl 4-methyl-1,3-thiazole-2,5-dicarboxylate (260) was 
synthesised from ethyl 2-chloroacetoacetate (269) and ethyl thiooxamate 
(268) according to the method of 800n185 (Scheme 83). Heterocycle (260) 
was isolated in 35% yield. Signals for the aromatic carbons are found in the 
13C NMR spectrum at 8 127, 159 and 159. 
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(269) (268) (260) 
Scheme 83 Synthesis of Heterocycle (260) 
Thiazolidine-2,4-dicarboxylic acid (261) and 5,5-dimethylthiazolidine-
2,4-dicarboxylic acid (262) were synthesised as diastereomeric mixtures by 
the method of Bentley et al.186 Direct condensation of glyoxylic acid with L-
cysteine and DL-penicillamine gave respective recoveries of 43% and 56%. 
The molecular ions are found at m/z =177.0096 and m/z = 205.0393 in the 
high resolution mass spectra for compounds (261) and (262), respectively. 
5.09 Conclusion 
In this chapter we have described the synthesis of a number of 
analogues of pyruvate and heterocyclic analogues of DHDPA and THDPA. 
The results of inhibition studies on these compounds, while informative on 
function of the DHDPS and DHDPR enzymes, do not vindicate further 
investigation in this area. These results along with those of the our substrate 
studies are discussed in detail in the following chapter. In conclusion 
therefrom we elaborate a possible alternate direction for inhibition of these 
enzymes. 
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Chapter 6 Biological Results and Discussion 
6.01 Introduction 
In previous chapters we described the preparation of substrates and 
analogues of the DHDPS and DHDPR enzymes. In this chapter we discuss 
the biological evaluation of these potential inhibitors and substrates and 
limitations thereon. In conclusion, we summarise this research project and 
indicate areas of possible further study. 
In sections 2.11 and 2.16 we discussed established assay systems for 
characterisation of DHDPS and DHDPA activity, respectively. Ideally, a 
suitable assay for monitoring enzymic activity involves observation of a 'real 
time' change in a physical property related to concentration. Suitable for this 
task is the observation of change in UV absorbance with respect to time. In 
accord with Beer's Law, UV absorbance is directly proportional to 
concentration. It is also possible, however, to monitor the extent of conversion 
post-reaction. A number of alternative quantitative analytical techniques are 
available for this evaluation, such as: UV, MS, NMR, fluorescence 
spectroscopy and radiolabelling. Commonly these analytical techniques are 
linked to LC systems to separate the analyte in question from other 'noise.' 
The advantages of a 'real time' assay are that we can see the results instantly, 
need not develop a purification procedure and can compare with a single 
standard. For the standard or 'blank' run the assay is performed with the 
enzyme and substrates at pre-set concentrations. Subsequent assays differ 
only in that varying levels of inhibitor are present. The extent of inhibition is 
determined by direct comparison of gradients of the absorption versus time 
curves (Figure 35). 
Blank (X) 
~~ 0.5 mM inhibitor (I) 
~,~"" ' •••• 1.0 mM inhibitor 
, .. 
#'.,' ....... "" .... 
. . . 
.. 
Time 
% inhibition= X;X100 
Figure 35 Typical Inhibition Profile 
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Substrate assays are performed in a similar manner where the potential 
substrate replaces a substrate in the assay at the same concentration. Due 
regard must be given to alteration of the chromophore when comparing 
activity with the blank. 
6.02 Standard Assays for OHOPS and OHOPR 
The DHDPS 'synthase' assay and DHDPS/DHDPR 'coupled' assay 
detailed in section 2.11 (Scheme 13) were used for the evaluation of our 
inhibitors. 
The standard 1 ml synthase assay has ASA and pyruvate at 1 mM, 
imidazole buffer (pH 7.4) at 100 mM and 10 III of purified DHDPS in 50% 
aqueous glycerol. Activity was determined by the change in absorbance at 
270 nm with respect to time. 
The standard 1 ml coupled assay has the substrates and buffer at the 
same concentration. NADPH co-factor was present at 0.250 mM. The DHDPS 
and DHDPR enzymes (10 Ill) in 50% aqueous glycerol were added as 10 fold 
and 250 fold diluted solutions (H20), respectively. Activity was determined by 
the change in absorbance at 340 nm with respect to time. 
Aqueous stock solutions of ASA, pyruvate and NADPH were prepared 
at 20 mM and stored, along with the enzymes, at less than -20 DC. Stocks of 
aqueous imidazole buffer were prepared at 1 M and stored at 4 DC. 
6.03 Limitations of the DHDPS 'Synthase' Assay 
Although the 'synthase' assay has previously been extensively used by 
our group, great difficulties were experienced with this assay. Many of our 
studies, including all those on previously tested 'inhibitors,' proved to be 
irreproducible. In some cases we observed an apparent negative inhibition, 
where the enzymic reaction appeared to be promoted by the potential 
inhibitor. In some cases the estimated 'inhibition' could vary by more than 
100% for successive repetitions of an experiment. The difficulties created by 
these early observations were a massive hurdle, and took in excess of a year 
to overcome. It was acknowledged at an early stage that a major problem was 
the high levels of UV absorption by our potential inhibitors at the assay 
wavelength, 270 nm. It is notable that almost all saturated carbonyl-containing 
compounds absorb strongly at this wavelength. This problem was 
compounded by the fact that our inhibitors were not particularly efficient and 
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were studied at relatively high concentrations, in the region of 1 mM. As a 
result, very little of the incident UV beam passed through the sample to the 
detector. This makes the experimental error a significant factor. Extensive 
studies with ethyl pyruvate thiosemicarbazide (230), which displayed 
consistent 'negative inhibition,' showed that a positive assay could be 
obtained in the absence of either of the natural substrates or in the absence of 
DHDPS. It is this non-enzymic interaction that is responsible for the apparent 
'negative' result. It is not difficult to envisage a nucleophilic!electrophilic 
interaction between the carbonyl-containing substrates of DHDPS and the 
nucleophilic compound (230). Furthermore, we could predict that this would 
be a common observation with all 'nucleophilic' inhibitors. Not surprisingly, 
therefore, we find this apparent 'negative inhibition' to be very common 
amongst many of our potential inhibitors which could be considered as 
nucleophilic. 
We can therefore picture a series of events with our problem UV 
assays. With a number of competing processes, we can see that the kinetics of 
this system are greatly complicated. Coupled with the problem of significant 
experimental error, this leads to irreproducibility of results and makes it almost 
impossible to study the chemical transformation of interest. Consequently we 
have to question many of our previous investigations in this area. We should 
also consider that if the natural substrates are important metabolites in living 
systems, such as pyruvate is in mammals, then we have direct evidence that a 
number of our nucleophilic inhibitors are likely to display significant toxic 
effects. 
Successful reproducible results were obtained with the synthase assay 
for compounds (51) and (205) as well as for the commercially available DPA 
(28), chelidonic acid (270) and glyoxylic acid (271). These results are 
summarised in Figure 36. Interestingly, none of these compounds can be 
considered as nucleophilic. 
The results for compounds (28) and (270) are similar to our previous 
studies. The structural similarity of these compounds with the enzymic product, 
DHDPA (24), indicates towards their competitive nature. Similarly, compound 
(271) most likely binds directly into the active site of DHDPS enzyme in direct 
competition with pyruvate. There may be scope in studying other pyruvate 
analogues lacking enolisable protons in the 3-position, such as fluoro-
substituted pyruvates. However, the highly toxic nature of such compounds 
must be borne in mind. The result for compound (270) also suggests 
possibilities for investigating alternate heterocyclic systems. Compound (51) 
was an intriguing case. Clearly this compound has little resemblence to the 
substrates and product. It is most likely that inhibition by compound (51) is of 
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a non-competitive nature. Most interesting however was the result for 
compound (205). This compound is the heterocyclic precursor to GSA (156). 
Although the level of inhibition was low, there is suggestion that GSA may be 
accepted into the active site of DHDPS. In chapter 4 we have concentrated 
exclusively on this goa/. This result in conjunction with complementary 
substrate studies is discussed further in section 6.07. 
,,\\\0111,. 
MeO C'" N "'CI"'I-Me 2 Ts '"'2 H~C):{:~H 
(51) 1C50 0.94 mM (205) 1C50 3.9 mM 
(28) ICS) 0.4 mM 
H3yOH 
(270) IC50 0.31 mM 
o 
(271) 1C50 1.0 mM 
Figure 36 Results for Inhibition of DHDPS 
6.04 The DHDPS/DHDPR 'Coupled' Assay. 
The availability of the DHDPR enzyme proved crucial to the solution of 
our testing problems. This enzyme allowed us to utilise the 'coupled' assay 
system for testing of our compounds. Examination of the consumption of 
NADPH at 340 nm almost totally excludes the observation of the non-enzymic 
reactions seen at 270 nm and greatly reduces the experimental error 
associated with the absorption of UV light at this wavelength. A further bonus 
is that we are testing our potential inhibitors against both DHDPS and 
OHOPR. This is significantly important for analogues of L-DHOPA (24) and 
THOPA (25), the respective natural substrate and product of DHDPR. 
Although some minor problems were encountered, such as the non-
enzymic consumption of NADPH by the thiosemicarbazone derivatives (220) 
and (230), this assay system has proved invaluable. 
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In section 5.04 the synthesis of a number of analogues of pyruvate was 
detailed. Of these compounds, only ethyl pyruvate semicarbazone (229) was 
found to display modest inhibition of DHDPR/DHDPS. The calculated ICso 
value for compound (229) was 3.8 mM. 
The syntheses of thiazine, thiazole and thiazolidine analogues of 
DHDPA and THDPA were detailed in section 5.07 and 5.08. The results from 
inhibition studies with DHDPS/DHDPR are summarised in Figure 37. 
\\\,(5) 
ROC·'" N~COR 
H 
L-(64) R :::: OH, IC50 0.038 mM 
(235) R::::; OEt, IC50 3.9 mM 
(245) R = N~, ICso 1.0 mM 
.\\\\(S )~III' 
RO C·" N ···CO R 2 H 2 
cis-(253) R = H, IC 50 0.40 mM 
cis-(256) R = Me, no inhibition 
(250) no inhibition 
(238) R = H, 1C50 2.7 mM 
(257) R = Et, no inhibition 
(260) IC50 12.7 mM 
D-(64) IC50 0.42 mM 
\\\\\(Sl 
RO C·'" NAco R 2 H 2 
trans-(253) R = H, 1C50 3.8 mM 
trans-(256) R :::: Me, no inhibition 
(243) no inhibition 
(259) 1Cso 6.6 mM 
(261) R' :::: H, 1C50 1.0 mM 
(262) R' = Me, ICso 2.8 mM 
Figure 37 Results for Inhibition of DHDPS/DHDPR 
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A typical inhibition profile is illustrated graphically for compound L-(64) 
in Figure 38. 
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Figure 38 A Typical Inhibition Profile for Inhibition of 
DHDPS/DHDPR 
From these inhibition studies it is clear that a number of the earlier 
results in this area were somewhat misleading. We need only compare the 
results obtained for the diacid L-(64) and the corresponding diester (235) to 
see that esters are very much poorer inhibitors. Unsurprisingly, the hydrogen 
bonding ability of the carboxylate function is key to binding. This, along with 
the essential binding of the f3-keto function of pyruvate (Scheme 14), 
explains the poor results obtained for the pyruvate ester derivatives. 
The results for inhibition of DHDPR/DHDPS by the sulfur-containing 
heterocycles, detailed in Figure 37, are a valuable insight into the binding 
characteristics of the enzymes. It is interesting to note the significant difference 
in inhibition between the different ring oxidation states. This indicates that very 
small changes in the orientation of the acid groups have a marked effect on 
the binding ability. Conversely, the ability of the enzymes to accommodate the 
bulky sulfur group in the 4-position readily, suggests a degree of variability in 
this region. It would be an interesting exercise to investigate if polar 
heteroatoms were equally tolerated in this position. It was not surprising that 
the enantiomer of compound (64) displayed different inhibitory properties. 
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The stereocentre of this compound is in the corresponding position to that of 
ASA for the natural biotransformation. Somewhat more surprising were the 
results for cis- and trans-isomers of thiomorpholine-3,5-dicarboxylic acid 
(253). The cis-isomer is a considerably better inhibitor of DHDPS/DHDPR. 
This result could be incorporated into an argument for the strict geometrical 
requirements of the two acid groups and could have further 
mechanistic/stereochemical implications. 
The five-membered ring system appears a poorer model for inhibition. 
Interestingly, the saturated system has greater inhibitory activity in this case. 
Once again strict structural and geometrical requirements are indicated for the 
hydrophilic portion with suggested tolerance of structural variability in the 
hydrophobic portion. 
A number of commercially available compounds were shown to exhibit 
no inhibition with DHDPS/DHDPR: lithium acetoacetate; ethyl acetoacetate; 
ethyl 2-hydroxybutanoate; ethyl acetopyruvate; and acetylacetone. Other 
commercially available compounds, which had shown signs of inhibition for 
the 'synthase' assay, did show similar trends for the coupled assay. The 
results for DPA (28), chelidonic acid (270) glyoxylic acid (271) and 
chelidamic acid (272) are detailed in Figure 39. 
n H02C ~+ C02' 
(28) IC 00 0.46 mM (270) 1Cso <0.3 mM 
HlyOH 
o 
D H02C N + C02' 
H2 
(271) 1Cso 0.31 mM (272) 1Cso 3.2 mM 
Figure 39 Results for Inhibition of DHDPS/DHDPR by 
Commercially Available Compounds 
The competitive nature of substrates of DHDPS makes inhibition 
studies with these compounds a valuable exercise. For this purpose we are 
fortunate that, with the exception of ASA methyl ester (129), these 
compounds are not substrates for the DHDPS/DHDPR coupled system. 
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Consequently, the extent of inhibition when these substrates are at 1 mM, the 
same as ASA in the assay, is a direct indication of competition for the active 
site. These results are presented along with positive inhibition results for other 
synthetic compounds in Figure 40. 
(154) 61% inhibition at 1 mM (155) 30% inhibition at 1 mM 
(129) (205) 28% inhibition at 1 mM 
Evidence of Inhibition,difficult 
to guage because of substrate activity 
(34) 1Csc 4.6 mM (51) 1Csc 2.8 mM 
t O~C02BU 
N(BOC)2 
(174) 1Coo 3.0 mM 
Figure 40 Inhibition of DHDPS/DHDPR by Substrates of DHOPS 
and Other Synthetic Compounds 
In this case, we would consider a 50% inhibition value as an indication 
of equal competition for the active site between the 'natural' and 'unnatural' 
substrates. In that respect, the results for these compounds are promising. In 
particular, the result for compound (154) suggests a preference for this 
compound over the 'natural' substrate. The result for 5-hydroxyproline (205) 
was similarly encouraging and offers further indication of substrate potential 
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for GSA (156). These results are considered further, from a substrate 
perspective, in section 6.07. 
The result for compound (51) is interesting when compared with the 
result for the 'synthase' assay (ICso value of 0.94 mM). The lower level of 
inhibition in the coupled system could suggest that the second enzymic 
transformation is rate-determining for the 'coupled' assay. Ideally, in an 
optimised two enzyme assay, both steps would proceed with equal velocity. 
6.05 Development of a New DHDPR Assay 
Previously in section 2.16 we mentioned the novel idea of utilising the 
reverse process to that promoted by the DHDPR enzyme as an assay system 
in a 'reverse reductase' assay (Scheme 17). Once again the theory is based 
on the reversible nature of enzymic catalysis. If the substrate is too unstable to 
synthesise then the product could be made and the reverse process 
examined. The instability of the DHDPA product of the reverse process is in 
our favour, because, by undergoing a spontaneous irreversible oxidation to 
DPA (28) displacement of the equilibrium generates more DHDPA. In 
developing this assay we had the option of monitoring the production of DPA 
(28) at 270 nm, as for the 'synthase' assay, or monitoring the reduction of the 
NADP+ co-factor to NADPH at 340 nm. 
The first stage of development involved the synthesis of the product of 
DHDPR, namely THDPA (25). Fortunately, this task has been performed 
previously by our group78,79 and is detailed in Section 2.16 (Scheme 21). 
Starting from DPA (28), esterification and catalytic hydrogenation of the 
aromatic ring proceeded in high yield. Tosylation of nitrogen on piperidine 
(50) by tosyl chloride in pyridine was achieved in 58% yield after 
crystallisation. The key step involves elimination of tosic acid, promoted by 
potassium tert-butoxide, followed by purification of (25) on ion-exchange 
resin and crystallisation from MeOH. The elimination was found to progress 
efficiently. Problems were however encountered with the crystallisation of 
(25). A large volume of MeOH was required to dissolve the crude material, 
which did not crystallise on cooling. Further development of the purification 
method is required. For our purpose the crude amorphous material was 
recovered from the methanolic solution and evaluated by 1 H NMR 
spectroscopy. The material was estimated as 58 wt% pure which 
corresponded to 87% conversion from dimethyl N-tosyl-cis-piperidine-2,6-
dicarboxylate (51). This material was suitable for evaluating the merits of the 
assay. 
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The assay was performed by monitoring the change in absorption, at 
340 nm, of a solution containing'THDPA, NADP+, imidazole buffer (pH 7.4) 
and DHDPR enzyme. High absorption at 270 nm by the' assay cocktail meant 
that monitoring at this wavelength was not viable. The activity was found to be 
rather low with the components- at similar concentrations to those described for 
the 'synthase' and 'coupled' assays. The activity was improved by increasing 
the concentration of enzyme, substrate or co-factor; It was considered that a 
higher pH would favour production-of NADPH. Investigation of the assay at pH 
8.0 and 9.0 showed this not to be the case. The optimum assay conditions for 
the 1 ml assay were therefore chosen as: 3 mM THDPA; 0.5 mM NADP+; 100 
mM imidazole buffer (pH 7.4) and 10 J.1.1 of a five fold diluted solution (H20) of 
purified DHDPR in 50% aqueous glycerol. A typical assay 'blank' is illustrated 
in Figure 41. Higher activity was possible at increased concentrations but a 
combination of economy of valuable material and optimised linear activity/time 
gradient made this the preferred system. 
50.00 100.00 150.00 200.00 
Time (sec) 
Figure 41 Graph of Absorbance/Time for a 'Reverse Reductase' 
Assay 
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6.06 Inhibition of DHDPR 
Using our newly developed 'reverse reductase' assay a number of our 
inhibitors were tested against DHDPR alone: compounds (28); L-(64); 0-
(64); cis-(253) and trans-(253). 
""C
8
r HOC····, NACO-2 H2+ 2 
OPA (28) 
HocJ:lco -2 H2+ 2 
L-(64) 0-(64) 
.(8),11', HO c···· N "'CO-
2 H2+ 2 
HOe~(~co-
2 H2+ 2 
cis-(253) trans-(253) 
The thiomorpholine analogues cis- and trans-(253) showed very little 
inhibition of DHDPR. Only the cis-isomer had a measurable ICso value, 
estimated at > 10 mM. A small increase in activity between respective inhibitor 
concentrations of 1 and 3 mM was attributed to non-enzymic interactions. 
The ICso value for 0-(64) was estimated as 3.3 mM but significant 
variability was observed between replicate runs. The enantiomer L-(64), 
which had proven the most potent inhibitor in our earlier studies, was similarly 
troublesome. Initial investigation suggested an IC50 value < 1 mM. However, a 
more detailed study again indicated problems of increasing activity with 
increasing inhibitor concentration. The resulting estimated ICso value was 9.1 
mM. 
The assay system worked consistently well with DPA (28) to give an 
estimated ICso value of 1.7 mM. The inhibition profile for this compound is 
illustrated graphically in Figure 42. 
In conclusion to our study of this new assay we emphaSise that these 
results constitute a preliminary investigation. A number of inconsistencies 
have been described. These problems may be resolved by removing 
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impurities from the assay mixture. This would be achieved by improved 
preparation of THDPA. Critically however it is stressed that the assay 'blanks' 
displayed consistency throughout this study. 
These provisional results, when compared with those for the 
DHDPS/DHDPR 'coupled' assay, appear to suggest a greater specificity for 
the DHDPR enzyme over the DHDPS enzyme. This is indicated by 
significantly higher levels of inhibition for the 'coupled' system. The positive 
result for DPA (28) over L-(64) is opposite to the findings for the 
DHDPS/DHDPR coupled assay. This hints that the DHDPS enzyme is 
responsibile for structural/geometric tolerance around the hydrophobic portion 
of the metabolite, suggested in conclusion to our results detailed in Figure 
37 (section 6.04). Clearly, further investigation is required. 
6,-------------------------~ y = 2.985x(O.214) 
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Figure 42 'Reverse Reductase' Inhibition Profile for DPA (28) 
6.07 Biotransformations with DHDPS 
A standard DHDPS substrate assay was performed in a similar manner 
to the previously described DHDPS 'synthase' inhibition assay. The 
'unnatural' metabolite analogue simply replaces the metabolite in the assay. 
The 'unnatural' metabolite was examined at different concentrations but the 
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relative activity was considered as that when the concentration is the same as 
the assay 'blank' (1 mM). Change in the UV chromophore must be given due 
regard. 
In section 5.02 we considered earlier work on pyruvate (21) analogues 
as substrates of DHDPS. In this section we concentrate on ASA (23) 
analogues. The compounds of interest are illustrated in Figure 43. The 
results quoted are relative to ASA by measure of change in absorbance with 
time at 270 nm. The results compare favourably with our inhibition studies on 
these compounds (Figure 40). As with our inhibition studies the high 
specificity of DHDPS means that little structural variation is tolerated for 
metabolites. 
(154) 313% activity at 1 mM (155) 9% activity at 1 mM 
cr %J:: 
(129) 14% activity at 1 mM (205) 12% activity at 1 mM 
(174) 3% activity at 1 mM 
Figure 43 Relative Substrate Activity of ASA Analogues 
Activity for compound (129) was first detected using our newly 
developed DHDPS/Porcine Kidney Acylase (PKA) coupled assay described in 
Scheme 58. This assay involves the replacement of the ASA analogue with 
an N-acylated equivalent and addition of 100 III of a 1 mg/ml solution of PKA 
to the assay. When ASA (1 mM) is replaced by N-acetyl-ASA (175) (1 mM) 
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the assay has approximately 80% of the activity of a standard 'synthase' 
assay. This can be increased to 100% by adding extra PKA. By this method 
the relative activity of N-acetyl-ASA methyl ester (179) compared to N-acetyl-
ASA (175) was found to be 7%. 
Interestingly, of all of the substrates tested, only compound (129) 
displayed dual substrate activity with both DHDPS and DHDPR by means of a 
'coupled' substrate assay. Surprisingly the relative dual activity was found to 
be 45%. It is not clear why greater substrate activity is displayed for the 
DHDPR/DHDPS system compared to DHDPS alone. 
The positive result for 5-hydroxyproline hydrochloride (205) is 
encouraging. Once again it must be stressed that our preparation of this 
compound produced a crude product (section 4.10). There were slight 
variations in replicate assays and evidence (UV) of non-enzymic interactions. 
However, this compound displayed positive results for inhibition of DHDPS 
(Figure 36) and clear substrate activity indicated by enhancement of activity 
with DHDPS present. Although requiring further validation, these results 
indicate for the first time that the open chain equivalent, GSA (156), has 
potential as a substrate of DHDPS. Strategies for this task were considered in 
detail in Chapter 4. 
Most intriguing of all was the result for 2-methyl-ASA-hydrate 
hydrochloride (154). The measured relative activity was 313% and the assay 
reaction proceeded to completion in just 10 minutes. This biotransformation 
was briefly discussed in Section 3.04. It has always been considered that in 
studying the 'natural' biotransformation (Scheme 84) at 270 nm we were 
monitoring the production of dipicolinic acid (28). The UV absorbance 
maximum for the assay involving compound (154) was at 271 nm. Compound 
(154) cannot readily aromatise because of the methyl group in the 2-position. 
If the product was the expected diene (110) (Scheme 36) then the 
expected UV absorbance maximum would be around 240 nm. To achieve 
aromatisation a high energy process such as demethylation, decarboxylation 
or a 1,2-methyl shift would have to occur (Scheme 36). 
The biotransformation was briefly studied by HPLC. The system used 
was a 125 mm C-8 reversed-phase column, isocratically eluted with 0.1% TFA 
in water at 1 ml/min. The retention time (At) for DPA (28) on this system was 
16.9 min. When a aliquot (50 Ill) of the assay mixture for the 'natural' 
substrates was chromatographed a peak which may be due to the metabolic 
product was identified at Rt = 14.7 min. When the assay mixture containing 
compound (154) in place of ASA was chromatographed a new peak was 
identified at Rt = 7.5 min. This peak was not due to compound (154). Attempts 
to isolate the unnatural product from a 100 mM scale assay by HPLC were 
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unsuccessful because of overlapping impurities. Further analysis under 
different HPlC conditions would be required for this task. 
It is interesting to note that the product of the assay with compound 
(154) appears to have significantly shorter retention on the reverse phase 
system. This suggests that it is a more polar compound, possibly even 
structurally different. Perhaps the product is released from the enzyme prior to 
cyclisation. However, this would require an alternative release mechanism 
from the enzyme. 
+ O~co"H DHDPS • 
(23) (21) 
n H02C ~+ C~- .............................. 
(28) 
~0 HOC'" ~NAco-2 H+ 2 
(33) 
, 
, 
, 
t 
(24) 
Scheme 84 The 'Natural' Biotransformation of DHDPS 
Clearly there are a number of unanswered questions in this case and 
further research is required. In our opinion, conversion of diene (110) into an 
aromatic system (Scheme 36) requires too high an energy input to be 
feasible. The most plausible explanation is that we are simply observing the 
formation of the diene (110). That being the case, then the same may be true 
for the assay with ASA. The product of the 'natural' assay would be DHDPA 
(24). This of course does not explain why the UV absorbance maxima is at 
271 nm or why the relative rate is so much higher than that observed for ASA. 
DHDPA formation is necessary for the next step in the biosynthetic 
mechanism, hydride transfer to the 4-position. Blickling and co-workers30 have 
shown that the product of DHDPS catalysed condensation of ASA and 
pyruvate at pH values above 9 is HDPA (33). From the argument presented 
here and from a thermodynamic point of view we would propose that the 
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dehydration of HDPA to DHDPA is enzymically promoted by DHDPS and that 
the product of the DHDPS enzyme with its 'natural' substrates at physiological 
pH is indeed DHDPA. 
One further investigation was performed in the field of 
biotransformations with DHDPS. The potential of altering enzyme specificity in 
an organic medium was considered. The secondary/tertiary structure of the 
DHDPS protein might be altered in such a medium. The study was conducted 
on a standard 'synthase' assay (1 ml) containing 80% volume of organic 
solvent. The solvents studied were: MeOH; EtOH; acetone; acetonitrile; 
dioxane; THF and ethylene glycol. The activities were all in the region of 5 to 
10%, except for THF which had an activity of 15%. This was considered too 
Iowan activity for further investigation. With hindsight, however, we should 
perhaps have looked at lower proportions of organic solvent and compared 
activities with 'unnatural' substrates. 
In conclusion to our substrate studies we can say that we are once 
again restricted by high substrate specificity. There are some interesting 
observations and further anomalies to investigate. Isolation of the enzymic 
product from biotransformation with compound (154) would be an interesting 
exercise and should reveal further clues to the mechanism of DHDPS. 
Undoubtedly, the most promising result was a suggestion of enzymic activity 
for 5-hydroxyproline hydrochloride (205). This not only suggests possible 
substrate activity for GSA (156) but also gives general indication that the 
enzyme may be able to work with 7-membered rings. This along with the 
speculated structural/geometric tolerance away from the amino and acid 
groups, discussed in conclusion to section 6.05, could indicate potential for 
other 7 -membered heterocycles as inhibitors of DHDPS. 
6.08 Final Conclusions and Future Direction 
In completion of this project we reflect on the challenges that we have 
faced, progress we have made and indicate areas of further study. 
In our search for inhibitors of the DHDPS and DHDPR enzymes we 
were somewhat disappointed with the results. For this reason we would not 
recommend further study on these particular types of inhibitor. However, we 
have gained valuable insight into the specific nature of the enzymes. It is felt 
that there is some structural/geometric tolerance within the active site of 
DHDPS away from the electrostatic binding site. 
145 
The highly specific nature of the enzymes mean that there are few 
substrate analogues which display substrate activity. One could question the 
value of investigating DHDPS as a biotransformation catalyst where a narrow 
spectrum of activity is apparent. Once again we would point towards gains in 
mechanistic understanding for potential benefit in inhibition studies. 
Most promising and pleasing were our studies on GSA as a potential 
substrate (Chapter 4). Despite fighting a seemingly lost cause for a 
appreciable period, we feel that with the positive result for 5-hydroxyproline 
hydrochloride (205), we have presented an argument to warrant further 
investigation in this area. Furthermore, we would consider our novel strategy 
of investigating the reverse process as the best way to further this study. On a 
cautious note however, we would recommend further verification of the result 
for compound (205). This would require an improved preparation of this 
compound. 
Finally, for future inhibition studies of DHDPS we would suggest the 
study of six- and seven-membered heterocycles with alternative heteroatoms 
in appropriate positions. The two acid groups adjacent to a central polar 
heteroatom should be preserved for efficient electrostatic binding in the active 
site. 
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Chapter 7 Experimental 
7.01 General Notes 
The characterisation data are presented in accord with the Journal of the 
Chemical Society, Perkin Transactions 1, 'Instructions for authors (1996)'187 
All melting points were measured with a Galfenkamp melting point 
apparatus and are uncorrected. Infra red spectra were recorded on a Philips 
analytical PU9800 FTIR spectrometer. Nuclear magnetic resonance spectra 
were recorded on a Bruker AM200 SY or WP200 SY operating at 200 MHz (oH) 
or 50 MHz (oC) or a Bruker AM360 SY operating at 360 MHz (oH) or 90 MHz 
(BC)· Mass spectra (MS) were recorded on an updated AEI MS12 or MS902 
spectrometers. The majority of MS were obtained using electron-impact 
ionisation (EI) mode. Chemical ionisation (CI) mode and fast atom 
bombardment (FAB) mode were used where stated. 
Analytical TLC was carried out using Merck silica gel 60 F254 aluminium 
backed plates of 0.25 mm thickness. Compounds were visualised using UV 
light or by staining with iodine or vanillin solution, with heat development. 
Column chromatography was carried out using Merck silica gel 60. 
All solvents and reagents were of analytical grade unless otherwise 
stated. Aqueous solutions were freeze dried using a Christ Alpha 1-4 freeze 
drier. All organic solvents and reagents specified as purified or dried were 
treated according under the standard purification and drying techniques detailed 
by Perrin and Armarego. 188 
Numbering of compounds is used to aid the identification of signals in the 
13C and 1H NMR spectra. 
7.02 Experimental to Chapter 3 
DL-Allylglycine tert-butyl ester hydrochloride (125)189 
NH3+ cr 
8+' 02C~ 6 1 3 5 
7 
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Compound (125) was synthesised from DL-allylglycine (3.45 g, 30.00 
mmol) and isobutylene (- 50 ml) in anhydrous dichloromethane (200 ml) and 
C.H2S04 (4.5 ml, excess) according to the method of McKendrick. 189 The 
desired ester was isolated as a white solid 5.19 g (24.99 mmol, 83.3%); mp 
134-136 °C (lit.19o 134-135 °C) Rf 0.26 (free amine, in EtOAc); (Found: M+, 
172.1338; C, 52.08; H, 8.78; N, 6.73. C9H18N02 requires M, 172.1338; C, 
52.05; H, 8.78; N, 6.75%). 
Potassium salt of OL-N-tert-butoxycarbonylallylglycine (273)56 
o 8 
HN~o)(9 
K' -02C~ 10 
1 3 5 
Compound (273) was synthesised from DL-allylglycine (2.30 g, 20.00 
mmol), KHC03 (2.20 g, 22.00 mmol) and di-t-butyl dicarbonate (4.37 g, 20.00 
mmol) in 1,4-dioxane (25 ml) and water (50 ml) according to the method of 
Robins and co-workers. 56 The desired carbamate was isolated as a white solid, 
4.93 9 (19.46 mmol, 97.3%); BH (200 MHz, 020) 1.27 (9H, s, 8, 9, 10-H3), 2.25 
(2H, m, 3-H2), 2.77 (1 H, m, 2-H), 4.98 (2H, m, 5-H2) and 5,61 (1 H, m, 4-H); Oc 
(50 MHz) 28.6 (C-8, 9, 10), 37.3 (C-3), 56.6 (C-2), 81.9 (C-7), 118.9 (C-5), 
134.8 (C-4), 166.5 (e-6) and 180.2 (C-1). 
DL-N-tert-Butoxycarbonylallylglycine tert-butyl ester (116)190 
o 12 
HN),k)(" 
+
9 I 4 14 
8 02C~ 
6 1 3 5 
7 
Compound (116) was synthesised from compound (125) (4.15 g, 20.00 
mmol), KHC03 (3.36 g, 40.00 mmol) and di-t-butyl dicarbonate (4.37 g, 20.00 
mmol) in 1,4-dioxane (60 ml) and water (60 ml) according to the method of 
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Tudor.190 The desired carbamate was isolated as a colourless oil and did not 
require further purification, 5.23 9 (19.27 mmol, 96.4%). New data: Rt 0.25 
(10% EtOAc in hexane); (Found: M+, 271.1802. C14H2SN04 requires M, 
271.1784). 
DL-N-tert-Butoxycarbonylaspartate-~-semialdehyde tert-butyl ester 
(122)190 
Compound (122) was synthesised from compound (116) (2.55 g, 9.40 
mmol) in anhydrous dichloromethane (50 ml), treating with triethylamine (2.62 
ml, 18.80 mmol), according to the method of Tudor.190 Purification was 
achieved on a silica column, eluting with 33% ether in hexane, to yield the 
desired aldehyde as white solid, 2.10 g (7.67 mmol, 81.6%); mp 39-40 oC; Rt 
0.41 (50% EtOAc in pet. ether (40/60 DC)); (Found: M+, 273.1556; C, 57.29; H, 
8.56; N, 4.95. C13H23NOS requires M, 273.1576; C, 57.12; H, 8.48; N, 5.12%). 
DL-Aspartate-~-semlaldehyde hydrate trlfluoroacetate (93) 189 
Compound (93) was synthesised from compound (122) (565 mg, 2.07 
mmol) in anhydrous dichloromethane (10 ml) and analytical grade trifluoroacetic 
acid (10 ml) according to the method of McKendrick.189 Removal of the solvent 
in vacuo, after 2h at 0 DC, under a nitrogen atmosphere, gave a residue which 
was trite rated in ether at room temperature for 18 h. The desired amino acid 
was isolated as a cream coloured solid by filtration and dried in a desiccator 
(P20 5) , 422 mg (1.69 mmol, 81.8%); mp 63-65 °C (Lit. 56 63-65 DC); (Found: 
MH+, 136.0617. C4H1ON04 requires M, 136.0610). 
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General procedure 1: 
The doubly protected amino acid was stirred in anhydrous HCI in EtOAc 
(10 equiv.), under nitrogen, at 0 °C for 4 h. The HCI, solvent and byproducts 
were removed in vacuo and the resulting oily solid was washed with ether (3 x 
20 ml). The etherial washings were decanted and the sample was dried in a 
desiccator (P20S). 
DL-Aspartate-~-semialdehyde hydrate hydrochloride (124)85 
cr NH3+ OH 
H02~OH 
1 3 
Compound (124) was synthesised from compound (122) (500 mg, 1.83 
mmol) and 2.16M anhydrous HCI in EtOAc (8.47 ml, 18.30 mmol) according to 
general procedure 1. The product was isolated as a hygroscopic white solid 
which was dried in a desiccator (P20S) and stored at -20°C, 367 mg (2.14 
mmol, 117% due to solvation); mp 79-80 °C (dec.); vmax{KBr disc)/cm-1 2924, 
1790, 1740; OH (200 MHz, 020) 2.04 (2H, m, 3-H2), 4.00 (1H, dd, J 7.7, 4.4 Hz, 
2-H) and 5.13 (1 H, t, J 5.8 Hz, 4-H); Oc (50 MHz) 37.2 (C-3), 50.8 (C-2), 88.7 
(C-4) and 172.4 (C-1). The 1H NMR spectrum shows the presence of solvent in 
the solid lattice, which is not removed on extensive drying under high vacuum. 
This material was suitable for work with the DHDPS enzyme. This compound 
did not give a satisfactory mass spectrum. 
DL-N-terl-Butoxycarbonylallylglycine cumyl ester (123) 
o 15 
HNJ,k)(" 
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To a solution of (273) (4.31 g, 20.00 mmol), DCC (4.56 g, 22.00 mmol) 
and DMAP (100 mg) in anhydrous dichloromethane (50 ml), under nitrogen, at 
room temperature, was added cumyl alcohol (2.72 g, 20.00 mmol). The 
resulting suspension was stirred at this temperature for 18 h. The mixture was 
filtered, cooled to -20°C for 2 h and filtered again to remove the final traces of 
DCU byproduct. Removal of the solvent in vacuo yielded a yellow oil which was 
purified on a silica dry flash column, eluting with 5% EtOAc in hexane, to give 
the pure ester as a white solid, 4.83 g (14.49 mmol, 72.4%); mp 64-66 °C; Rf 
0.45 (33% EtOAc in hexane); (Found: M+-C02C(Me)2Ph, 170.1185; C, 4.48; H, 
7.83; N, 67.84. C19H27N04 requires M-C02C(Me)2Ph, 170.1181; C, 68.44; H, 
8.16; N, 4.20%); vmax(KBr disc)/cm-1 3348, 2979, 1738, 1706, 1526, 1448, 
1363; OH (200 MHz, CDCI3) 1.33 (9H, s, 15, 16, 17-H3), 1.69 (6H, s, 11, 12-H3), 
2.47 (2H, m, 3-H2), 4.25 (1 H, m, 2-H), 4.90 (1 H, br d, J 8.0 Hz, N-H), 5.05 (2H, 
m, 5-H2), 5.60 (1 H, m, 4-H) and 7.11 to 7.31 (5H, m, Ar-H's); Be (50 MHz) 28.3 
(C-15, 16, 17), 28.5 (C-ll, 12), 36.8 (C-3), 53.2 (C-2), 79.6 and 83.0 (C-6 and 
C-14), 118.9 (C-5), 124.3 and 128.2 (C-8, 8' and C-9, 9'),127.2 (C-l0), 132.4 
(C-4), 145.1 (C-7) 155.5 (C-13) and 170.6 (C-l); m/z 170 (M+-C02C(Me)2Ph, 
5.7%),119,91,77,70 and 57 (100%). 
DL-Allylglycine methyl ester (126)83 
Compound (126) was prepared by treating a solution of DL -allylglycine 
(1.00g, 8.69 mmol) in methanol (30 ml) with anhydrous HCI at 0 °C until the 
solid dissolved. The solution was left to stand for 18 h. After this time, the 
solvent was removed in vacuo. The resulting residue was treated with 0.5 M 
aqueous NaOH (20 ml) and extracted into EtOAc (3 x 20 ml). The organic 
extract was dried (MgS04), filtered and concentrated in vacuo to yield the 
desired ester as a colourless oil, 371 mg (2.87 mmol, 33.1%); Rf 0.19 (33% 
EtOAc in hexane); (Found: MH+, 130.0863. C6H12N02 requires M, 130.0868); 
vmax(CHCI3)/cm-l 3025, 2954, 1736, 1439, 1217; OH (200 MHz, CDCI3) 1.57 
(2H, s, N-H2), 2.36 (2H, m, 3-H2), 3.48 (1 H, dd, J 7.1,5.2 Hz, 2-H), 3.65 (3H, s, 
6-H3), 5.07 (2H, m, 5-H2) and 5.68 (1 H, m, 4-H); oe (50 MHz) 39.0 (C-3), 51.6 
(C-2), 53.7 (C-6), 118.5 (C-5), 133.3 (C-4) and 175.5 (C-l); m/z (CIINH3) 130 
(MH+, 100%). 
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General procedure 2: 
Oi-tert-butyl dicarbonate ((BOC)20) was added to a solution of the amino 
acid and KHC03 in dioxane/water (1:1) and stirred for 18 h at room 
temperature. The solvents were removed in vacuo and the resulting residue 
was suspended in water and extracted with EtOAc. The combined organic 
extract was dried, filtered and concentrated. 
DL-N-tert-Butoxycarbonylallylglycine methyl ester (127) 191 
Compound (127) was prepared from compound (126) (360 mg, 2.79 
mmol), KHC03 (586 mg, 5.85 mmol) and di-tert-butyl dicarbonate (662 mg, 3.07 
mmol) in 1,4-dioxane (20 ml) and water (20 ml) according to general 
procedure 2. After reaction the solvents were removed in vacuo and the 
resulting residue was suspended in water (15 ml) and extracted with EtOAc (3 x 
15 ml). The combined organic extract was dried (MgS04), filtered and 
concentrated in vacuo to yield the desired carbamate as a colourless oil, 578 
mg (2.52 mmol, 90.4%); At 0.42 (33% EtOAc in hexane); (Found: MH+, 
230.1369. Cl1H20N04 requires M, 230.1392); vmax(CDCI3)/cm-1 3023, 3017, 
2982, 1741, 1711, 1501; OH (200 MHz, COCI3) 1.38 (9H, s, 9, 10, 11-H3), 2.44 
(2H, m, 3-H2), 3.65 (3H, s, 6-H3), 4.30 (1 H, m, 2-H), 5.06 (2H, m, 5-H2), 5.15 
(1 H, br s, N-H) and 5.64 (1H, m, 4-H); Oc (50 MHz) 28.1 (C-9, 10, 11),36.5 (C-
3),52.0 (C-6), 52.8 (C-2), 79.6 (C-8), 118.8 (C-5), 132.3 (C-4), 155.1 (C-7) and 
172.4 (C-1); m/z (CI/NH3) 247 (M-NH4+, 100%), 230 (MH+, 25%), 208, 191, 
174. 
General procedure 3: 
Ozone gas was bubbled through a solution of the protected amino acid in 
anhydrous dichloromethane at -78 ac. Triethylamine (2 equiv.) was added to 
the resulting blue coloured solution, a colour change to light yellow was 
observed and the solution was allowed to warm slowly to room temperature. 
The solvent was removed in vacuo and the resulting residue purified by column 
chromatography. 
152 
DL-N-tert-Butoxycarbonylaspartate-p-semialdehyde methyl ester (128) 
Compound (128) was prepared by ozonolysis of compound (127) (540 
mg, 2.36 mmol) in anhydrous dichloromethane (30 ml) according to general 
procedure 3. After 1 h, the reaction was quenched by the addition of Et3N (2 
equiv.). Purification was achieved on a silica dry flash column, eluting with 20% 
EtOAc in hexane, to yield the desired aldehyde as a coluorless oil, 290 mg 
(1.25 mmol, 53.1 %); Rt 0.23 (50% EtOAc in hexane); (Found: MH+, 232.1186. 
C1OH1aNOs requires M, 232.1185); vmax(KBr disc)/cm-1 3024,1711, 1501; OH 
(200 MHz, COCI3) 1.37 (9H, s, 8, 9, 10-H3), 2.99 (2H, m, 3-H2), 3.68 (3H, s, 5-
H3), 4.54 (1 H, m, 2-H), 5.41 (1 H, br m, N-H) and 9.66 (1 H, s, 4-H); Be (50 MHz) 
2B.1 (C-B, 9, 10), 45.8 (C-3), 48.4 (C-5), 52.6 (C-2), 80.1 (C-7), 155.3 (C-6), 
171.5 (C-1) and 199.4 (C-4); mlz (CJ/NH3) 149 (M-NH4+, 100%),232 (MH+, 
12.6%),219,193,175,163,149. 
Methyl DL-aspartate-p-semialdehyde hydrate hydrochloride (129) 
Compound (128) (151 mg, 0.653 mmoJ) was dissolved in anhydrous 
EtOAc (3 ml) and treated with 2.5M anhydrous HCI in EtOAc (2.61 ml, 6.53 
mmol) according to general procedure 1. The product was isolated as a 
hygroscopic light yellow solid which was dried in a desiccator (P20S) and stored 
at -20°C, 112 mg (0.603 mmol, 92.4%); mp 62-64 °C (dec.); (Found: M+, 
132.0670. CSH10N03 requires M, 166.0661); vmax(KBr disc)/cm-1 3435, 1712, 
1635, 1385; OH (200 MHz, 020) 2.07 (2H, m, 3-H2), 3.67 (3H, s, 5-H3), 4.13 
(2H, dd, J 7.4, 4.4 Hz, 2-H) and 5.13 (1H, dd, J 6.0,4.8 Hz, 4-H); Oc (50 MHz) 
37.2 (C-3), 50.7 (C-5), 54.5 (C-2), 88.5 (C-4) and 171.1 (C-1); mlz 
(FAB/glycerol) 132 (M+, 22%), 115,88. The 1H NMR spectrum shows the 
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presence of solvent in the solid lattice, which is not removed on extensive 
drying under high vacuum. This material was suitable for work with the DHDPS 
enzyme. 
N-Benzylimino-DL-alanine sodium salt (132)192 
7' 
This was adapted from the method of Davis and co-workers. 131 DL-
Alanine (4.45 g, 50.00 mmol) and freshly activated 4A molecular sieves (20 g) 
were added to a solution of sodium ethoxide in anhydrous ethanol, prepared by 
adding sodium metal (1.15 g, 50.00 mmol) to anhydrous ethanol (50 ml) in a 
flame dried flask under a stream of nitrogen with cooling (ice bath). The 
resulting suspension was stirred at room temperature, under nitrogen for 18 h. 
The suspension was filtered to remove the molecular sieves, washing with 
MgS04 dried analytical grade ethanol (250 ml) to solublise the product. The 
filtrate was concentrated in vacuo, washed with MgS04 dried analytical grade 
acetone (2 x 50 ml) to remove unreacted benzaldehyde, filtered and dried in a 
desiccator (P20S) to yield the desired imine as a white solid, 8.57 g (43.05 
mmol, 86.1 %); (Found: MH+, 177.0781. C10H10N02 requires MH, 177.0790); 
vmax(KBr disc)/cm- 1 3423 (br), 2978, 2867, 1642, 1595; OH (200 MHz, CDC~) 
1.37 (3H, d, J 6.9 Hz, 3-H3), 3.90 (1 H, q, J 6.8 Hz, 2-H), 7.31 and 7.69 (5H, 2 x 
m, Ar-H) and 8.22 (1H, s, 4-H); oc (50 MHz) 21.0 (C-3), 72.7 (C-2), 129.5, 129.6 
and 131.8 (Ar C-H), 137.6 (C-5), 163.2 (C-4) and 180.7 (C-1); m/z (FAB) 222 
(M+Na+, 100%), 176 (M+, 7.8%). 
N-tert-Butoxycarbonylglycine (119)193 
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Compound (119) was synthesised from glycine (11.26 g, 150.0 mmol), 
KHC03 (24.88 g, 180.00 mmol) and di-tert-butyl dicarbonate (36.01 g, 165.0 
mmol) in 1 A-dioxane (100 ml) and water (100 ml) according to general 
procedure 2. After reaction the mixture was washed with ether (100 ml) and 
the aqueous portion was acidified to pH 2 with 2M HCI (aq) before extraction 
with EtOAc (3 x 100 ml). The combined organic extract was dried (Na2S04), 
filtered and concentrated in vacuo to yield the desired carbamate as a white 
solid, 26.02 g (148.5 mmol, 99.0%); mp 88-89 °C (Lit. 193 87-88 DC). 
L-N-tert-Butoxycarbonylalanine (133)194 
Compound (133) was synthesised from alanine (13.36 g, 150.0 mmol), 
KHC03 (24.88 g, 180.0 mmol) and di-tert-butyl dicarbonate (36.01 g, 165.0 
mmol) in 1 A-dioxane (100 ml) and water (100 ml) according to general 
procedure 2. After reaction the mixture was washed with ether (100 ml) and 
the aqueous portion was acidified to pH 2 with 2M HCI (aq) before extraction 
with EtOAc (3 x 100 ml). The combined organic extract was dried (Na2S04), 
filtered and concentrated in vacuo to yield the desired carbamate as a white 
solid, 27.59 g (145.8 mmol, 97.2%); mp 79-81 °C (Lit. 194 80-82 DC). 
N-tert- Butoxycarbonylglycine crotyl ester (120) 189 
71 6 2 8 10 
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To a solution of compound (119) (7.01 g, 40.00 mmol), DCC (8.25 g, 
40.00 mmol) and DMAP (100 mg) in anhydrous dichloromethane (100 ml), 
under nitrogen, at room temperature, was added crotyl alcohol (2.88 g, 40.00 
mmol). The resulting suspension was stirred at this temperature for 18 h. The 
mixture was filtered, cooled to -20°C for 2 h and filtered again to remove the 
final traces of DCU byproduct. The filtrate was washed with sat. NaHC03 (aq) 
(2 x 100 ml) and the organic portion was dried (MgS04), filtered and 
concentrated in vacuo to a yellow oil. Purification was achieved on a silica dry 
flash column, eluting with 5% EtOAc in hexane, to give the pure ester as a 
155 
colourless oil, 7.83 9 (34.16 mmol, 85.4%); Rt 0.40 (33% EtOAc in hexane); 
The IR and low resolution mass spectra were consistent with the literature;189 
(Found: M+-CH2CH=CH(Me), 174.0772. C7H12N04 requires M, 174.0766); OH 
(200 MHz, CDCI3) 1.39 (9H, s, 5, 6, 7-H3), 1.67 (3H, dd, J 6.3, 1.3 Hz, ll-H3), 
3.85 (2H, d, J 5.6 Hz, 2-H2), 4.52 (2H, dd, J 6.5, 0.9 Hz, 8-H2), 5.10 (1 H, br-s, 
N-H), 5.52 (1 H, m, 9-H) and 5.75 (1 H, m, 9-H); Be (50 MHz) 17.7 (C-11), 28.2 
(C-5, 6, 7), 42.3 (C-2), 65.9 (C-8), 79.8 (C-4), 124.4 (C-l0), 132.1 (C-9), 155.8 
(C-3) and 170.1 (C-l). 
DL -2-( tert-B utoxycarbonylamino )-3-methyl-4-pentenoic acid (134) 189 
1 
10 )(OJN ~2: ~ 
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Compound (134) was synthesised according to the method of 
McKendrick. 189 Compound (120) (3.44 g, 15.00 mmol) in anhydrous THF (15 
ml) was added to diisopropylamine (3.19 g, 31.50 mmol) and 1.6M BuLi in 
hexanes (19.69 ml, 31.5 mmol) in anhydrous THF (30 ml). Subsequent addition 
of TMS chloride (3.42 g, 31.50 mmol) and methanol (15 ml), followed by the 
recommended 'work up' procedure yielded a diastereomeric mixture the desired 
amino acids as a yellow solid, 1.26 9 (5.49 mmol, 36.6%); Rt 0.23 (50% EtOAc, 
1 % AcOH in hexane); OH (200 MHz, CDCI3) 1.02 (3H, d, J 7.0 Hz, 6-H3), 1.37 
(9H, 5, 9, 10, ll-H3), 2.65 (1 H, m, 3-H), 4.29 (1 H, dd, J 8.8, 4.6 Hz, 2-H), 5.04 
(2H, m, 5-H2), 5.69 (1 H, m, 4-H), 8.65 (1 H, br s, N-H) and 10.9 (1 H, ,br 5, C02-
H); Oe (50 MHz) 15.0 (C-6), 28.3 (C-9, 10, 11), 40.3 (C-3), 57.2 (C-2), 80.1 (C-
8), 116.2 (C-5), 138.5 (C-4), 155.5 (C-7) and 176.2 (C-1), (Signals visible for the 
minor diastereoisomer 14.7 (C-4), 39.9 (C-2) and 58.8 (C-3). Estimated 
diastereomeric ratio of 1:9 in favour of anti-diastereomer. 
N-Acetylglycine allyl ester (136) 
II 2 5 7 ~N~eo~ 
4 H 1 2 6 
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To a solution of N-acetylglycine (5.85 g, 50.00 mmol), DCC (10.32 g, 
50.00 mmol) and DMAP (200 mg) in anhydrous dichloromethane (50 ml). under 
nitrogen, at room temperature, was added allyl alcohol (2.90 g, 50.00 mmol). 
The resulting suspension was stirred at this temperature for 18 h. The mixture 
was filtered, cooled to -20°C for 2 h and filtered again to remove the final traces 
of DCU byproduct. Removal of the solvent in vacuo yielded a dark yellow oil 
which was purified on a silica dry flash column. eluting with 25% EtOAc in 
hexane, to give the pure ester as a lightly coloured solid, 6.31 g (40.15 mmol. 
80.3%); mp 50-51°C; Rt 0.32 (EtOAc); (Found: M+, 157.0734; C, 54.62; H, 
7.37; N, 9.15. C7H11N03 requires M, 157.0739; C, 53.49; H, 7.37; N, 8.91%); 
vmax(KBr disc)/cm-1 3266,3086, 1738, 1644, 1565; BH (200 MHz, CDeI3) 1.74 
(3H, s, 4-H3), 3.73 (2H, d, J 5.5 Hz. 5-H2). 4.33 (2H. m. 2-H2). 5.00 (2H. m. 7-
H2). 5.60 (1 H. m. 6-H) and 6.71 (1 H. br s. N-H); De (50 MHz) 21.0 (C-4), 39.6 
(C-2). 64.2 (C-5). 117.1 (e-7). 129.8 (e-6). 168.1 and 169.2 (e-1 and C-3); m/z 
157 (M+, 2.1 %). 116. 100. 72 (100%) and 42. 
a-Benzyloxoiminoglyoxylic acid (141) 135 
Compound (141) was synthesised from glyoxylic acid (3.009. excess) in 
water (50 ml) and O-benzylhydroxylamine hydrochloride (4.79 g, 30.00 mmol) in 
water (250 ml) according to the method of Ottenheijm and co-workers.135 After 
extraction into dichloromethane (2 x 100 ml), the organic extract was dried 
(Na2S04), filtered and concentrated in vacuo to yield the desired O-alkylimine 
as a white solid. 5.33 g (29.72 mmol, 99.0%); mp 74-75 °C (Lit.135 78-80 DC); 
(Found: M+-N=C(H)C02H. 107.0496; C. 60.09; H, 4.85; N. 7.73. C7H70 
requires M, 107.0497; C, 60.32; H. 5.06; N. 7.82%); vmax(KBr disc)/cm-1 3420 
(br). 3033,2947, 1712. 1679, 1590, 1438; BH (200 MHz. CDCI3) 5.29 (2H, s. 3-
H2). 7.36 (5H. s. Ar-H). 7.55 (1 H, s, 2-H) and 11.80 (1 H, br s. C02-H); Be (50 
MHz) 78.4 (C-3), 128.6 (C-2), 135.6 (C-4), 140.9 (br) (Ar C-H) and 166.5 (C-1); 
m/z 179 (M+, 0.2%), 108,91 (100%),77.65.51. 
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a-Benzyloxoiminopyruvic acid (142)135 
Compound (142) was synthesised from sodium pyruvate (3.50 g, 
excess) in water (50 ml) and ()'benzylhydroxylamine hydrochloride (4.79 g, 
30.00 mmol) in water (150 ml) according to the method of Ottenheijm.135 After 
extraction into dichloromethane (2 x 100 ml), the organic extract was dried 
(Na2S04), filtered and concentrated in vacuo to yield the desired O-alkylimine 
as a white solid, 5.72 g (29.61 mmol, 98.7%); mp 77-79 °C (Lit.135 83-85 °C); 
(Found: M+, 193.0721; C, 62.29; H, 5.62; N, 7.43. C1OH11N03 requires M, 
173.0738; C, 62.16; H, 5.74; N, 7.25%); vmax(KBr disc)/cm-1 3027, 2973, 2937, 
2589, 1697, 1609, 1450; DH (200 MHz, CDC's) 2.09 (3H, s, 3-H3), 5.31 (2H, s, 
4-H2), 7.38 (5H, s, Ar-H) and 10.00 (1 H, s, C02-H); DC (50 MHz) 10.7 (C-3), 
78.0 (C-4), 128.3, 128.5, 128.6 (Ar C-H), 136.1 (C-5), 148.7 (C-2) and 165.5 (C-
1); m/z 193 (M+, 0.1 %), 108, 91 (100%), 77, 65, 51. 
General procedure 4: 
Isobutylene (20 to 50 ml, excess) was added, via a cold finger 
condenser, to a suspension of the amino acid in anhydrous dichloromethane at 
-78 °C. Concentrated H2S04 was added and the suspension stirred at -78 °C 
for 8 h and then at room temperature for a further 10 h. After this time, the 
resulting solution was basified to pH 9 with sat. NaHC03 and the two phase 
mixture was stirred rapidly for 30 min. The organic portion was then washed 
with brine (3 x 100 ml), dried (Na2S04), filtered and concentrated in vacuo. 
a-Benzyloxoiminoglyoxylate tert-butyl ester (143)134 
6' 
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Compound (143) was synthesised from compound (141) (2.00 g, 11.16 
mmol) and isobutylene (- 20 ml) in anhydrous dichloromethane (100 ml) and 
C.H2S04 (2 ml) according to general procedure 4. Purification was achieved 
on a silica dry flash column, eluting with hexane to remove the polyisobutylene 
byproduct and then 5% EtOAc in hexane, to yield the desired ester as a 
colourless oil, 2.39 9 (10.16 mmol, 91.0%); Rt 0.35 (10% EtOAc in hexane); 
(Found: M+, 235.1207. C13H17N03 requires M, 235.1208); vmax(CHCl3 
solution)/cm-1 3006,2980, 1728, 1710, 1598; bH (200 MHz, CDCI3) 1.53 (9H, s, 
9, 10, ll-H3), 5.27 (2H, s, 3-H2), 7.25 to 7.39 (5H, m, Ar-H3 and 7.47 (lH, s, 2-
H); be (50 MHz) 28.0 (C-9, 10, 11),77,8 (C-3), 82.6 (C-8), 128.4, 128.5, 128.6 
(Ar C-H), 136.1 (C-4), 142.4 (C-2) and 160.9 (C-l); m/z235 (M+, 0.2%),179, 
162,91 (100%),77,57; GC (CP SiI5CB; 30 m x 0.32 mm i.d. x 0.12 J-lm) 14.84 
min. 
a-Benzyloxoiminopyruvate tert-butyl ester (144) 
7' 
6'~B 
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Compound (144) was synthesised from compound (142) (5.80 g, 30.00 
mmol) and isobutylene (- 30 ml) in anhydrous dichloromethane (200 ml) and 
C.H2S04 (1.5 mJ) according to general procedure 4. Purification was achieved 
on a silica dry flash column, eluting with hexane to remove the polyisobutylene 
byproduct and then 5% EtOAc in hexane, to yield the desired ester as a 
colourless oil, 6.67 9 (26.75 mmol, 89.2%); Rt 0.37 (10% EtOAc in hexane); 
(Found: M+, 249.1357. C14H19N03 requires M, 249.1364); vmax(thin film)/cm- 1 
2980,2935,1613,1452,1370,1335; ()H (200 MHz, CDCI3) 1.47 (9H, s, 10,11, 
12-H3), 1.96 (3H, s, 3-H3), 5.21 (2H, s, 4-H2) and 7.21 to 7.32 (5H, s, Ar-H); be 
(50 MHz) 11.6 (C-3), 28.0 (C-l0, 11, 12),77.3 (C-4), 82.2 (C-9), 128.1, 128.3, 
128.4 (ArC-H), 136.8 (C-5), 150.3 (C-2) and 162.7 (C-l); m/z249 (M+, 0.1%), 
193,176,91 (100%),77,57. 
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General procedure 5: 
This was adapted from the communications of Hanessian and Yang134 
and Luche and co-workers,133 regarding the zinc induced coupling of allyl 
bromides and aldehydes, ketones or imines. The allyllic bromide (1.4 equiv.) 
was added via a Gilson pipette to a solution of the O-alkyloximine t-butyl ester 
in sat. NH4CI (aq) and THF (5 : 1 respectively). Freshly activated zinc dust (1.8 
equiv.) was then added in small portions to the stirred two phase solution at 
room temperature. The reaction was monitored by TLC and was generally 
complete within 5 min. The suspension was filtered to remove the zinc residues, 
extracted with EtOAc (3 x 100 ml) and the organic extract was dried (Na2S04), 
filtered and concentrated in vacuo to a colourless oil. 
DL-N-Benzyloxoallylglycine tert-butyl ester (145) 
I 12 
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Compound (145) was synthesised from compound (143) (1.18 g, 5.01 
mmol), freshly distilled allyl bromide (595 ~I, 7.00 mmol) and freshly activated 
zinc powder (588 mg, 9.00 mmol) in sat. NH4CI (aq) (20 ml) and THF (4 ml) 
according to general procedure 5, to yield the desired amino acid as a 
colourless oil, 1.37 g (4.94 mmol, 98.6%); Rf 0.26 (10% EtOAc in hexane); 
(Found: M+, 277.1676. C1SH23N03 requires M, 277.1677); vmax(thin film)/cm-1 
2974,2927, 1729, 1450, 1367; OH (360 MHz, CDCI3) 1.48 (9H, 5, 12, 13,14-
H3), 2.32 (2H, m, 3-H2), 3.58 (1 H, t, J 6.7 Hz, 2-H), 4.72 (2H, s, 6-H2), 5.08 (2H, 
m, 5-H2), 5.71 (1 H, m, 4-H), 5.77 (1 H, br 5, N-H) and 7.31 (5H, m, Ar-H); OC (50 
MHz) 28.1 (C-12, 13, 14),33.9 (C-3), 63.6 (C-2), 76.0 (C-6), 81.6 (C-11), 117.9 
(C-5), 127.7 (C-4), 128.2, 128.3, 133.2 (Ar C-H), 137.7 (C-7) and 172.4 (C-1); 
m/z277 (M+, 0.1%), 221,176,108,91 (100%),77,57. 
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DL-2-(Benzyloxoamino)-3-methyl-4-pentenoate tert-butyl ester (147) 
10 0 12 I 3 13 
11 # s· 
4 6 
1a I 
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Compound (147) was synthesised from compound (143) (5.10 g, 21.67 
mmol), crotyl bromide (85% pure) (3.67 ml, equivalent to 30.34 mmol) and 
freshly activated zinc powder (1.98 g, 30.34 mmol) in sat. NH4CI (aq) (20 ml) 
and THF (4 ml) according to general procedure 3. A further 1 g of powdered 
zinc was added after 30 min and the mixture was left for another 10 min before 
'work up' to yield the desired amino acid as a colourless oil, 6.25 9 (21.45 
mmol, 99.0%); Rf 0.36 (10% EtOAc in hexane); (Found: MH+, 292.1918 
C17H2SN03 requires MH, 292.1913); vmax{thin film)/cm-1 2977, 2932, 1730, 
1454, 1368, 1156; OH (200 MHz, CDCI3) 0.95 (2H, d, J 6.9 Hz, 6-H3), 1.39 (9H, 
s, 13, 14, 15-H3), 2.31 (1 H, m, 3-H), 3.31 (1 H, ,br m, 2-H), 4.60 (2H, s, 7-H2), 
4.94 (2H, m, 5-H2), 5.59 (1 H, m, 4-H), 5.86 (1 H, br s, N-H) and 7.22 (5H, m, Ar-
H). Complementary signals visible for minor diastereoisomer at 0 = 0.96, 1.41 
and 4.62 ppm; OC (50 MHz) 17.0 (C-6), 28.1 (C-13, 14, 15),38.8 (C-3), 68.3 (C-
2),75.7 (C-7), 81.5 (C-12), 115.6 (C-5), 127.6, 128.2,128.4 (Ar Q-H), 137,9 (C-
8), 139.2 (C-4) and 172.3 (C-1). Complementary signals for minor 
diastereoisomer at 0 = 16.8, 38.4, 68.6, 75.9, 81.7, 127.7, 128.2, 128.5 and 
172.4 ppm; mlz(CI) 292 (MH+, 100%),236,197,190,146,108,91; GC (CP Sil 
5GB; 30 m x 0.32 mm Ld. x 0.12 J.1m) major diastereoisomer 18.84 min, minor 
diastereoisomer, 19.06 min. 
DL-2-(Benzyloxoamino)-2-methyl-4-pentenoate telt-butyl ester (146) 
S 7 H ,,~o/N , 
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Compound (146) was synthesised from compound (144) (6.31 g, 25.31 
mmol), freshly distilled allyl bromide (3.01, 35.43 mmol) and freshly activated 
zinc powder (2.98 g, 45.56 mmol) in sat. NH4CI (aq) (125 ml) and THF (25 ml) 
according to general procedure 5, to yield the desired amino acid as a 
colourless oil, 6.98 g (23.95 mmol, 94.6%); At 0.32 (10% EtOAc in hexane); 
(Found: M+, 291.1819. C17H25N03 requires M, 291.1834); vmax(thin film)/cm-1 
2979, 2932, 1731, 1453, 1369; ~H (360 MHz, CDCI3) 1.28 (3H, s, 6-H3), 1.47 
(9H, s, 13, 14, 15-H3), 2.37 (2H, m, 3-H2), 4.74 (2H, d, J 1.3 Hz, 7-H2), 5.11 
(2H, m, 5-H2), 5.77 (1H, m, 4-H), 5.99 (1H, br s, N-H) and 7.30 (5H, m, Ar-H); 
OC (50 MHz) 19.7 (C-6), 28.0 (C-13, 14, 15),39.9 (C-3), 65.4 (C-2), 76.6 (C-7), 
81.2 (C-12), 118.6 (C-5), 127.6,127.9,128.2 (Ar C-H), 132.7 (C-4), 137.9 (C-8) 
and 173.7 (C-1); mlz291 (M+, 0.1%),190,91 (100%),77,57. 
General procedure 6: 
Adapted from the method of Cicchi et al. 137 and that of Nitta and 
Kobayashi, 136 the N-alkyloxide was dissolved in acetonitrile and water (15 : 1 
respectively) and MO(CO)6 (0.7 equiv.) was added. The reaction vessel was 
degassed three times, filled with nitrogen and heated to reflux for 3 h. The 
MO(CO)6 dissolved on heating and a colour change from colourless to yellow to 
black was observed within 1 h. After cooling the solvents were removed in 
vacuo to leave a black coloured residue which was suspended in ether (50 ml) 
and extracted with 1 M Hel (aq) (3 x 50 ml). The combined aqueous extract was 
basified to pH> 12 with 40% NaOH (aq) and extracted with EtOAc (3 x 200 ml). 
The combined EtOAc extract was dried (MgS04), filtered and concentrated to 
yield the desired amine as a lightly coloured oil. 
Alternatively, after reflux the cooled reaction mixture was filtered through 
a silica plug flushing with an excessive volume of 1 % c.NH3 (aq) in EtOAc. The 
filtrate was monitored in portions by TLC. The combined washings were 
concentrated in vacuo with ethanol and the product was further purified on a 
silica dry flash column, eluting with 1 % c.NH3 (aq) in EtOAc to yield the pure 
amine as a darkly coloured oil. 
DL-Allylglycine tert-butyl ester (148) 
NH2 
8+
9 02C~ 6 1 3 5 
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Compound (148) was synthesised from compound (145) (1.35 g, 4.87 
mmol) and MO(CO)6 (899 mg, 3.41 mmol) in acetonitrile (60 ml) and water (4 
ml) according to general procedure 6. The reaction mixture was 'worked up' 
using the chromatographic method described, to yield the desired amine as a 
dark coloured oil, 356 mg (2.08 mmol, 42.7%); Rf 0.26 (EtOAc); (Found: MH+, 
172.1338. C9H17N02 requires MH, 172.1338); 8H (360 MHz, CDCI3) 1.33 (9H, 
S, 7, 8, 9-Hg), 1.91 (2H, br s, N-H2), 2.25 (2H, m, 3-H2) 3.26 (1H, dd, J 6.8,5.3 
Hz, 2-H), 4.99 (2H, m, 5-H2) and 5.59 (1 H, m, 4-H). The IR, 13C NMR and low 
resolution mass spectra were consistent with that of compound (125) 
(hydrochloride salt). 
DL-3-Methylallylglycine tert-butyl ester (150) 
Compound (150) was synthesised from compound (147) (874 mg, 3.00 
mmol) and MO(CO)6 (554 mg, 2.10 mmol) in acetonitrile (45 ml) and water (3 
ml) according to general procedure 6. The reaction mixture was 'worked up' 
using the acid extraction method described, to yield the desired amine as a 
yellow oil 430 mg (2.32 mmol, 77.4%); Rf 0.14 (EtOAc); (Found: MH+, 
186.1496. C1OH19N02 requires MH, 186.1494); vmax(CHCI3)/cm-13020, 2980, 
2934, 1723, 1369, 1216, 1155; 8H (200 MHz, CDCI3) 0.93 (3H, d, J 7.0 Hz, 6-
H3), 1.39 (9H, s, 8, 9, 10-H3), 2.00 (2H, br s, N-H2), 2.49 (1 H, m, 3-H), 3.26 
(1 H, d, J 4.6 Hz, 2-H), 5.00 (2H, m, 5-H2) and 5.67 (1 H, m, 4-H). 
Complementary signals visible for minor diastereoisomer at 8 1.01 and 3.14 
ppm; <>e (50 MHz) 13.9 (C-6), 27.9 (C-a, 9, 10),41.5 (C-3), 58.5 (C-2), 80.9 (C-
7), 115.3 (C-5), 139.9 (C-4) and 173.6 (C-1). Complementary signals visible for 
minor diastereoisomer at <> 16.4, 27.8, 41.7, 59.1, 116.0, 138.6 and 173.7 ppm; 
mlz(CI) 186 (MH+, 100%), 147,130,117,96,84. 
DL-2-Methylallylglycine tert-butyl ester (149) 
163 
Compound (149) was synthesised from compound (146) (2.91 g, 10.00 
mmol) and MO(CO)6 (1.85 g, 7.00 mmol) in acetonitrile (150 ml) and water (10 
ml) according to general procedure 6. The reaction mixture was 'worked up' 
using the chromatographic method described, to yield the desired amine as a 
yellow oil, 890 mg (4.80 mmol, 48.0%); Rt 0.11 (EtOAc); (Found: M+-Ot8u, 
112.0762.C10H19N02 requires M-OtBu, 172.0762); vmax(thin film)!cm- 1 2978, 
2933,1726,1457,1369,1143; ()H (200 MHz, CDCI3) 1.22 (3H, s, 6-H3), 1.39 
(9H, s, 8, 9, 10-H3), 1.75 (2H, br s, N-H), 2.16 and 2.43 (2H, 2 x m, 3-H2), 5.07 
(2H, m, 5-H2) and 5.66 (1 H, m, 4-H); ()C (50 MHz) 26.3 (C-6), 27.9 (C-8, 9, 10), 
45.1 (G-3), 57.4 (C-2), 80.8 (G-7), 119.0 (C-5), 133.0 (C-4) and 176.3 (G-1); m/z 
(GI) 186 (M+, 46.6%),158,147, 129, 112,96,84. 
DL-N-tert-Butoxycarbonyl-3-methylallylglycine tert-butyl ester (135) 
Method 1 
To a solution of compound (134) (1.26 g, 5.49 mmol), DGC (1.78 g, 8.64 
mmol) and DMAP (10 mg) in anhydrous dichloromethane (30 ml), under 
nitrogen, at room temperature, was added tert-butyl alcohol (640 mg, 8.64 
mmol). The resulting suspension was stirred at this temperature for 18 h. The 
mixture was filtered, cooled to -20°C for 2 h and filtered again to remove the 
final traces of DCU byproduct. The filtrate was washed with sat. NaHG03 (aq) 
(2 x 100 ml) and the organic portion was dried (MgS04), filtered and 
concentrated in vacuo to a brown oil. Purification was achieved on a silica dry 
flash column, eluting with 5% EtOAc in hexane, to give the desired ester as a 
lightly coloured oil, 680 mg (2.38 mmol, 43.4%). 
Method 2 
Compound (135) was synthesised from compound (150) (1.75 g, 9.45 
mmol), KHC03 (1.04 g, 10.40 mmol) and di-tert-butyldicarbonate (2.27 g, 10.40 
mmol) in 1,4-dioxane (50 ml) and water (50 ml) according to general 
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procedure 2. Purification was achieved on a silica dry flash column, eluting 
with 5% EtOAc in hexane, to yield the desired carbamate as a colourless oil, 
2.289 (7.99 mmol, 84.5%); Rt 0.46 (20% EtOAc in hexane); (Found: M+, 
285.1935. C1sH27N04 requires M, 285.1940); vmax(thin film)/cm- 1 3372, 2975, 
2934, 1711, 1513; 8H (200 MHz, CDCI3) 0.98 (3H, d, J 6.9 Hz, 6-H3), 1.37 and 
1.39 (18H, 2 x s, 8, 9, 10- and 13,14, 15-H3), 2.55 (1H, m, 3-H), 4.11 (1 H, m, 2-
H), 4.86 (1 H, br m, N-H), 5.00 (2H, m, 5-H2) and 5.65 (1 H, m, 4-H). 
Complementary signal visible for minor diastereoisomer at 8 1.01 ppm; 8c (50 
MHz) 15.2 (e-6), 28.0 and 28.2 (C-8, 9, 10 and C-13, 14,15), 40.8 (C-3), 57.6 
(C-2), 79.5 and 81.7 (C-7 and C-12), 115.6 (C-5), 138.9 (C-4), 155.4 (C-11) and 
170.6 (C-1). Complementary signals visible for minor diastereoisomer at 815.9, 
40.3,57.9,81.8,116.2,137.9,155.6 and 170.7 ppm; m/z285 (M+, 0.5%), 229, 
186,174,158,146,130,102,83,57 (100%). 
DL-N-tert-Butoxycarbonyl-2-methylallylglycine tert-butyl ester (151) 
o 15 14 
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Compound (151) was synthesised from compound (149) (750 mg, 4.05 
mmol), KHC03 (410 mg, 4.05 mmol) and di-tert-butyldicarbonate (1.09 g, 5.00 
mmol) in 1,4-dioxane (20 ml) and water (20 ml) according to general 
procedure 2. Purification was achieved on a silica dry flash column, eluting 
with 5% EtOAc in hexane, to yield the desired carbamate as a colourless oil, 
558 mg (1.96 mmol, 48.3%); At 0.29 (10% EtOAc in hexane); (Found: M+, 
285.1941. C1SH27N04 requires M, 285.1940); vmax<thin film)/cm- 1 3426,2980, 
2934, 1716, 1494; 8H (200 MHz, CDCI3) 1.36 and 1.39 (18H, 2 x s, 8, 9, 10-
and 13, 14, 15-H3), 1.43 (3H, s, 6-H3), 2.44 (2H, dd, J 13.8, 7.2 Hz, 3-H2), 5.00 
and 5.07 (2H, 2 x m, 5-H2), 5.20 (1 H, br s, N-H) and 5.61 (1 H, m, 4-H); 8c (50 
MHz) 23.2 (C-6), 27.8 and 28.2 (C-8, 9,10 and C-13, 14, 15),41.1 (C-3), 59.1 
(C-2), 78.9 and 81.4 (C-7 and C-12), 118.8 (C-5), 132.6 (C-4), 154.1 (C-11) and 
173.0 (C-1); m/z (CI) 286 (MH+, 100%),230,186,130,84,58. 
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DL-N-tert-Butoxycarbonyl-3-methylaspartate-~-semialdehyde tert-butyl 
ester (153) 
Compound (135) (296 mg, 1.04 mmol) was ozonised for 60 min in 
anhydrous dichloromethane (30 mJ) and the resulting ozonide quenched with 
triethylamine (290 ~I, 2.08 mmol), according to general procedure 3. 
Purification was achieved on a silica dry flash column, eluting with 5% EtOAc in 
hexane, to yield the desired aldehyde as a colourless oil, 175 mg (0.61 mmol, 
58.6%); Rt 0.33 (33% EtOAc in hexane); (Found: MH+, 288.1807; C, 58.55; H, 
8.59; N, 4.82. C14H2SNOS requires MH, 288.1811; C, 58.51; H, 8.77; N, 
4.87%); vmaithin film)!cm-1 2982,2937,1713,1601,1499,1370; ()H (200 MHz, 
CDCI3) 1.04 (3H, d, J 7.2 Hz, 5-H3), 1.38 and 1.41 (18H, 2 x s, 7, 8, 9- and 12, 
13, 14-H3), 2.97 (1H, m, 3-H), 4.58 (1H, dd, J 7.9,3.7 Hz, 2-H), 5.32 (lH, br s, J 
7.7 Hz, N-H) and 9.63 (1H, s, 4-H). Complementary signals for minor 
diastereoisomer at 8 0.91, 1.36, 2.79, 4.67 5.22 and 9.68 ppm; 8e (50 MHz) 
8.50 (C-5), 27.7 and 28.2 (C-7, 8, 9 and C-12, 13, 14),49.0 (C-3), 53.8 (C-2), 
80.0 and 83.1 (C-6 and C-ll), 155.4 (C-10), 169.2 (C-1) and 201.0 (C-4). 
Complementary signals for minor diastereoisomer at 8 8.2, 27.8, 28.1, 49.4, 
53.6,80.1,82.9,155.2,169.6 and 201.1 ppm; mlz (CI) 288 (MH+, 36.9%), 249 
(100%),232,188,86. 
DL-N-tert-Butoxycarbonyl-2-methylaspartate-~-semialdehyde tert-butyl 
ester (152) 
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Compound (151) (843 mg, 2.95 mmol) was ozonised for 90 min in 
anhydrous dichloromethane (30 ml) and the resulting ozonide quenched with 
triethylamine (823 ~I, 5.91 mmol), according to general procedure 3. 
Purification was achieved on a silica column, eluting with 10% EtOAc in 
hexane, to yield the desired aldehyde as a white solid, 611 mg (2.13 mmol, 
72.1 %); mp 47-48 °C; Af 0.25 (20% EtOAc in hexane); (Found: M+, 288.1821; 
C, 58.35; H, 8.96; N, 4.93. C14H25NOS requires MH, 288.1811; C, 58.51; H, 
8.77; N, 4.87%); vmax(KBr disc)/cm-1 3372, 2975, 2934, 1716, 1512; BH (200 
MHz, CDCI3) 1.08 and 1.13 (18H, 2 x s, 7, 8, 9- and 12,13, 14-H3), 1.20 (3H, s, 
5-H3), 2.60 and 3.04 (2H, dd and br d respectively, J 16.9,1.1 Hz and J 17.0 
Hz, 3-H2), 5.29 (1 H, br s, N-H) and 9.38 (1 H, dd, J 1.9, 1.2 Hz, 4-H); Be (50 
MHz) 24.0 (C-5), 27.5 and 28.1 (C-7, 8, 9 and C-12, 13, 14),49.2 (C-3), 58.6 
(C-2), 79.4 and 82.2 (C-6 and C-l1), 154.2 (C-l0), 172.2 (C-l) and 199.6 (C-4); 
mlz (CI) 288 (MH+, 73.7%), 249 (100%), 232,193, 186, 176,86. 
DL-3-Methylaspartate-f3-semialdehyde hydrate hydrochloride (155) 
Compound (155) was synthesised from compound (153) (300 mg, 1.04 
mmol) in anhydrous EtOAc (3 ml) and 2.5M anhydrous HCI in EtOAc (4.18 ml, 
10.44 mmol) according to general procedure 1. The product was isolated as a 
hygroscopic white solid which was dried in a desiccator (P205) and stored at 
-20°C, 189 mg (1.02 mmol, 98.1%); mp 87°C (dec.); vmax(KBr disc)/cm-1 3419, 
2978,1790,1739,1598,1509; BH (200 MHz, 020) 1.32 (2H, s, 5-H3), 2.22 (lH, 
m, 3-H), 3.99 (1 H, m, 2-H)-H3) and 4.93 (1 H, m, 4-H); Be (50 MHz) 9.7 (C-5), 
40.2 (C-3), 54.8 (C-2), 92.0 (C-4) and 172.4 (C-l). The 1H NMA spectrum 
shows the presence of solvent in the solid lattice, which is not removed on 
extensive drying under high vacuum. The spectra are further complicated by the 
presence of diastereomers. This compound did not give a satisfactory mass 
spectrum, but was however suitable for work with the OHOPS enzyme. 
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DL-2-Methylaspartate-B-semialdehyde hydrate hydrochloride (154) 
Compound (154) was synthesised from compound (161) (190 mg, 0.66 
mmol) in 2.16M anhydrous HCI in EtOAc (3.06 ml, 6.61 mmol) according to 
general procedure 1. The product was isolated as a hygroscopic white solid 
which was dried in a desiccator (P20S) and stored at -20°C, 151 mg (0.81 
mmol, 123% due to solvation); mp 92°C (dec.); vmax(KBr disc)/cm-1 3428, 
2923, 1789, 1733, 1633; BH (200 MHz, D20) 1.38 (3H, s, 5-H3), 1.84 and 2.07 
(2H, 2 x dd, J 15.0, 6.7 Hz and 15.0,5.1 Hz respectively, 3-H2) and 5.04 (1H, 
dd, J 6.7, 5,1 Hz, 4-H). Signals observed for solvation at 0.95 (t), 3.34 (q) and 
3.42 (q) ppm; Be (50 MHz) 23.3 (C-5), 43.2 (C-3), 58.9 (C-2), 88.2 (C-4) and 
174.8 (C-1); m/z 150 (M+, 3.2%), 136, 120 (100%),97. This compound did not 
give a satisfactory mass spectrum. 
7.03 Experimental to Chapter 4 
DL-N-Acetylallylglycine (113) 115 
o 
HN~' 
H02C~ 
1 3 5 
This was prepared according to the method of Black and Wright. 115 
Freshly distilled acetic anhydride (7.55 ml, 80.00 mmol) was added, via a 
syringe pump, over a period of 90 min to a solution of DL-allylglycine (4.60 g, 
40.00 mmol) in 2M NaOH (aq) (20 ml) at 0 DC. The pH was carefully monitored 
and kept at pH > 9.5 by addition of 40 % NaOH (aq) as required. After addition 
of the anhydride the solution was acidified to pH 1 with c.HCI (aq) (- 10 ml) and 
extracted with EtOAc (3 x 150 ml). The combined organic extract was dried 
(Na2S04), filtered and concentrated in vacuo to a white solid. Purification was 
achieved by crystallisation from acetone / pet. ether (40-60 DC) to yield the 
desired amide as colourless plates, 4.68 g (29.78 mmol, 74.4%); mp 109-112 
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°C (acetone J pet. ether(40J60)) (Lit.195 114 °e); (Found: M+, 157.0745; C, 
53.27; H, 7.10; N, 8.93. C7H11N03 requires M, 157.0739; C, 53.49; H, 7.05; N, 
8.91%); vmax{KBr disc)Jcm-1 3342, 2934, 1722, 1596, 1544; eSH (200 MHz, 
CD30D) 1.97 (3H, s, 7-H3), 2.52 (2H, m, 3-H2), 4.44 (1H, dd, J 8.2, 5.2 Hz, 2-
H), 5.11 (2H, m, 5-H2), and 5.78 (1 H, m, 4-H); eSc (50 MHz) 22.3 (C-7), 36.9 (C-
3), 53.4 (C-2), 118.6 (C-5), 134.5 (C-4), 173.2 and 174.7 (C-1 and C-6); m/z 
157 (M+, 1.3%), 139, 116,98,71 and 42 (100%). 
DL-N-Acetylallylglycine tert-butyl ester (176)190 
o 
HN~" 
8+' o.c~ 6 1 3 5 
7 
Compound (176) was synthesised from compound (113) (1.57 g, 10.00 
mmol) and isobutylene (- 30 ml) in anhydrous dichloromethane (100 ml) and 
C.H2S04 (1.5 ml) according to general procedure 4. Purification was achieved 
on a silica dry flash column, eluting with hexane to remove the polyisobutylene 
byproduct and then EtOAc to yield the desired ester as a white solid, 2.03 9 
(9.53 mmol, 95.3%); mp 53-55°C; Rf 0.20 (50% EtOAc in hexane); (Found: C, 
61.86; H, 8.70; N, 6.52. C11H19N03 requires C, 61.97; H, 8.92; N, 6.57%). The 
NMR spectra are consistent with the literature. 190 
DL-N-Acetylaspartate-~-semialdehyde tert-butyl ester (177)190 
o 
HN~" 
7+' 02C~O 5 1 
6 
Compound (176) (1.07 g, 5.00 mmol) was ozonised in anhydrous 
dichloromethane (30 ml) and the resulting ozonide quenched with triethylamine 
169 
(1.39 ml, 10.00 mmol), according to general procedure 3. Purification was 
achieved on a silica dry flash column, eluting with 25% EtOAc in hexane, to 
yield the desired aldehyde as a colourless oil, 887 mg (4.12 mmol, 82.4%); Rt 
0.29 (EtOAc); (Found: MH+, 216.1239. C1OH17N04 requires MH, 216.1236). 
The NMR spectra are consistent with the Iiterature.190 
DL-N-Acetylaspartate-~-semialdehyde hydrate (175) 190 
o 
6~NH OH 
H02C~OH 
1 3 
Compound (175) was synthesised from compound (177) (350 mg, 1.63 
mmol) in anhydrous dichloromethane (2 ml) and analytical grade trifluoroacetic 
acid (2 ml) according to the method of Tudor.190 Removal of the solvent in 
vacuo, after 1 h at -9°C under a nitrogen atmosphere, gave a residue which 
was trite rated in ether at room temperature for 18 h. The desired acid was 
isolated as a white solid by filtration and dried in a desiccator (P20S), 170 mg 
(0.96 mmol, 58.9%); mp 98-100 DC; cSH (200 MHz, 020) 1.84 (3H, S, 6-H3), 1.90 
(2H, m, 3-H2), 4.28 (1 H, dd, J 8.5, 5.3 Hz, 2-H) and 4.94 (1 H, dd, J 6.6, 4.9 Hz, 
4-H); DC (50 MHz) 22.4 (C-6), 38.8 (C-3), 50.6 (C-2), 88.7 (C-4), 174.9 and 
176.0 (C-1 and C-5). 
DL-N-Acetylallylglycine methyl ester (178)162 
o 
HN~' 
Me02C~ 
6 1 3 5 
A solution of compound (113) (2.00 g, 12.73 mmol) in methanol (50 ml) 
at 0 DC was saturated with anhydrous HCI gas (- 15 min). The solution was 
then stirred for 18 h at room temperature. After concentration in vacuo the 
resulting residue was purified on a silica dry flash column eluting with 50% 
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EtOAc in hexane to yield the desired ester as an oily white solid, 1.63 9 (9.52 
mmol, 74.8%); Rf 0.32 (EtOAc); (Found: M+, 171.0911;. CaH13N03 requires M, 
171.0895); vmax(thin film)/cm-1 3282 (br), 3078,2954, 1748,1656,1547,1437, 
1375; OH (200 MHz, CDCI3) 1.75 (3H, S, 8-H3), 2.26 (2H, m, 3-H2), 3.47 (3H, s, 
6-H3), 4.41 (1 H, m, 2-H), 4.82 and 4.88 (2H, 2 x m, 5-H2), 5.43 (1 H, m, 4-H) 
and 6.16 (1 H, br d, J 6.0 Hz, N-H); OC (50 MHz) 21.3 (C-8), 34.7 (C-3), 50.0 (C-
2),50.6 (C-6), 117.4 (C-5), 130.6 (C-4), 168.2 and 170.7 (C-1 and C-7); m/z 
171 (M+, 4.9%), 139, 130, 112,88 (100%), 70. 
DL-N-Acetylaspartate-~-semialdehyde methyl ester (179) 196 
o 
HN~7 
Me02C~O 
3 
5 1 
Compound (178) (1.00 g, 5.84 mmol) was ozonised in anhydrous 
dichloromethane (50 ml) and the resulting ozonide quenched with triethylamine 
(1.63 ml, 11.68 mmoJ), according to general procedure 3. Purification was 
achieved on a silica dry flash column, eluting with EtOAc, to yield the desired 
aldehyde as a colourless oil, 694 mg (4.05 mmol, 69.4%); Rf 0.16 (EtOAc); 
(Found: MH+, 174.0791. C7H12N04 requires M, 174.0766; vmax(KBr disc)/cm-1 
3024,3009, 1748, 1678, 1508; OH (200 MHz, CDCI3) 1.96 (3H, s, 7-H3), 2.93 
(2H, d, J 4.9 Hz, 3-H2), 3.67 (3H, m, 5-H3), 4.82 (1 H, m, 2-H), 6.89 (1 H, br d, J 
7.5 Hz, N-H) and 9.65 (1 H, s, 4-H); OC (50 MHz) 22.6 (C-7), 45.2 (C-3), 46.9 (C-
2),52.5 (C-5), 170.0 and 171.1 (C-1 and C-6) and 199.4 (C-4); m/z 173 (M+, 
3.0%),141,130,114 (100%), 86. 
DL-2-(DiphenylmethyJeneamino )-5-hexenonitrile (183)99 
11 
171 
Compound (183) was synthesised from N-(diphenylmethylene}-
aminoacetonitrile (11.01 g, 50.00 mmol), benzyl triethylammonium chloride 
(BTEAC) (1.01 g, 4.44 mmol) and 4-bromo-1-butene (8.10 g, 60.00 mmol) in 
50% NaOH (aq) (12 g, 150.0 mmol) and toluene (11 ml) according to the 
method of O'Donnell and Eckrich,99 for a related synthesis. After reaction the 
reaction mix was diluted with water (400 ml) and extracted with 
dichloromethane (4 x 200 ml). The combined organic extract was washed with 
water (3 x 100 ml), brine (100 ml), dried (MgS04), filtered and concentrated in 
vacuo to a red oil. Purification was achieved on a silica dry flash column, eluting 
with 5% EtOAc in hexane, to yield the desired compound as a yellow oil, 12.65 
g (46.11 mmol, 92.2%); Rf 0.35 (10% EtOAc in hexane); SH (200 MHz, CDCI3) 
2.00 (2H, m, 4-H2), 2.20 (2H, m, 3-H2), 4.24 (1 H, t, J 6.6 Hz, 2-H), 4.97 (2H, m, 
6-H2), 5.67 (1 H, m, 5-H) and 7.18 to 7.82 (10H, m, Ar-H's); <>c (50 MHz) 29.5 
(C-4), 33.9 (C-3), 52.3 (C-2), 116.0 (C-6), 119.5 (C-1), 127.4, 128.2, 129.3, 
131.2 and 136.3 (Ar C-H), 130.0 (C-5), 135.2 and 138.4 (C-8 and C-12) and 
173.1 (C-7). The NMR spectra are consistent with the Iiterature. 197 
DL-2-Amino-5-hexenonitrile (184)197 
,H2 4 6 
NC~ 
1 3 5 
Compound (184) was synthesised from (183) (6.86 g, 25.00 mmol) in 3M 
Hel (aq) (25 ml) and ether (25 ml) according to the method of eonnell.197 After 
reaction the aqueous portion was washed with ether (25 ml) and basified with 
2M NaOH (aq) (50 ml). The desired amine was then extracted into EtOAc (3 x 
50 ml), dried (MgS04), filtered and concentrated in vacuo to a colourless oil, 
1.66 9 (15.07 mmol, 60.8%); Rt 0.20 (50% EtOAc in hexane); (Found: M+-H, 
109.0785 eSH10N2 requires M-H, 109.0766); SH (200 MHz, CDCJ3) 1.64 (2H, br 
s, N-H2), 1.75 (2H, m, 3-H2), 2.14 (2H, m, 4-H2), 3.62 (1 H, t, J 7.2 Hz, 2-H), 
5.01 (2H, m, 6-H2) and 5.72 (1 H, m, 5-H); <>c (50 MHz) 29.6 (C-3), 34.3 (C-4), 
42.7 (C-2), 116.4 (C-6), 122.2 (e-1) and 136.3 (e-5). The NMR spectra are 
consistent with the literature. 197 
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DL-2-Amino-5-Hexenoic acid hydrochloride (185)197 
A suspension of (184) (2.47 g, 22.42 mmol) in 5% NaOH (aq) (100 ml) 
was heated to reflux for 24 h. After cooling the mixture was acidified to pH 1 
with c.HCI (aq), washed with EtOAc (2 x 100 ml), concentrated in vacuo, and 
dried in a desiccator (P205) to yield the desired amino acid as a white solid, 
10.66 g (including 125 mmol, 7.29 g NaCI) (estimated 3.37 g, 15.38 mmol 
(185).NH4CI, 68.6%) The characterisation data was consistent with the 
Iiterature:197 oH (200 MHz, 020) 2.18 and 2.32 (4H, 2 x m, 3- and 4-H2), 4.25 
(1 H, m, 2-H), 5.25 (2H, m, 6-H2) and 5.98 (1 H, m, 5-H); oc (50 MHz) 29.6 and 
30.1 (C-3 and C-4), 53.7 (C-2), 117.9 (C-6), 137.8 (C-5) and 173.4 (C-1). 
DL-N-Acetyl-2-amino-5-hexenoic acid (186) 198 
A suspension of (184) (220 mg, 2.00 mmol) in 5% NaOH (aq) (20 ml) 
was heated to reflux for 24 h. On cooling, the solution was washed, acidified 
and concentrated as described previously to give compound (185). Freshly 
distilled acetic anhydride (1.89 ml, 20.00 mmol) was added, via a syringe pump, 
over a period of 120 min to a solution of the crude (185) (4.60 g, 40 mmol) in 
2M NaOH (aq) (5 ml) at 0 DC. The pH was carefully monitored and kept at > 9.5 
by addition of 40% NaOH (aq) as required. After addition of the anhydride the 
solution was acidified to pH 1 with c.HCI (aq) (- 7 ml) and extracted with EtOAc 
(5 x 50 ml). The combined organic extracts were dried (Na2S04), filtered and 
concentrated in vacuo to a yellow oil. Purification was achieved by 
crystallisation from acetone/pet. ether (40-60 DC) to yield the desired amide as 
colourless plates, 197 mg (1.15 mmol, 57.5% for two steps from compound 
(184»; mp 110-113 °C (Lit. 198 114-116 DC); Rf 0.27 (30% MeOH in CHCI3); 
(Found: M+, 171.0896; C, 55.82; H, 7.32; N, 7.99. CSH13N03 requires M, 
178.0895; C, 56.12; H, 7.65; N, 8.18%); vmax(KBrdisc)/cm-1 3346, 1717, 1598, 
173 
1544; DH (200 MHz, CD30D) 1.65 (2H, m, 4-H2), 1.78 (3H, s, 8-H3), 1.93 (2H, 
m, 3-H2), 4.16 (1 H, dd, J 9.0, 4.8 Hz, 2-H), 4.76 to 4.89 (3H, br m, N-H and 6-
H2) and 5.61 (1 H, m, 5-H); 8c (50 MHz) 24.7 (C-8), 33.4 and 34.3 (C-3 and C-
4), 55.5 (C-2), 118.5 (C-6), 140.7 (C-5), 175.8 and 177.9 (C-1 and C-7); m/z 
170 (M+-H, 0.7%), 126,117,84 and 43 (100%). 
DL-N-Acetyl-2-amino-5-hexenoic acid tert-butyl ester(187) 
o 
~NH 
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Compound (187) was synthesised from compound (186) (950 mg, 5.55 
mmol) and isobutylene (- 30 ml) in anhydrous dichloromethane (80 ml) and 
C.H2S04 (1 ml) according to general procedure 4. Purification was achieved 
on a silica dry flash column, eluting with hexane to remove the polyisobutylene 
byproduct and then 20% EtOAc in hexane to yield the desired ester as a white 
solid, 1.08 g (4.77 mmol, 86.0%); mp 39-42 °C; AI 0.48 (EtOAc); (Found: M+-
OtBu, 154.0863; C, 63.48; H, 9.31; N, 6.22. CaH12N02 requires M, 154.0864; 
C, 63.40; H, 9.31; N, 6.22%); vmax(KBr disc)/cm-1 3300, 2978, 1736, 1654, 
1552, 1150; DH (200 MHz, CDCI3) 1.47 (9H, 5, 10, 11, 12-H3), 1.61 to 2.22 (4H, 
m, 3- and 4-H2), 2.02 (3H, S, 8-H3), 4.52 (1 H, m, 2-H), 5.03 (2H, m, 6-H2), 5.79 
(1 H, m, 5-H) and 6.31 (1 H, br d, J 7.4 Hz, N-H); <>c (50 MHz) 21.5 (C-8), 26.3 
(C-10, 11, 12),27.7 and 30.3 (C-3 and C-4), 50.6 (C-2), 80.4 (C-9), 113.8 (C-6), 
135.6 (C-5), 168.1 and 170.2 (C-1 and C-7); m/z 154 (M+-OtBu, 3.9%),126,84 
(100%),57,43. 
DL-N-Acetyl-5-hydroxyproline tert-butyl ester (189) 
174 
Compound (187) (984 mg, 4.33 mmol) was ozonised for 2 h in 
anhydrous dichloromethane (30 ml) and the resulting ozonide quenched with 
triethylamine (1.39 ml, 10 mmol), according to general procedure 3. 
Purification was achieved on a silica dry flash column, eluting with 50% EtOAc 
in hexane, yielded a mixture of diastereoisomers of compound (189) as a white 
solid, 767 mg (3.35 mmol, 77.3%); mp 83-85 °C; Rt 0.21 and 0.26 (EtOAc); 
(Found: M+, 229.1329. C11H19N04 requires M, 229.1314); vmax(KBr disc)/cm-1 
3240 (br), 2976,1742,1730,1628,1616; OH (200 MHz, COCI3) 1.45, 1.47, 1.48 
and 1.48 (9H, 4 x s, 9, 10, 11-H3), 1.80 to 2.57 (4H, m, 3- and 4-H2), 2.30 (3H, 
s, 7-H3), 4.22 to 4.43 (2H, m, 2- and O-H), 4.49 and 5.75 (1H, 2 x m, 5-H); oc 
(50 MHz) 19.3, 19.9,20.1 and 20.6 (e-7), 24.4, 24.9, 26.7, 27.1, 28.8, 29.5, 
32.1 and 33.3 (e-3 and e-4), 26.2 (e-9, 10, 11), 57.7, 57.9, 59.1 and 59.4 (C-
2), 79.5, 80.6 and 80.B (C-B), 80.2, BO.7 and 81.4 (C-5), 168.9, 169.1, 169.3, 
169.5, 169.6, 169.B and 169.9 (C-1 and C-6); m/z 229 (M+, 0.1%), 128, 86 
(100%), 69, 57, 43. The NMR spectra are complicated by the presence of both 
diastereomers and rotomers. 
DL-N-Acetyl-S-hydroxyproline (190) 
To a solution of (189) (370 mg, 1.61 mmol) in anhydrous 
dichloromethene (5 ml) at -9°C, under a nitrogen atmosphere, was added 
analytical grade trifluoroacetic acid (3 ml) and the solution was stirred at this 
temperature for 2 h. Removal of the solvent in vacuo gave a residue, which was 
trite rated in ether at room temperature for 18 h. The desired diastereomeric 
mixture of acids were isolated a white hygroscopic solid by filtration and dried in 
a desiccator (P20S), 147 mg (0.85 mmol, 52.7%); mp 48-50 °C; (Found: M+-
H20, 155.0579. C7H9N03 requires M, 155.0582); vmax{KBr disc)/cm-1 3442 
(br), 1736 (br), 1632 (br); OH (200 MHz, 020) 1.31, 1.91 and 2.29 (4H, 3 x m, 3-
and 4-H2), 2.05 and 2.08 (3H, 2 x s, 7-H3), 4.16 and 4.35 (1 H, 2 x m, 2-H) and 
5.49 (1 H, m, 5-H); DC (50 MHz) 21.6 and 21.7 (e-7), 26.6 and 27.2 (C-3), 33.8 
and 34.4 (C-4), 59.4 and 60.1 (C-2), 83.2 and 83.6 (C-5), 174.6, 174.8, 176.4 
and 176.5 (C-1 and C-6); m/z 155 (M+-H20, 12.6%), 113,69 (100%) and 42. 
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C)-Methyl L-glutamate hydrochloride (165)147 
This was prepared according to the method of McKendrick.147 Thionyl 
chloride (10.95 g, 92.04 mmol) was added slowly to a stirred suspension of L-
glutamic acid (10.07 g, 68.44 mmol) in HPLC grade methanol (50 ml) at 0 °C. 
The resulting solution was stirred at this temperature for a further 15 min and 
then at room temperature for 45 min. Ether (200 ml) was added and a white 
solid precipitated. After a further 30 min at room temperature the solid was 
filtered, washed with ether (2 x 50 ml) and dried in a desiccator (P20S) to yield 
the desired ester as a white solid, 13.35 g (67.55 mmol, 98.7%); mp 147-149 
°C; (Found: M+, 162.0763; C, 36.45; H, 6.05; N, 6.97. CSH12N04 requires M, 
162.0766; C, 36.46; H, 6.12; N, 7.09%). 
C)-Methyl L-glutamate tert-butyl ester (196)199 
Compound (196) was synthesised from compound (165) (10.00 g, 50.60 
mmol) and isobutylene (- 30 ml) in anhydrous dichloromethane (250 ml) and 
c.H2S04 (3 ml) according to the method of McKendrick.199 Purification was 
achieved on a silica dry flash column, eluting with hexane to remove the 
polyisobutylene byproduct and then EtOAc to yield the desired ester as a 
colourless oil, 9.70 9 (44.64 mmol, 88.2%); Rf 0.25 (EtOAc); (Found: MH+, 
218.1390. C10H20N04 requires M, 218.1387). 
176 
<>-Methyl L-N-tert-butoxycarbonylglutamate tert-butyl ester (197)200 
Compound (197) was synthesised from compound (196) (9.55 g, 43.95 
mmol), KHC03 (4.84 g, 48.34 mmol) and di-tert-butyldicarbonate (10.55 g, 
48.34 mmol) in 1,4-dioxane (50 ml) and water (50 ml) according to general 
procedure 2. Purification was achieved on a silica dry flash column, eluting 
with 10% EtOAc in hexane, to yield the desired carbamate as a white solid, 
9.95 9 (31.35 mmol, 71.3%); mp 62-63 °C; Rt 0.11 (10% EtOAc in hexane); 
(Found: MH+, 318.1918; C, 56.81; H, 8.57; N, 4.35. C15H2SN06 requires M, 
318.1916; C, 56.76; H, 8.57; N, 4.41%); vmax(KBr disc)/cm-1 3350,2982,1728, 
1702,1530,1162; <>H (200 MHz, CDCI3) 1.41 and 1.44 (18H, 2 x s, 8, 9,10-
and 13,14, 15-H3), 1.88 and 2.14 (2H, 2 x m, 3-H2), 2.37 (2H, m, 4-H2), 3.65 
(3H, s, 6-H3), 4.15 (1 H, m, 2-H) and 5.08 (1 H, br d, J 8.0 Hz, N-H); oc (50 MHz) 
27.8 and 28.2 (C-8, 9,10 and C-13, 14, 15),27.9 (C-3), 30.0 (C-4), 51.6 (C-6), 
53.3 (C-2), 79.6 and 82.0 (C-7 and C-12), 155.3 (C-11), 171.2 and 173.2 (C-1 
and C-5); m/z 317 (M+, 0.2%), 216, 188, 174, 160, 116,84,57 (100%). 
<>-Methyl L-NN-bis-tert-butoxycarbonylglutamate tert-butyl ester (198) 
14'0 
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DMAP (98 mg, 0.80 mmol) was added to a solution of compound (197) 
(2.54 g, 8.00 mmol) in anhydrous acetonitrile (20 ml), under a nitrogen 
atmosphere. Di-tert-butyldicarbonate (1.92 g, 8.80 mmol) in anhydrous 
acetonitrile (5 ml) was then added and the resulting solution was stirred at room 
177 
temperature for 18 h. The orange solution was concentrated in vacuo at room 
temperature, diluted with ether (40 ml) and washed with 1M KHS04 (aq) (3 x 30 
ml), sat. NaHC03 (aq) (30 ml) and sat. brine (30 ml). The organic portion was 
dried (MgS04), filtered and concentrated in vacuo to a yellow oil. Purification 
was achieved on a silica dry flash column, eluting with 5% EtOAc in hexane, to 
yield the desired dicarbamate as a colourless oil, 2.29 g (5.49 mmol, 68.6%); RI 
0.29 (20% EtOAc in hexane); (Found: MH+, 418.2433. C20H36NOS requires M, 
418.2440); vmax(CHCl3 solution)/cm-1 3026, 2983, 1786, 1734, 1696, 1369; OH 
(200 MHz, CDCI3) 1.33 (9H, s, 8, 9, 10-H3), 1.39 (18H, s, 13, 14, 15- and 13', 
14', 15'-H3), 2.04 (2H, m, 3-H2), 2.38 (2H, m, 4-H2), 3.55 (3H, S, 6-H3) and 4.68 
(1 H, m, 2-H); Oc (50 MHz) 24.4 (C-3), 27.7 (C-8, 9, 10), 27.8 (C-13, 14, 15 and 
C-13', 14', 15'),30.6 (C-4), 51.4 (C-6), 57.9 (C-2), 81.1 (C-7), 82.7 (C-12 and C-
12'),152.1 (C-11 and C-11'), 169.1 and 173.0 (C-1 and C-5); m/z418 (MH+, 
0.1%),316,232,216,160,116,84,57 (100%). 
tert-Butyl L-2-( tert-butoxycarbonylamino )-5-hydroxypentanoate (201 )201 
o 14 HN~O~" 
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Compound (201) was prepared by a method adapted from that of Brown 
and Narasimhan. 158 To a solution of compound (197) (2.12 g, 6.68 mmol) in 
anhydrous ether (20 ml), at -10°C (NH4CI / ice bath) under nitrogen, was 
added lithium borohydride (145 mg, 6.68 mmol). On addition of trimethylborate 
(0.2 ml, 1.79 mmol) a rapid exothermic reaction with evolution of gas was 
observed. The solution was stirred at -10°C for 90 min before addition of more 
trimethylborate (0.544 ml, 4.88 mmol). Stirring was continued at -10°C for a 
further 2.5 h before quenching with sat. NH4CI (aq) (20 ml) and extraction with 
EtOAc (3 x 30 ml). The combined organic extract was dried (MgS04), filtered 
and concentrated in vacuo to a white solid. Purification was achieved on a silica 
dry flash column, eluting with 20% EtOAc in hexane, to yield the desired alcohol 
as an oily white solid, 1.50 9 (5.18 mmol, 77.6%); Rt 0.23 (50% EtOAc in 
hexane); (Found: M+, 290.1954. C14H2SNOS requires M, 290.1967); 
vmax(CHCl3 solution)/cm-1 3436. 2982, 2254. 1709, 1501, 1369; OH (200 MHz, 
CDCI3) 1.37 and 1.40 (18H, 2 x s, 7, 8, 9- and 12,13, 14-H3), 1.47 - 1.85 (4H, 
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br m, 3- and 4-H2), 2.42 (1H, br s, O-H), 3.59 (2H, t, J 6.1 Hz, 5-H2), 4.13 (1H, 
br dd, J 13.7,7.2 Hz, 2-H) and 5.18 (1H, br d, J 7.8 Hz, N-H); <>c (50 MHz) 27.9 
and 28.2 (C-7, 8, 9 and C-12, 13, 14), 28.2 (C-3), 29.6 (C-4), 53.5 (C-2), 62.0 
(C-5), 79.7 and 81.8 (C-6 and C-11), 155.5 (C-10) and 171.9 (C-1); mlz 290 
(M+, 0.5%), 188, 160, 132,88,71,57 (100%). 
DL-NN-bis-(tert-Butoxycarbonyl)allylglycine tert-butyl ester (202) 
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Compound (202) was prepared according to the method of Ragnarsson 
and co-workers146 for a related synthesis. DMAP (191 mg, 1.56 mmol) was 
added to a solution of compound (116) (4.24 g. 15.60 mmol) in anhydrous 
acetonitrile (20 ml). under a nitrogen atmosphere. Di-t-butyldicarbonate (3.75 g. 
17.16 mmol) in anhydrous acetonitrile (10 ml) was then added and the resulting 
solution was stirred at room temperature for 18 h. The yellow solution was 
concentrated in vacuo at room temperature. diluted with ether (50 ml) and 
washed with 1 M KHS04 (aq) (3 x 30 ml), sat. NaHC03 (aq) (30 ml) and sat. 
brine (30 ml). The organic portion was dried (MgS04). filtered and concentrated 
in vacuo to a yellow oil. Purification was achieved on a silica column. eluting 
with 3% EtOAc in hexane, to yield the desired dicarbamate as a white solid. 
4.38 9 (11.79 mmol, 75.6%); mp 70-71 °C; Rf 0.36 (10% EtOAc in hexane); 
(Found: MH+. 372.2386; C, 61.52; H, 8.99; N, 3.64. C19H3SN06 requires MH. 
372.2386; C, 61.43; H. 8.95; N, 3.77%); vmax(KBr disc)/cm-1 2988.2974, 1737, 
1694. 1381, 1368; OH (200 MHz, CDCI3) 1.38 (9H. s, 7, 8, 9-Hs), 1.43 (18H, 8. 
12,13,14- and 12',13', 14'-H3), 2.65 (2H, m, 3-H2), 4.76 (1H. dd, J 9.9,5.3 Hz. 
2-H), 4.99 (2H, m, 5-H2) and 5.66 (1 H, m, 4-H); OC (50 MHz) 27.8 (C-7, 8, 9), 
27.9 (C-12. 13, 14 and C-12', 13', 14'),33.8 (C-3), 58.2 (C-2), 81.1 (C-6), 82,5 
(C-11 and C-11'), 117.4 (C-5), 134.3 (C-4). 152.2 (C-10 and C-10') and 169.2 
(C-1); mlz(CI) 372 (MH+, 39.3%), 333 (100%).316.289,272,233,172. 
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DL-NN-bis-(tert-Butoxycarbonyl)glutamate-y-semialdehyde tert-butyl ester 
(174) 
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Compound (174) was prepared according to the method of Yates159 for a 
related synthesis. To a solution of compound (202) (371 mg, 1.00 mmol) in 
anhydrous ether (5 ml) was added borane.DMS (2M complex in THF) (165 j.JI, 
0.33 mmol) under a nitrogen atmosphere and the solution was stirred at room 
temperature for 3 h. Anhydrous dichloromethane (3 ml), freshly activated 4A 
molecular sieves (6 g) and 4-methylmorpholine-N-oxide (NMO) (351 mg, 3.00 
mmol) were added and the suspension was stirred for a further 1 h at room 
temperature. Tetra-n-propylammonium perreuthinate (TPAP) (20 mg, 57 j.Jmol) 
was added and the suspension was stirred at room temperature for 10 min. A 
colour change from brown to jet black was observed. The reaction mix was 
filtered through a silica plug, washed with EtOAc (3 x 100 ml) and monitored by 
TLC. The crude product was concentrated to a yellow oil and then purified on a 
silica dry flash column, eluting with 5% EtOAc in hexane, to yield the desired 
aldehyde as a white solid, 140 mg (0.36 mmol, 36.1%); mp 42-44 DC; Rf 0.20 
(20% EtOAc in hexane); (Found: M+, 388.2332; C, 58.90; H, 8.55; N, 3.48. 
C19H34N07 requires M, 388.2335; C, 58.89; H, 8.58; N, 3.61%); vmax(CHCl3 
solution)/cm-1 3690, 3022,2983,2360,1786,1732,1696,1369; <>H (200 MHz, 
CDCI3) 1.38 (9H, s, 7, 8, 9-H3), 1.43 (18H, s, 12, 13, 14- and 12', 13', 14'-H3), 
2.07 (2H, m, 3-H2), 2.45 (2H, m, 4-H2), 4.67 (1 H, dd, J 9.6, 5.1 Hz, 2-H) and 
9.70 (1H, s, 5-H); <>c (50 MHz) 21.9 (C-3), 27.8 (C-7, 8, 9), 27.9 (C-12, 13, 14 
and C-12', 13', 14'), 40.6 (C-4), 58.0 (C-2), 81.4 (C-6), 82.9 (C-11 and C-11'), 
152.3 (C-10 and C-10'), 169.1 (C-1) and 201.1 (C-5); mlz (CI/NH3) 388 (MH+, 
58%),349,288,270 (100%), 249, 193, 170. 
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tert-Butyl L-2-(bis-tert-butoxycarbonylamino)-5-hydroxypentanoate (200) 
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Compound (200) was prepared by a method adapted from that of 
Vogel.202 To a solution of compound (202) (743 mg, 2 mmol) in anhydrous 
ether (10 ml) under a nitrogen atmosphere at room temperature was added 
BH3.DMS (2M in THF) (0.5 ml, 1 mmol) and the solution was stirred for 3 h. 
After this time excess borane was quenched by the addition of water (0.5 ml). 
When evolution of H2 gas had subsided 3% NaOH (aq) (0.5 ml, 3.75 mmol) was 
added and followed by careful dropwise addition of 30% w/v H202 (aq) (0.4 ml, 
3.53 mmol). No significant rise in temperature was noted and the solution was 
stirred at room temperature for a further 1 h. Water (20 ml) was then added the 
product was extracted into EtOAc (3 x 20 ml). The combined organic extract 
was dried (MgS04), filtered and concentrated in vacuo to a colourless oil. 
Purification was achieved on a silica dry flash column eluting with 20% EtOAc in 
hexane to yield the desired alcohol as a colourless oil, 336 mg (0.86 mmol, 
43.1 %); Rt 0.35 (50% EtOAc in hexane); (Found: MH+, 390.2488;. C'9H36N07 
requires M, 390.2491); vmax(CHCI3)/cm-1 3022, 2983, 1733, 1694, 1369 ; OH 
(200 MHz, CDCI3) 1.37 (9H, s, 7, 8, 9-H3), 1.43 (18H, s, 12, 13, 14- and 12', 
13', 14'-H3), 1.62 (2H, m, 4-H2), 1.83 (2H, m, 3-H2), 3.65 (lH, m, 2-H) and 4.66 
(1H, m, 5-H2); OC (50 MHz) 25.6 (C-3), 27.8 (C-7, 8, 9),27.9 (C-12, 13, 14 and 
C-12', 13', 14'),29.4 (C-4), 58.6 (C-2), 62.1 (C-5), 81.2 (C-6), 82.8 (C-11 and C-
11'), 152.4 (C-l0 and C-l0') and 169.8 (C-l); m/z (CIINH3) 390 (MH+, 55%), 
351,307 (100%), 290, 251,191. 
DL-N-tert-Butoxycarbonyl-5-hydroxyproline tert-butyl ester (204)149 
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To a solution of compound (116) (543 mg, 2.00 mmol) in anhydrous 
ether (10 ml) was added borane.DMS (2M complex in THF) (500 ~I, 0.50 mmol) 
under a nitrogen atmosphere and the solution was stirred at room temperature 
for 3 h. Anhydrous dichloromethane (6 ml), freshly activated 4A molecular 
sieves (10 g) and 4-methylmorpholine-N-oxide (NMO) (703 mg, 6.00 mmol) 
were added and the suspension was stirred for a further 1 h at room 
temperature. Tetra-n-propylammonium perreuthinate (TPAP) (35 mg, 1 00 ~mol) 
was added and the suspension was stirred at room temperature for 5 min. A 
colour change from brown to jet black was observed. The reaction mix was 
filtered through a silica plug, washed with EtOAc (3 x 100 ml) and monitored by 
TLC. The crude product was concentrated to a yellow oil and then purified on a 
silica column, eluting with 33% ether in hexane, to yield the desired compound 
as a colourless oil, 89 mg (0.31 mmol, 15.5%) The characterisation data was 
consistent with the literature:149 At 0.43 (ether); OH (200 MHz, CDCI3) Signals 
visible for both diastereoisomers: 1.37, 1.38, 1.39 and 1.41 (18H, 4 x s, 8, 9,10 
and 12, 13, 14-H3), 1.72 -2,44 (4H, br m, 3- and 4-H2), 3.60 and 3.80 (1H, 2 x s, 
O-H), 4.13 (1 H, m, 2-H) and 5.49 (1 H, m, S-H). 
DL-5-Hydroxyproline hydrochloride (205) 161 
Compound (174) (200 mg, 0.52 mmol) was dissolved in anhydrous EtOAc (2.5 
ml) and treated with 2.5M anhydrous Hel in EtOAc (4 ml, 10 mmol) according to 
general procedure 1. The product was isolated as a hygroscopic white solid, 
which was dried in a desiccator (P20S) and stored at -20°C, 79 mg (0.47 mmol, 
90.4%); vmax(KBr disc)/cm-1 3427,2980, 1738, 1396; OH (200 MHz, D20) 1.5 to 
2.0 (4H, br m, 3- and 4-H2), 4.08 (1 H, dd, J 5.5, 4.4 Hz, 2-H) and 6.30 (1 H, m, 
5-H); 8e (50 MHz) 28.3 (C-3), 42.9 (C-4), 49.7 (e-2), 86.6 (C-5) and 169.0 (e-
1). There is evidence of doubling of signals in the 13C NMA spectrum due to the 
presence of diastereoisomers. This compound did not give a satisfactory mass 
spectrum. 
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7.04 Experimental to Chapter 5 
General Procedure 7: 
Imines were prepared according to the method of Vogel.203 The 
semicarbazide or hydrazine and sodium acetate (2 equiv.) were dissolved in 
water and a solution of the pyruvic ester (1 equiv.) in ethanol was added. 
Sufficient ethanol was added to ensure homogeneity. After about 30 min at 
room temperature the resulting solid was filtered and recrystallised from 
water/ethanol. 
Methyl pyruvate thiosemicarbazone (220)204 
Compound (220) was synthesised from thiosemicarbazide (910 mg, 
10.00 mmol) in 1M HCI (aq) (10 ml) and methyl pyruvate (1.02 g, 10.00 mmol) 
in water (20 ml) and ethanol (20 ml) according to general procedure 7. After 
crystallisation from water / ethanol the product was isolated as white prisms, 
1.49 9 (8.45 mmol, 84.5%); The characterisation data was consistent with the 
literature:204 mp 134-136 °C; Af 0.18 (33% EtOAc in pet. ether (40/60 °C)); 
(Found: M+, 175.0409. C5H9N302S requires M, 175.0415); A.max(H20)/nm 292 
(£Idm3mol-1cm-1 27830). 
Ethyl pyruvate semicarbazone (229) 
Compound (229) was synthesised from semicarbazide hydrochloride 
(558 mg, 5.00 mmol) and ethyl pyruvate (581 mg, 5.00 mmol) in water (20 ml) 
and ethanol (10 ml) according to general procedure 7. After crystallisation 
from ethanol the product was isolated as white prisms, 1.70 g (9.81 mmol, 
98.1%); mp 200-201 °C (EtOH); Rt 0.27 (5% MeOH in CHCI3); (Found: M+, 
173.0793. C6H11N303 requires M, 173.0800); Amax(H20)/nm 258 (e/dm3mol-
183 
1cm-1 11970); vmax{KBr disc)/cm-1 3507, 3322, 3174, 1698, 1599, 1296; Ot-J (200 
MHz, Ds-DMSO) 1.28 (3H, t, J 7.1 Hz, 6-H3), 2.02 (3H, s, 3-H3), 4.21 (2H, q, J 
7.1 Hz, 5-H2), 6.55 (2H, br s, N-H2) and 9.94 (1 H, s, N-H); Be (50 MHz) 12.3 (C-
3),14.1 (C-6), 60.8 (C-5), 136.3 (C-2), 156.1 (C-1) and 164.4 (C-4); m/z 173 
(M+, 0.1%), 130, 100,83,73,57 (100%). 
Ethyl pyruvate thiosemicarbazone (230) 
Compound (230) was synthesised from thiosemicarbazide (910 mg, 
10.00 mmol) in 1M HCI (aq) (10 ml) and ethyl pyruvate (1.16 g, 10.00 mmol) in 
water (90 ml) and ethanol (10 ml) according to general procedure 7. After 
filtration the product was isolated as a white solid, 581 mg (3.35 mmol, 67.0%); 
mp 137°C; Rf 0.36 (33% EtOAc in pet. ether (40/60 DC»~; (Found: M+, 
189.0575; C, 37.91; H, 5.79; N, 22.19. CSH11N302S requires M, 189.0572; C, 
38.04; H, 5.85; N, 22.28%); Amax(H20)/nm 291 (ddm3mol-1cm-1 34360); 
vmax(KBr disc)/cm-1 3424,3270,3206,3164, 1712, 1605, 1507; BH (200 MHz, 
CDCI3) 1.35 (3H, t, J 7.1 Hz, 6-H3), 2.16 (3H, 5, 3-H3), 4.31 (2H, q, J 7.1 Hz, 5-
H2), 7.06 (1 H, br s, N-H) and 7.60 (2H, br s, N-H2); Be (50 MHz) 12.1 (C-3), 
14.1 (C-6), 62.1 (C-5), 108.9 (C-4), 139.1 (C-2) and 180.0 (C-1); m/z 189 (M+, 
8.7%),116 (100%), 75, 57, 43. 
Ethyl hydrazinoacetate derivative of ethyl pyruvate (231) 
To a suspension of ethyl hydrazinoacetate hydrochloride (464 mg, 3.00 
mmol) and dry Et3N (0.42 ml, 3.00 mmol) in anhydrous dichloromethane (10 ml) 
under a nitrogen atmosphere was added ethyl pyruvate (348 mg, 3.00 mmol). 
The reaction mixture was then stirred at room temperature for 40 h. After this 
time the solution was concentrated to a deep yellow coloured oil which was 
purified on a silica column, eluting with 50% EtOAc in pet. ether (40/60 DC), to 
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yield the desired imine as a white solid, 480 mg (2.22 mmol, 74.0%); mp 108· 
109 DC ; Rt 0.31 (50% EtOAc in pet. ether (40/60 DC»; (Found: M+, 216.1107; 
C, 49.83; H, 7.54; N, 12.76. C9H16N204 requires M, 216.1110; C, 49.99; H, 
7.46; N, 12.96%); vmax(KBr disc)/cm- 1 3352, 2982,1730,1697,1581,1373, 
1324; OH (200 MHz, CDCI3) 1.28 and 1.33 (6H, 2 x t, J 7.1 and 7.1 Hz, 7- and 9-
H3), 2.02 (3H, S, 3-H3), 4.20 and 4.29 (4H, 2 x q, J 7.1 and 7.1 Hz, 6- and 8-H2) 
and 6.04 (1H, brm, N-H); oe (50 MHz) 11.1 (C-3), 14.1 and 14.2 (C-7 and C-9), 
52.4 (C-4), 61.4 and 61.8 (C-6 and C-8), 134.8 (C-2), 153.6 (C-1) and 170.2 (C-
5); mlz216 (M+, 8.4%),171,143,115,97,69 (100%), 55,42. 
Methyl hydrazinocarboxylate derivative of ethyl pyruvate (232) 
o 
.Jl N CO 6 
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Compound (232) was synthesised from methyl hydrazinocarboxylate 
(1.80 g, 20.00 mmol) in 1 M HCI (aq) (20 ml) and ethyl pyruvate (2.32 g, 10.00 
mmol) in ethanol (10 ml) according to general procedure 7. After filtration the 
product was isolated as white prisms, 3.07 g (16.29 mmol, 81.4%); mp 134-136 
DC (EtOH / acetone); (Found: M+, 188.0792; C, 44.75; H, 14.92; N, 6.28. 
C7H12N204 requires M, ;188.0797; C, 44.68; H, 14.89; N, 6.43%); 
Amax(H20)/nm 250 (E/dm3mol-1cm-1 17260); vmax(KBr disc)/cm-1 3240, 3175, 
1698, 1611, 1450, 1375; OH (200 MHz, CDCI3) 1.25 (3H, t, J 7.1 Hz, 6-H3), 2.05 
(3H, s, 3-H3), 3.75 (3H, s, 7-H3), 4.21 (2H, df J 7.1 Hz, 5-H2) and 9.03 (1 H, br Sf 
N-H); Oe (50 MHz) 11.6 (C-3), 14.0 (C-6), 53.4 (C-7), 61.9 (C-5), 141.3 (C-2), 
154.4 (C-1) and 164.4 (C-5); mlz188 (M+, 1.3%),143,129,115 (100%), 83, 73, 
59. 
Ethyl3-iso-propoxypyruvate semicarbazone (234) 
185 
To a solution of semicarbazide hydrochloride (1.12 g, 10.00 mmol) in 
water (10 ml) at 0 °C was added ethyl bromopyruvate (1.95 g, 10.00 mmol). 
After 20 min the acidic suspension was neutralised with sat. NaHC03 (aq) and 
the crude mixture of products (TLC) was filtered off. Purification was achieved 
on a silica column, eluting with 10% iprOH in CH3CI, to yield compound (234) 
as a white solid, 123 mg (0.53 mmol, 5.3%); mp 72-73 °C; Rt 0.49 (10% iPrOH 
in CH3CI); (Found: M+Jpr, 188.0684; C, 46.76; H, 7.50; N, 18.08. C9H17N304 
requires MJPr, 188.0672; C, 46.74; H, 7.41; N, 18.17%); Amax(H20)/nm 260 
(Eldm3mol-1cm-1 25420); vmax(KBr disc)/cm-1 ; OH (200 MHz, CD30D) 1.20 (6H, 
d, J 6.1 Hz, 4- and 6-H3), 1.33 (3H, t, J 7.1 Hz, -H3), 3.67 (1 H, sept, J 6.1 Hz, 5-
H), 4.30 (2H, q, J 7.1 Hz, 7-H2) and 4.58 (2H, S, 3-H2); OC (50 MHz) 14.4 (C-8), 
22.1 (C-4 and C-6), 63.1 (C-7), 64.0 (C-3), 74.0 (C-5), 137.5 (C-2), 165.2 (C-1) 
and 168.3 (C-9); m/z 231 (M+, 0.5%), 173, 158, 130, 100, 84, 73, 55 and 43 
(100%). 
Ethyl bromopyruvate methyl oxime (224)204 
To a solution of methoxylamine hydrochloride (835 mg, 10.00 mmol) in 
water (10 ml) was added a solution of ethyl bromopyruvate (1.95 g, 10.00 
mmol) in ethanol (10 ml) and the resulting solution was stirred at room 
temperature for 72 h. Removal of the solvent with ethanol in vacuo resulted in 
an oily solid, which was washed through an alumina plug with dichloromethane 
(50 ml) and reconcentrated to yield the pure oxime as a yellow coloured oil, 
1.13 g (5.05 mmol, 50.5%); The characterisation data was consistent with the 
literature:204 Rf 0.56 (50% EtOAc in pet. ether (40/60 °C»); (Found: M+, 
224.9835. CsH1OBrB1N03 requires M, 224.9824); Amax(H20)/nm 234 (Eldm3mol-
1cm-1 10720); m/z 225 (M+ (Br81), 11.2%), 223 (M+ (Br79), 11.0%), 181, 179, 
152, 150, 120, 122, 106, 76, 41 (100%). 
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(R)-3,4-Dihydro-2H-1 ,4-thiazine-3,5-dicarboxylic acid L-(64) 173 
Bromopyruvic acid monohydrate (7.76 g, 46.48 mmol) was added to a 
solution of L-cysteine hydrochloride monohydrate (7.42 g, 42.25 mmol) in water 
(30 ml) and mixed in a sonic bath at room temperature for 15 min. The resulting 
precipitate was filtered, washed with water (3 x 10 ml) and dried in a desiccator 
(P20S) to yield a white solid, 7.02 g (37.00 mmol, 87.6%) The characterisation 
data was consistent with the literature:205 mp 254-260 °C (dec. at 160 OC); 
[a]D20 -70.70 (c 2.439, MeOH); (Found: M+, 189.0096; C, 38.04; H, 3.61; N, 
7.41. CSH7N04S requires M, 189.0094; C, 38.09; H, 3.73; N, 7.40%); 
Amax(H20)/nm 307 (e/dm3mol-1cm-1 5200). 
(S)-3,4-Dihydro-2H-1,4-thiazine-3,5-dicarboxylic acid 0-(64) 
H.... s 
H,.)f ~ 
HO cAN 5 co H 
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Bromopyruvic acid monohydrate (209 mg, 1.25 mmol) was added to a 
solution of D-cysteine hydrochloride monohydrate (200 mg, 1.14 mmol) in water 
(2 ml) and mixed in a sonic bath at room temperature for 15 min. The resulting 
precipitate was filtered, washed with water (3 x 5 ml) and dried in a desiccator 
(P20 S) to yield a white solid, 178 mg (0.94 mmol, 82.5%); mp 254-260 °C (dec. 
at 160 OC); [a]o20 +70.60 (c 0.445, MeOH); (Found: M+, 189.0096; C, 37.72; H, 
3.45; N, 7.24. CsH7N04SS requires M, 189.0094; C, 38.09; H, 3.73; N, 7.40%). 
()H (200 MHz; D20/NaOD) 2.69 (1H, dd, J 12.5,6.8 Hz, 2-Ha), 2.87 (1H, dd, J 
12.5, 3.0 Hz, 2-Hb), 3.73 (1 H, dd, J 6.8, 3.0 Hz, 3-H) and 5.72 (1 H, s, 6-H); Be 
(50 MHz; Ds-DMSO) 25.7 (C-2), 52.2 (C-3), 97.7 (C-6), 128.6 (C-5), 168.4 (C-8) 
and 171.7 (C-7). All spectral data were the same as compound L-(64). 
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Diethyl (R)-3,4-dihydro-2H-1 ,4-thiazine-3,5-dicarboxylate (235)205 
Compound (235) was synthesised from L -cysteine ethyl ester 
hydrochloride (9.28 g, 50.00 mmol), triethylamine (13.9 ml, 100.0 mmol) and 
ethyl bromopyruvate (6.27 ml, 50.00 mmol) in anhydrous dichloromethane (100 
ml) according to the method of Tudor. 205 After 18h, at room temperature under 
a nitrogen atmosphere, the suspension was washed with water (2 x 100 ml) and 
the organic portion was dried (Na2S04), filtered and concentrated in vacuo to a 
red oil. Purification was achieved on a silica gel dry flash column, eluting with 
5% EtOAc in hexane, to yield the desired thiazine as a yellow oil, 10.67 g 
(43.50 mmol, 87.0%); Rf 0.40 (33% EtOAc in hexane); (Found: M+ 245.0731. 
C1OH1SN04S requires M, 245.0722); A.max(H20)/nm 308 (E/dm3mol-1cm-1 5350). 
Dimethyl (R)-3,4-dihydro-2H-1 ,4-thiazine-3,5-dicarboxylate (240) 
To a suspension of L-(64) (3.00 g, 15.86 mmol) in methanol (70 ml) was 
added concentrated sulfuric acid (1 ml) and the mixture was heated to reflux for 
18 h. After this time the solvent was removed in vacuo and the resulting residue 
was carefully neutralised with sat. NaHC03 (aq) (50 ml) and extracted with ethyl 
acetate (2 x 50 ml). The combined organic extract was dried (MgS04), filtered 
and concentrated in vacuo to yield a red oil. Purification was achieved on a 
silica column, eluting with 10 % EtOAc in hexane, to yield the desired diester as 
a lightly coloured solid, 2.10 g (9.67 mmol, 61.0%); mp 39-41 oC; Rt 0.44 (50% 
EtOAc in hexane); (Found: M+, 217.0390; C, 44.33; H, 5.07; N, 6.22. 
CaH11N04S requires M, 217.0409; C, 44.23; H, 5.10; N, 6.45 %); 
Amax(H20)/nm 310 (E/dm3mol-1cm-1 12150); vmax(thin film)/cm-1 3402 (br), 2954, 
1744,1710,1606,1438 and 1256; ~H (200 MHz; CDCI3) 2.95 (1H, ddd, J 12.4, 
6.5,0.66 Hz, 2-Ha), 3.14 (1H, ddd, J 12.4,3.0,0.78 Hz, 2-Hb), 3.71 and 3.72 
(6H, 2 x s, 8 and 10-H3), 4.21 (1 H, dd, J 6.5, 3.0 Hz 3-H), 4.53 (1 H, br 5, N-H) 
188 
and 6.09 (lH, s, 6-H); Be (50 MHz) 26.7 (C-2), 52.1 and 52.7 (C-8 and C-10), 
52.9 (C-3), 101.4 (C-6), 127.7 (C-5), 162.6 (C-9) and 170.6 (C-7); m/z 217 (M+, 
26.8%),158,126 (100%),98,87,54 and 44. 
Oi-tert-butyl (R)-3,4-dihydro-2H-1 ,4-thiazine-3,5-dicarboxylate (241) 
H a~, 2 S 
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Compound (241) was synthesised from compound L-(64) (3.78 g, 20.00 
mmol) and isobutylene (- 20 ml) in anhydrous dichloromethane (250 ml) and 
C.H2S04 (3 ml) according to general procedure 4. Purification was achieved 
on a silica dry flash column, eluting with hexane to remove the polyisobutylene 
byproduct and then 5% EtOAc in hexane, to yield the desired ester as a yellow 
coloured oil, 4.84 g (16.06 mmol, 80.3%); Rt 0.58 (50% EtOAc in hexane); 
(Found: M+, 301.1350. C14H23N04S requires M, 301.1348); v max(KBr}/cm-1 
3398,2975,1744,1697,1498; ()H (200 MHz, CDCI3) 1.44 and 1.46 (18H, 2 x s, 
9,10,11- and 14,15, 16-H3), 2.89 (1H, dd, J 12.3,7.0 Hz, 2-Ha), 3.13 (1H, dd, 
J 12.3, 2.2 Hz, 2-Hb), 4.08 (1 H, m, 3-H), 4.66 (1 H, br s, N-H) and 6.02 (1 H, s 6-
H); Be (50 MHz) 26.9 (C-2), 27.9 and 28.0 (C-9, 10, 11 and C-14, 15, 16),53.5 
(C-3), 81.4 and 82.3 (C-8 and C-13), 99.8 (C-6), 129.2 (C-5), 161.4 (C-12) and 
169.2 (C-7); m/z301 (M+, 3.4%),189,169,144,126,98,72 and 57 (100%). 
DL -6-0eutero-3,4-dihydro-2,2-dimethyl-2 H-1 ,4-thiazine-3,5-dicarboxylic 
acid (243) 
8 
~ 
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Bromopyruvic acid monohydrate (835 mg, 5.00 mmol) and 0 L-
penicillamine (746 mg, 5.00 mmol) were dissolved in 020 (5 ml), enclosed and 
left to stand at room temperature for 18 h. Precipitation of a white solid began 
after about 1 h. The suspension was filtered and the solid portion dried in a 
desiccator (P20S) to yield the desired thiazine as a white solid, 795 mg (3.64 
mmol, 72.9 %) mp 146-150 oC (dec.) (D20); (Found: M+, 218.0479. 
CSH10DN04S requires M, 218.0472); Amax(H20)!nm 310 (fidm3mol-1cm-1 
6190); v max(KBr)/cm-1 3390,2974 (br), 1706, 1660, 1424 and 1295; <>H (200 
MHz; D20!CD30D) 1.20 and 1.38 (6H, 2 x s, 7- and 8-H3), and 3.72 (1 H, s, 3-
H); Be (50 MHz) 25.4 and 28.4 (C-7 and C-8), 40.9 (C-2), 63.5 (C-3), 102.3 (C-
6), 127.7 (C-5), 165.4 (C-10), and 173.2 (C-9); mlz 218 (M+, 2.0%), 154, 128, 
112, 82, 74, 59 and 44 (100%). 
Diethyl DL-3,4-dihydro-2,2-dimethyl-2H-1 ,4-thiazine-3,5-dicarboxylate (244) 
A solution of DL-penicillamine (2.00 g, 13.40 mmol) in glacial acetic acid 
(10 ml) was added to a stirred solution of bromopyruvic acid (2.24 g, 13.40 
mmol) in glacial acetic acid (4 ml) and the resulting solution was stirred at room 
temperature overnight. After this time the solvent was removed under vacuum, 
freshly dried ethanol (50 ml) and C.H2S04 (0.4 ml) were added and the solution 
was heated at reflux for 2 h. After cooling, the excess solvent was removed in 
vacuo and the resulting residue was suspended in sat. NaHC03 (aq) (50 ml) 
and extracted with EtOAc (3 x 50 ml). The combined organic extract was dried 
(MgS04), filtered and concentrated. Purification was achieved on a silica 
column, eluting with 20% EtOAc in hexane, to yield the desired thiazine diester 
as a yellow oil, 240 mg (0.88 mmol, 6.6%); Rf 0.49 (50% EtOAc in hexane); 
(Found: M+, 245.0726. C1OH1SN04S requires M, 245.0722); Amax(H20)/nm 310 
(£Idm3mol-1cm-1 7020); vmax(thin film)!cm-1 3409 (br), 2982,1738, 1704, 1607, 
1462, 1369, 1250 and 1026; OH (200 MHz, CDCI3) 1.22 and 1.39 (6H, 2 x s, 7-
and 8-H3), 1.23 and 1.24 (6H, 2 x t, J 7.1 Hz and 7.1 Hz, 11- and 14-Hs), 3.77 
(1H, brd, J 2.8 Hz, 3-H), 4.17 (4H, 2 x q, J 7.1 Hz, 10- and 13-H2), 4.74 (1H, br 
5, N-H) and 6.18 (1H, s, 6-H); Be (50 MHz) 12.6 (C-11 and C-14), 23.2 and 25.9 
(C-7 and C-8), 38.9 (C-2), 59.5 and 59.8 (C-10 and C-13), 61.0 (C-3), 100.3 (C-
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6), 124.6 (C-5), 160.7 (C-12) and 168.2 (C-9); mlz 273 (M+, 17.5%), 260, 
200,154 (100%), 126,82,71,55 and 41. 
(R)-3,4-Dihydro-2H-1 ,4-thiazine-3,5-dicarboxamide (245)205 
Compound (245) was synthesised from compound (235) (10.67 g, 43.50 
mmol) in methanol (200 ml), saturated with anhydrous ammonia gas, according 
to the method of Tudor.205 After 48 h at room temperature, filtration yielded the 
desired diamide as a cream coloured solid, 4.84g (25.85 mmol, 59%); mp 204-
206 °C (MeOH); Rf 0.38 (30% MeOH in CHCI3); (Found: M+, 187.0409. 
CsHgN302S requires M, 187.0415); A.max(H20)/nm 299 (eldm3mol-1cm-1 2640); 
mlz 172,158,142,126 (100%), 98, 72 and 54. 
Dimethyl 1,4-thiazine-3,5-dicarboxylate (250) 
A solution of (240) (1.09 g, 5.00 mmol) in dichloromethane (20 ml) was 
added dropwise to a solution of DDQ (1.25 g, 5.50 mmol) in dichloromethane 
(70 ml) and stirred for 1 h at room temperature. The resulting suspension was 
filtered through celite and the filtrate was washed with sat. NaHC03 (3 x 100 
ml). The organic portion was dried (Na2S04), filtered and concentrated in vacuo 
to a orange coloured solid. Purification was achieved on a silica dry flash 
column eluting with 25% EtOAc in hexane, followed by crystallisation from 
ether/hexane to yield the desired thiazine as a yellow crystalline solid, 778 mg 
(3.61 mmol, 72.3%); mp 84-85 oC (Et20); Rt 0.16 (50% EtOAc in hexane); 
(Found: M+, 215.0255; C, 44.75; H, 4.19; N, 6.47. CaHgN04S requires M, 
215.0252; C, 44.64; H, 4.22; N, 6.51 %); A.max(H20)/nm 371, 264 and 222 
(£ldm3mol-1cm-1 4180, 7222 and 10320 respectively); vmax(KBr)/cm-1 3052, 
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2950, 1709, 1496, 1438, 1340, 1258, 1232 and 1089; BH (200 MHz, CDCI3) 
3.39 (2H, d, J 1.2 Hz, 2-H2), 3.90 and 3.96 (6H, 2 x s, 8- and 10-H3) and 7.66 
(1 H, t, J 1.2 Hz, 6-H); Be (50 MHz) 20.42 (C-2), 52.49 and 53.44 (C-8 and C-
10), 128.86 (C-6), 136.69 and 137.44 (C-3 and C-5), 162.92 and 163.66 (C-7 
and C-9); m/z215 (M+, 73.9%),184,170,155 (100%),128,97,84,70 and 59. 
cis- and trans-Dimethyl thiomorpholine-3,5-dicarboxylate (256)179 
cis- and trans-(256) were synthesised from methyl DL-2,3-
dibromopropionate (2.62 ml, 20.00 mmol) and dry triethylamine (2.79 ml, 20 
mmol) in anhydrous ethanol (40 ml) and L-cysteine methyl ester hydrochloride 
(3.44 g, 20.00 mmol) and dry triethylamine (5.58 ml, 40 mmol) in anhydrous 
ethanol (50 ml) according to the method of Paradisi et al. 179 After cooling the 
solvent was removed in vacuo and the residue was suspended in water (50 ml) 
and extracted with EtOAc (3 x 50 ml). The combined organic extract was dried 
(MgS04), filtered and concentrated to an oil. The ratio of cis to trans 
diastereoisomers in the product was shown to be 40.3: 59.7 respectively (GC). 
Careful purification on a silica column, eluting with 5% and then 10% EtOAc in 
hexane, resulted in the separation of the pure diastereoisomers. 
cis-Diastereoisomer (meso): lightly coloured solid, 1.49 9 (6.81 mmol, 34.1%) 
mp 40-41 oC (Lit. 179 43-44 OC); Rf 0.46 (EtOAc); (0.]020 ()O (c 1.0, MeOH); 
(Found: M+, 219.0556; C, 43.70; H, 5.98; N, 6.24. CaH13N04S requires M, 
219.0565; C, 43.82; H, 5.98; N, 6.39%); Amax(H20)/nm 975 (Eldm3mol-1cm- 1 
2400): BH (200 MHz, CDCI3) 2.59 (2H, dd, J 13.5, 10.5 Hz, 2-Ha and 2'-Ha·), 
2.68 (1 H, s, N-H), 2.72 (2H, dd, J 13.5,2.6 Hz, 2-Hb and 2'-Hb·), 3.64 (2H, dd, J 
10.6,2.6 Hz, 3- and 3'-H) and 3.70 (6H, s, 6 and 6'-H3); Be (50 MHz) 28.9 (C-2 
and C-2'), 52.4 (C-6 and C-6'), 59.4 (C-3 and C-3'), and 170.8 (C-5 and C-5'); 
m/z219 (M+, 8%),160 (100%),132,114,100,87,74,54 and 42. 
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trans-Diastereoisomer (threo): lightly coloured solid, 1.81 g (8.26 mmol, 41.3%); 
mp 30-34 °C (Lit.179 60 OC); Rf 0.37 (EtOAc); [a]o20 -71.80 (c 1.0, MeOH) (Lit. 179 
-73°); (Found: M+, 219.0556; C, 43.64; H, 5.86; N, 6.20. CaH13N04S requires 
M, 219.0565; C, 43.82; H, 5.98; N, 6.39%); Amax(H20)/nm 976 (eldm3mol-1cm-1 
2410); ()H (200 MHz, CDCI3) 2.79 (5H, m, 8- and 12-H2 and N-H), 3.70 (6H, s, 
14- and 16-H3), and 3.94 (2H, dd, J 6.2, 4.0 Hz, 9- and 11-H); <>c (50 MHz) 29.6 
(C-8 and C-12), 52.1 (C-14 and C-16), 55.1 (C-g and C-11) and 171.8 (C-13 
and C-15); mlz219 (M+, 10%), 160 (100%), 132, 114, 100,87,74,54 and 42. 
cis-(meso)-Thiomorpholine-3,5-dicarboxylic acid, cis-(253)178 
H.", S H 1:~" 2 2' ,\' .' .. , .. \' Hb Hb, 3 3' HO C\'\'···· N """IICO-
2 H + 2 
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A suspension of compound cis-(256) (210 mg, 0.96 mmo/) in 0.200 M 
KOH (aq) (9.58 ml, 2 equiv.) was heated at reflux for 18 h. After cooling the 
solution was washed with ether (2 x 10 ml). The aqueous portion was adjusted 
to pH 1 by the careful addition of c. HCI (aq). Concentration under reduced 
pressure and drying in a desiccator (P20S) yielded compound cis-
(253).HCI.2KCI as a light yellow coloured solid, 332 mg (0.88 mmol, 92.0%); 
(Found: M+, 192.0320 C6H9N04S requires MH, 192.0330). vmax(KBr disc)/cm- 1 
3426 (br), 2960 (br), 1761, 1741,1378,1192; cSH (200 MHz, 020) 3.00 (4H, m, 
2- and 2'-H2) and 4.16 (2H, dd, J 11.7, 3.3 Hz, 3- and 3'-H); Be (50 MHz) 26.7 
(C-2 and C-2'), 59.1 (C-3 and C-3') and 170.2 (C-5 and C-5'); mlz (FAB) 191 
(M+, 100%), 154, 136, 107,90,78,40. 
The literature 178 melting point for the free amino acid is 253-254 °C 
(dec.). The isomer isolated from the aqueous recrystallisation was not specified. 
trans-(3R,5R)-Thiomorpholine-3,5-dicarboxylic acid, trans-(253)178 
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A suspension of compound trans-(256) (548 mg, 2.50 mmol) in 0.200 M 
KOH (aq) (25 ml, 2 equiv.) was heated at reflux for 18 h. After cooling the 
solution was washed with ether (2 x 20 ml). The aqueous portion was adjusted 
to pH 1 by the careful addition of c.HCI (aq). Concentration under reduced 
pressure and drying in a desiccator (P20S) yielded compound trans-
(253).HCI.2KCI as a light yel/ow coloured solid, 930 mg (2.47 mmol, 98.7%); 
(Found: M+, 191.0255. CsH9N04S requires M, 191.0252); vmax(KBr disc)/cm-1 
3460,3410,3005, 1664, 1579; DH (200 MHz, 020) 2.89 (4H, m, 2- and 6-H2) 
and 4.17 (2H, m, 3- and 5-H); DC (50 MHz, Os-OMSO) 27.4 (C-2 and C-6), 54.8 
(C-3 and C-5) and 170.7 (C-7 and C-8); m/z 191 (M+, 13.7%), 173, 146, 100 
(100%),73. 
(R)-N-Ethoxyoxalylcysteine ethyl ester (265)205 
Ethyl oxalyl chloride (4.47 ml, 40.00 mmol) was added slowly over 10 
min to a stirred suspension of L -cysteine ethyl ester hydrochloride (7.43 g, 
40.00 mmol) and triethylamine (11.15 ml, 80.00 mmol) in anhydrous 
dichloromethane (100 ml), at room temperature under a nitrogen atmosphere. A 
rapid evolution of Hel gas and exotherm was observed. The reaction mix was 
allowed to cool to room temperature and stirred for a total of 3 h. The resulting 
suspension was washed with water (3 x 100 ml) and the organic portion was 
dried (MgS04), filtered and concentrated in vacuo to a lightly coloured oil. 
Purification on a silica gel dry flash column, eluting with 25% EtOAc in hexane, 
yielded the desired amide as a colourless oil, 9.40 9 (37.71 mmol, 94.3%); Rf 
0.38 (50% EtOAc in hexane); (Found: M+, 249.0666. C9H1SNOSS requires M, 
249.0671); vmax(thin film)/cm-1 3395, 3020, 1740, 1705, 1515; BH (200 MHz; 
CDCI3) 1.32 and 1.40 (6H, 2 x t, J 7.2 and 7.2Hz, 5- and 9-H3), 1.55 (1 H, t, J 
9.0 Hz, SoH), 3.08 (2H, dd, J 9.0, 4.5 Hz, 3-H2), 4.28 (2H, dq, J 7.2, 1.2 Hz, 4-
or 8-H2), 4.38 (2H, q, J 7.2 Hz, 4- or 8-H2), 4.84 (1 H, dt, J 7.8, 4.5 Hz, 2-H) and 
7.99 (1 H, br d, J 7.6 Hz, N-H2); Bc (50 MHz) 12.2 and 12.4 (C-5 and C-9), 24.5 
(C-3), 52.5 (C-2), 60.5 and 61.6 (C-4 and C-8), 154.6 (C-1), 158.1 (C-7) and 
167.2 (C-6); m/z249 (M+, 0.5%), 204,176,158,148,132,118 (100%) and 101. 
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(R)-N,S-Oiethoxyoxalylcysteine ethyl ester (274) 
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To a suspension of L-cysteine ethyl ester hydrochloride (1.87 g, 10.00 
mmol) in anhydrous dichloromethane (40 ml), under a nitrogen atmosphere, 
was added ethyl oxalyl chloride (2.23 ml, 20.00 mmol) and the solution was 
stirred at room temperature for 48 h. After this time the reaction mix was 
washed with water (3 x 20 ml) and the organic portion was dried (MgS04), 
filtered and concentrated in vacuo to a yellow oil. Purification was achieved on 
dry silica flash column, eluting with 25% EtOAc in hexane, to yield compound 
(274) as a colourless oil, 2.92 g (8.36 mmol, 83.6%); At 0.30 (50% EtOAc in 
hexane); (Found: M+, 349.0825. C13H19NOSS requires M, 349.0831) 
vmax(KBr)/cm-1 3353 (br), 2986, 1738, 1699, 1525, 1292, 1202 and 1025 ; DH 
(200 MHz, CDCI3) 1.32 (3H, t, J 7.1 Hz, 5-H3), 1.40 (6H, t, J 7.1 Hz, 9- and 13-
H3), 3.48 and 3.63 (2H, 2 x dd, J 14.2, 5.9 Hz and 14.2,4.8 Hz, 3-Ha and 3-Hb), 
4.26 (2H, t, J 7.1 Hz, 4-H2), 4.37 and 4.38 (4H, 2 x q, J 7.1 Hz and 7.1 Hz, 8-
and 12-H2), 4.87 (1 H, m, 2-H2) and 7.76 (1 H, br d, J 7.7 Hz, N-H); DC (50 MHz) 
13.9,14.1 and 14.2 (C-5, C-9 and C-13), 30.5 (C-3), 51.9 (C-2), 62.7, 63.5 and 
63.9 (C-4, C-8 and C-12), 158.45 (C-l0), 159.57 (C-6), 168.66, 168.72 and 
168.93 (C-1, C-7 and C-ll); m/z 349 (M+, 1.7%),276,248 (100%), 202,176, 
158, 118, 102,86,74,59 and 42. 
N-Ethoxyoxalyl-2-methyleneglycine ethyl ester (266) 
Ethyl oxalyl chloride (1.12 ml, 10.00 mmol) was added slowly to a 
suspension of L-cysteine ethyl ester hydrochloride (1.86 g, 10.00 mmol) and 
Et3N (10 ml, excess) in anhydrous dichloromethane under a nitrogen 
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atmosphere at 0 °C. The suspension was then stirred at room temperature for 2 
h after which time the first step, sUbstitution at nitrogen, was adjudged to be 
complete (TLC). The reaction mixture was recooled to 0 °C and phosphorus 
trichloride (0.87 ml, 10.00 mmol) was added slowly. After 10 min at 0 °C the 
reaction was quenched by adding water (50 ml) and stirred for a further 10 min. 
The organic portion was separated, washed with water (50 ml), dried (MgS04), 
filtered and concentrated to a red oil. Purification was achieved on a silica 
column, eluting with 25% EtOAc in hexane, to yield compound (266) as a white 
solid, 160 mg (0.74 mmol, 7.4%); mp -200 °C (dec.); Rf 0.48 (50% EtOAc in 
hexane); (Found: M+, 215.0796. C9H13NOs requires M, 215.0794); 
vmax(KBr)/cm-1 3411 (br), 2988, 1718, 1514, 1257 and 1018; OH (200 MHz, 
CDCI3) 1.29 and 1.33 (6H, 2 x t, J 7.1 Hz and 7.1 Hz, 5- and 9-H3), 4.25 and 
4.31 (4H, 2 x q, J 7.1 Hz and 7.1 Hz, 4- and 8-H2), 5.98 (1 H, d, J 1.5 Hz, 3-Hb) 
(coupling lost by irradiating at 9.26 ppm), 6.63 (1 H, s, 3-Ha), and 9.26 (1 H, br s, 
N-H); Oc (50 MHz) 13.8 and 13.9 (C-5 and C-9), 62.3 and 63.5 (C-4 and C-8), 
110.7 (C-3), 130.4 (C-2), 154.5 (C-6), 159.7 and 162.9 (C-1 and C-7); m/z 215 
(M+, 25.8%),142,114,96,86,72,57,49 and 42 (100%). 
DiethyI1,3-thiazole-2,4-dicarboxylate (238)184 
Method 1 
Compound (238) was synthesised from compound (265) (7.48 g, 30.00 
mmol) and phosphorus pentasulfide (13.34 g, 30.00 mmol) in freshly distilled 
dried pyridine (50 ml) according to the method of Tudor.205 An exotherm was 
noted prior to heating and it was observed that the solid quickly dissolved on 
heating. After reflux, the solvent was removed in vacuo and the resulting 
residue was suspended in water (200 ml) and extracted with EtOAc (3 x 100 
ml). The organic extract was dried (MgS04), filtered and concentrated in vacuo 
to a brown residue. Purification was achieved on a silica column, eluting with 
10% EtOAc in hexane, to yield the desired thiazole as an orange solid, 992 mg 
(4.33 mmol, 14.4%). 
Method 2 
Compound (238) was synthesised from ethyl thiooxamate (2.04 g, 15.34 
mmol) and ethyl bromopyruvate (3.09 g, 20.00 mmol) in ethanol (20 ml) 
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according to the method of Erlenmeyer and co-workers.184 After heating at 
reflux for 3 h the solvent was removed in vacuo, the resulting residue dissolved 
in sat. Na2C03 (aq) (25 ml) and extracted with ether (3 x 25 ml). The organic 
extract was dried (MgS04), filtered and concentrated in vacuo to a red oil. 
Purification was achieved on a silica column, eluting with 20% EtOAc in 
hexane, followed by crystallisation from ether/pet. ether (40-60 DC) yielded the 
desired thiazole as a white crystalline solid, 2.12 g (9.26 mmol, 60%) The 
characterisation data was consistent with the Iiterature:206 mp 43-44 0C (Lit.184 
43-44 OC); Rt 0040 (50% EtOAc in hexane); (Found: C, 47.36; H, 4.73; N, 6.01. 
C9H11N04S requires C, 47.16; H, 4.80; N, 6.11%); Amax(H20)/nm 272, 209 
(cldm3mol-1cm-1 7020, 19930 respectively). 
1,3-Thiazole-2,4-dicarboxylic acid dipotassium salt (257) 184 
Compound (257) was prepared from a method adapted from that of 
Erlenmeyer and co-workers. 184 Compound (238) (713 mg, 3.11 mmol) was 
dissolved in ethanol (4 ml) and a solution of KOH (397 mg, 7.08 mmol) in water 
(0.5 ml) was added. The resulting suspension was heated to 60-70 °C in a 
sonic bath for 1 h. The resulting solid was dissolved in water, precipitated with 
ethanol, filtered and dried in a desiccator (P20S)· Purification was achieved by 
crystallisation from -5% aqueous ethanol to yield the desired dicarboxy/ate salt 
as a cream coloured solid, 410 mg (1.64 mmol, 23.2%); mp 360-362 °C (dec. at 
-320 OC); Amax(H20)/nm 268 (ddm3mol-1cm-1 4820); vmax(KBr)/cm-1 3424 (br), 
3076, 1609, 1485, 1462, 1365 and 1097; ~ (200 MHz, 020) 8.04 (1H, s, 5-H) 
Be (50 MHz) 129.5 (C-5), 154.0 (C-4), 166.8 (C-2) and 169.8 (C-6 and C-7). 
1 ,3-Thiazole-2,4-dicarboxamide (258)206 
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Compound (258) was synthesised from compound (238) (865 mg, 3.77 
mmol) in methanol (20 ml), saturated with anhydrous ammonia gas, according 
to the method of Connell206 to yield the desired diamide as a white solid, 550 
mg (3.21 mmol, 85.2%); OH (200 MHz, CDCI3) 7.76 and 8.21 (4H, 2 x br s, 7-
and 9-H2) and 8.46 (lH, s, 5-H); oe (50 MHz) 129.0 (C-5), 150.4 (C-4), 160.5 
(C-2), 161.8 and 163.0 (C-6 and C-7). 
1,3-Thiazole-2,4-dinitrile (239)206 
Compound (239) was synthesised from compound (258) (470 mg, 2.75 
mmol) and phosphorus oxychloride (2.56 ml, 10 equiv.) in 1,1,2,2-
tetrachloroethane according to the method of Connell206 to yield the desired 
dinitrile as white needles, 162 mg (1.20 mmol, 43.6%); mp 82-83 oC; At 0.46 
(50% EtOAc in hexane); OH (200 MHz, CDCI3) 8.35 (1 H, s, 5-H); oe (50 MHz) 
111.0 and 112.0 (C-6 and C-7), 129.3 (C-4), 134.6 (C-5) and 138.5 (C-2). 
Ethyl 2-amino-1 ,3-thiazole-4-carboxylate (259) 
Ethyl bromopyruvate (6.28 ml, 50.00 mmol) was added to a suspension 
of thiourea (3.81 g) and triethylamine (6.97 ml, 50.00 mmol) in ethanol (100 ml) 
and stirred at room temperature for 72 h. After this time, saturated aqueous 
Na2C03 (25 ml) was added to the suspension and the residual solid was 
filtered. The filtrate was concentrated in vacuo and purified on a silica column, 
eluting with 30% EtOAc in hexane, followed by crystallisation from acetone/pet. 
ether (40-60 DC) to yield compound (259) as an orange solid, 5.25 g (30.48 
mmol, 61.0%); mp 169-171 oC; At 0.35 (EtOAc); (Found: M+, 172.0304; C, 
41.80; H, 4.70; N, 16.20. CsHaN202S requires M, 172.0306; C, 41.85; H, 4.68; 
N, 16.27%); Amax(H20 )/nm 281, 238 and 210 (E/dm3mol- tcm-1 4750, 7430 and 
20510 respectively); vmax(KBr)/cm-1 3440,3264,3126,1690,1618,1538,1340 
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and 1242; OH (200 MHz, D6-acetone) 1.17 (3H, t, J 7.1 Hz, 8-H3), 4.11 (2H, q, J 
7.1 Hz, 7-H2), 6.91 (2H, br s, N-H2), and 7.30 (1 H, s, 5-H); Oc (50 MHz) 14.6 
(C-8), 60.9 (C-7), 117.2 (C-5), 143.9 (C-4), 161.9 (C-2), and 169.5 (C-6); m/z 
172 (M+, 56.0%), 144, 127, 100 (100%), 84,71,58 and 44. 
Diethyl 4-methyl-1,3-thiazole-2,5-dicarboxYlate (260)185 
Compound (260) was synthesised from ethyl 2-chloroacetoacetate 
(0.484 ml, 3.50 mmol), ethyl thiooxamate (466 mg, 3.50 mmol) and ethanol (10 
ml) according to the method of Boon.185 After reflux the ethanol was removed in 
vacuo, the residue was neutralised with sat. NaHC03 (aq) (25 ml) and extracted 
with Et20 (3 x 25 ml). The combined organic extract was dried (MgS04), 
filtered, and concentrated. Purification was achieved on a silica column, eluting 
with 10% EtOAc in hexane to yield the desired thiazole as a cream coloured 
solid, 298 mg (1.22 mmol, 35.0%); mp 53-54 oC (Lit. 59 DC); At 0.26 (25% 
EtOAc in hexane); (Found: M+, 243.0565; C, 49.42; H, 5.29; N, 5.65. 
C1OH13N04S requires M, 243.0565; C, 49.37; H, 5.39; N, 5.76%); 
Amax(H20)/nm 293, 246 and 206 (Eldm3mol-1cm-1 12490, 6340 and 12370 
respectively); vmax(KBr)/cm-1 2989, 1740, 1723, 1518, 1444, 1268, 1233 and 
1104; OH (200 MHz, CDCI3) 1.40 and 1.45 (6H, 2 x t, J 7.1 Hz, 8- and 11-H3), 
2.81 (3H, s, 12-H3), 4.38 and 4.50 (4H, 2 x q, J 7.1 Hz, 7- and 10-H2); oc (50 
MHz) 14.0 (C-8 and C-11), 17.4 (C-12), 61.7 and 62.6 (C-7 and C-10), 127.4 
(C-5), 158.9 (C-4), 159.4 (C-2), 161.0 and 161.3 (C-S and C-9); m/z243 (M+, 
15.0%), 198, 171 (100%), 143, 126, 113,98,85,68 and 45. 
(2R,4R)- and (2S,4R)-Thiazolidine-2,4-dicarboxylic acid (261) 
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L-Cysteine hydrochloride (4.00 g, 25.40 mmol) was suspended in ethanol 
(10 ml) and warmed to 70 0C. Glyoxylic acid (2.76 g, 30.00 mmol) was added in 
portions over 5 min to the resulting solution and a yellow colouration was 
observed. The solution was stirred at 70 °C for a further 5 min and the solvent 
was removed in vacuo to yield a yellow oil. Water (50 ml) was added to the 
mixture and the solution was left to crystallise at 0° C for 72 h. The white 
crystals were filtered off and dried in a desiccator (P20S), 1.95 g (11.01 mmol, 
43.3%); mp 179-183 0C (dec. at 170 OC) (H20); (Found: M+, 177.0096; C, 
34.07; H, 4.11; N, 7.49. CsH7N04S requires M, 177.0096; C, 33.89; H, 3.98; N, 
7.91%); vmax(KBr)!cm-1 3432 (br), 3049, 1719, 1628, 1542, 1413, 1384, 1334 
and 1272; OH (200 MHz, CD30D) 1.20 (2H, m, 5-H2), 4.13 (1 H, m, 4-H) 
(decoupling at 1.20 ppm simplifies this multiplet), 4.50 and 4.S3 (1 H, 2 x d, J 6.4 
Hz and S.9 Hz, two diastereomeric forms of 2-H); oe (SO MHz, 020! NaOO) 
38.4 (C-5), 68.0 and 69.4 (C-2 and C-4), 177.S and 178.2 (C-6 and C-7); m/z 
177 (M+, 0.3%),132,118,86 (100%),60 and 44. 
DL-5,5-Dimethylthiazolidine-2,4-dicarboxylic acid (262)186 
Compound (262) was synthesised from DL-Penicillamine hydrochloride 
(1.24 g, 6.70 mmol) and glyoxylic acid (2 g, excess) in ethanol (10 ml) by the 
same method as that used for (261) and according to the method of Bentley et 
al. 186 After 20 min at 70°C the solvent was removed in vacuo, water (20 ml) 
was added and the solution was left to crystallise at 0° C for 72 h. The desired 
thiazolidine was isolated as white needles after filtration and drying in a 
desiccator (P20S), 773 mg (3.77 mmol, 56.2%); mp 198-199 °C (dec. at 175 OC) 
(H20); (Found: M+, 205.0393; C, 40.12; H, 5.36; N, 6.50. C7H11N04S requires 
M, 205.0409; C, 33.89; H, 3.98; N, 7.91%); vmax(KBr)/cm-1 3432 (br), 2987, 
1727,1640,1587,1461,1375,1282 and 1247; OH (200 MHz, D6-DMSO) 1.20 
and 1.59 (6H, 2 x s, 8- and 9-H3), 3.65 (1 H, s, 4-H), 4.95 (1 H, s, 2-H) and 13.01 
(weak, br s, 6- and 7-0H); oe (50 MHz) 26.6 and 27.5 (C-8 and C-9), 57.7 (C-
5),61.9 (C-4), 73.9 (C-2), 170.1 and 172.4 (C-6 and C-7); m/z205 (M+, 3.1%), 
160 (100%),114,100,86,75,55 and 43. 
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7.05 Experimental to Chapter 6 
Dimethyl dipicolinate (34)19 
Compound (34) was synthesised from dipicolinic acid (16.71 g, 100.0 
mmol) in methanol (200 ml) and C.H2S04 (2 ml) according to the method of 
Robins and co-workers.79 After reflux (30 h) the solvent was removed in vacuo, 
the residue was dissolved in sat. NaHC03 (aq) (100 ml) and extracted with 
CHCI3 (2 x 100 ml). The combined organic extract was then washed with water 
(50 ml), dried (MgS04), filtered and concentrated to yield the desired diester as 
white prisms, 17.93 g (91.87 mmol, 91.9%); mp 118-120 °C (Lit.79 117-119 °C); 
Rt 0.18 (50% EtOAc in pet. ether (40/60 °C»; (Found: M+, 196.0579. C9H10N04 
requires M, 196.0610); Amax(H20)/nm 222 (fidm3mol-1cm-1 9710). 
Dimethyl cis-piperidine-2,6-dicarboxylate (50)19 
Compound (50) was synthesised from compound (34) (5.86 g, 30.00 
mmol) in CHCI3 (100 ml) by Pt02 (3 x 100 mg) catalysed hydrogenation, 
according to the method of Robins and co-workers.79 The reaction was 
monitored by TLC and the catalyst was added in three portions over an eight 
day period when deemed appropriate. A colour change from brown to black for 
the catalyst indicates reductive degradation. Filtration through celite with 
methanol (200 mJ), followed by concentration and recrystallisation from 
methanol yielded the desired piperidine as a white solid, 5.65 9 (28.07 mmol, 
93.6%); mp 208-210 °C (Lit,79 210-212 °C); Rt 0.77 (50% EtOAc in Pet. Et. 
(40/60»; (Found: M+, 201.1024. C9H1SN04 requires M, 201.1001). 
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Dimethyl N-( 4-toluenesulfonyl)-cis-piperidine-2,6-dicarboxylate (51)79 
Compound (51) was synthesised from compound (50) (1.01 g, 5.00 
mmol) and p-toluenesulfonyl chloride (1.91 g, 10.00 mmol) in freshly dried 
pyridine (10 ml) according to the method of Robins and co-workers79 to yield 
the desired tosylate as white needles, 1.03 g (2.89 mmol, 57.9%); mp 59-61 ec 
(Lit.79 58-61 ec); Rf 0.42 (50% EtOAc in hexane); (Found: M+, 355.1094. 
C16H21 N06S requires M, 355.1089); Amax(H20)/nm 275 (E/dm3mol-1cm-1 1170). 
Dipotassium salt of DL-2,3,4,5-tetrahydrodipicolinate (52)79 
Compound (52) was synthesised from compound (51) (400 mg, 1.13 
mmol) and potassium tert-butoxide (450 mg, 4.01 mmol) in dry dichloromethane 
(10 ml) according to the method of Robins and co-workers,79 Crystallisation 
from methanol proved to be very difficult to reproduce. The purity of the crude 
material (417 mg) was estimated as approximately 58% by 1 H NMR 
spectroscopy. The 1 H NMR spectrum indicates the presence of tert-butoxide 
and para-toluenesulfinate impurities. The crude material is a yellow solid and 
was found to be suitable for work with the OHOPR enzyme; 242 mg (0.98 
mmol, 86.7%); The characterisation data was consistent with the Iiterature:79 ~ 
(200 MHz, 020) 1.47 to 2.01 (6H, m, 2-, 3- and 4-H2) and 3.46 (1 H, dd, J 7.9, 
3.5 Hz, SoH). Signals visible for the enamine form at () = 3.97 (1 H, m, 5-H) and 
5.47 (1 H, t, J 4.1 Hz,2-H). 
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7.06 Biotransformations with DHDPS 
Dimethyl DL-1-hydro-2-methylpyridine-2,6-dicarboxylate (110) 
3 
N~12 10 9 Me02C"'"'' 5 N~C02Me 6 H 7 8 
In earlier chapters we have discussed typical enzyme inhibition and 
substrate assays. These assays were performed on an analytical scale. In order 
to attempt isolation of an enzymic product for full characterisation it was 
necessary to scale up the process to a preparative level. To achieve this goal 
solutions of sodium pyruvate (400 mM) and compound (154) (400 mM) were 
prepared in distilled water. Aliquots (250 I.d) of these solutions were added in 
turn to a 1 M aqueous imidazole buffer (pH 7.4; 250 Ill) at room temperature in a 
1 ml (0.5 cm) quartz cuvette. The enzymic reaction was initiated on addition of 
purified DHDPS in 50% aqueous glycerol (20 Ill). The progress of the reaction 
was monitored spectrophotomerically at 370 nm. The absorbance maxima of 
the product is at 271 nm, monitoring the 'tail end' of this increasing absorbance 
ensures that we remain within the limits of detection for the incident UV beam. 
The enzymic reaction was complete after 90 min. The analysis of the enzymic 
reaction was discussed in chapter 6. 
A number of variants of this assay were successfully performed with 
lesser concentrations of compound (154) and other substrates, including the 
natural substrate (124). Results from these assays were similarly discussed in 
chapter 6. 
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